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ABSTRACT 
 
Creatine monohydrate (CrM) and nitrate are popular supplements for improving 
exercise performance; yet they have not been investigated in combination. We 
performed two studies to determine the safety and exercise performance-characteristics 
of creatine nitrate (CrN) supplementation.  
In Study 1, 13 participants ingested 1.5 g CrN (CrN-L), 3 g CrN (CrN-H), 5 g 
CrM or a placebo (PL) in a crossover study to determine supplement safety.   
Hepatorenal and muscle enzymes, heart rate, blood pressure and side effects were 
measured before supplementation, 30 minutes after ingestion, and then hourly for 5 
hours post-supplementation. In Study 2, 48 participants received the same CrN 
treatments vs. 3 g CrM in a double-blind, 28-day trial inclusive of a 7-day interim testing 
period and loading sequence (4 servings/d). Day-0 and day-28 measured bench press 
performance, Wingate testing and a 6x6-s bicycle ergometer sprints. Data were analyzed 
using a general linear model and results are reported as mean ± standard deviation or 
mean change ± 95% confidence interval (CI). 
Both studies yielded several significant, yet stochastic changes in blood markers 
that were not indicative of potential harm or consistent for any treatment group. Equally, 
all treatment groups reported a similar number of minimal side effects. In Study 2, there 
was a significant increase in plasma nitrates for both CrN groups by day-7, subsequently 
abating by day-28. Muscle creatine increased significantly by day-7 in the CrM and 
CrN-H groups, but decreased by day-28 for CrN-H. By day-28, there were significant 
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increases in bench press lifting volume (kg) for all groups (PL, 126.6, 95% CI 26.3, 
226.8; CrM, 194.1, 95% CI 89.0, 299.2; CrN-L, 118.3, 95% CI 26.1, 210.5; CrN-H, 
267.2, 95% CI 175.0, 359.4, kg). Only the CrN-H group was significantly greater than 
PL (p<0.05). Similar findings were observed for bench press peak power (PL, 59.0, 95% 
CI 4.5, 113.4; CrM, 68.6, 95% CI 11.4, 125.8; CrN-L, 40.9, 95% CI -9.2, 91.0; CrN-H, 
60.9, 95% CI 10.8, 111.1, Watts) and average power.    
Creatine nitrate was well-tolerated, demonstrated similar performance benefits to 
3 g CrM, and was void of significant hemodynamics or blood enzymes changes 
associated with supplement safety. 
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NOMENCLATURE 
 
µM Micromolar 
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AP Average Power 
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CrPyr Creatine Pyruvate 
DBP Diastolic Blood Pressure  
DXA Dual Energy X-ray Absorptiometry 
FCr Free Creatine 
FFM Fat-Free Mass 
FM Fat Mass 
g Grams 
g/kg Grams per Kilogram Body Weight  
HR Heart Rate  
J Joules 
J/kg Joules per kilogram  
LBM Lean Body Mass 
LDH Lactate Dehydrogenase 
mL Milliliter 
MP Mean Power 
PCr Phosphocreatine 
PL Placebo 
PP Peak Power 
SBP Systolic Blood Pressure  
W Watts 
W/kg Watts per Kilogram Body Weight 
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CHAPTER I  
INTRODUCTION 
 
Background 
Creatine (Cr) was discovered as an organic component of meats over 150 years 
ago.  Cr (2-[Carbamimidoyl(methyl)amino]acetic acid) is a nitrogenous amine that 
humans can endogenously synthesize from three amino acids – glycine, arginine, and 
methionine (126). Animal products such as meats and fish are primary sources of dietary 
creatine. Nevertheless, a typical western diet does not lead to a significant increase in 
muscle creatine concentrations (8, 42). Therefore, providing supplemental creatine 
should lead to increases in total creatine concentrations, which, in turn, can improve 
exercise performance. Cr is a high-energy buffer that plays an important role during high 
intensity exercise that requires rapid adenosine triphosphate (ATP) synthesis. This rapid 
production of ATP is mostly met by the phosphagen energy system.  In this energy 
system creatine kinase catalyzes phosphocreatine and adenosine diphosphate (ADP) to 
creatine and ATP.   
The form of Cr most extensively investigated  is creatine monohydrate (CrM) 
(19).  Several supplementation protocols have been employed to increase muscle Cr 
stores. Some protocols recommend a loading phase and a maintenance phase. The 
loading phase consists of providing a higher dose of Cr, usually 20 – 25 g for 5 – 7 days, 
while the maintenance phase consists of a lower dose, usually 3 – 5 g/d for the remainder 
of the supplementation period.  Researchers have reported a 20% increase in muscle Cr 
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stores after the brief loading phase period (58). Alternatively, other supplementation 
protocols have omitted the loading phase altogether.  This type of supplementation 
protocol has been shown to increase muscle Cr stores as well, but at a much slower rate. 
Hultman et al. (58) reported a 20% increase in muscle Cr stores after supplementing with  
3 – 5 g/d for one month. Similar Cr supplementation protocols have been shown to 
increase total creatine (TCr) concentration by 10 – 40% in healthy adults (44). Increased 
TCr concentration, when accompanied by a resistance training program, leads to 
improved strength, power, and lean body mass (52, 117, 120, 121). Furthermore, there is 
substantial evidence suggesting CrM is safe with no detrimental effects on health.   
Despite supporting evidence, novel forms of Cr appear in the marketplace with 
claims of being more efficacious than CrM.  Research does not support the majority of 
the claims purported by the novel forms of Cr. For example, Kre-Alkalyn
®
, a buffered 
form of Cr, claims to enhance the delivery of usable Cr (40). A recent study by Jagim et 
al. (63), compared the effects of CrM and Kre-Alkalyn
®
 on muscle Cr content, body 
composition, and adaptations to training. Results indicated that Kre-Alkalyn
®
 did not 
promote greater changes in any variable measured when compared to CrM.   
Nitrate supplements have received much attention due to their effects on 
vasodilation, blood pressure, improved work efficiency, and reduce phosphocreatine 
(PCr) degradation (79, 80, 118). Nitrate supplementation is most commonly consumed 
as beetroot juice (BRJ) or sodium nitrate (55). Nitrate doses have been prescribed in 
absolute and relative amounts ranging from 300 – 600 mg (55) and 0.1 mmol/kg/d, 
respectively (78, 81). In relative terms, a 70 kg person prescribed 0.1 mmol/kg/d would 
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ingest 7 mmol/d which is approximately 435 mg nitrate. Exercise performance has been 
measured after short term (2 – 3 h prior to exercise) and longer term (2 – 7 d) 
supplementation. Muggeridge et al. (88), observed lowered oxygen consumption during 
submaximal exercise as well as significantly faster time performance after consuming 
approximately 310 mg nitrate 3 h prior to testing. Larsen et al. (78), observed a reduction 
in oxygen cost during submaximal exercise performance on a cycle ergometer after 
supplementing with nitrate (0.1 mmol/kg/d) for 3 d. Nitrate supplementation research 
has mainly been shown beneficial in endurance exercise (55).   
Nitrate supplementation research and its effect on anaerobic exercise are lacking. 
Additionally there is currently no research that has examined nitrate in combination with 
Cr supplementation.  A novel form of Cr, creatine nitrate (CrN), has gained some recent 
attention (66), but to our knowledge there are no studies that have examined the effects 
of CrN supplementation and anaerobic exercise performance. The existing separate 
evidence of Cr and nitrate research suggests that the novel form of Cr, CrN, may 
potentially yield greater improvements in anaerobic exercise performance when 
compared to supplementation with CrM.   
Research related to the safety and efficacy of CrN currently is lacking. Thus, the 
present study examined the acute safety and chronic efficacy of CrN supplementation on 
exercise performance. Study 1 examined the hemodynamic, hematologic, and dose 
effects of ingesting two doses of CrN compared to CrM and placebo (PL). Study 2 
examined the effects of 28 days of two doses of CrN compared to CrM and PL on body 
composition and exercise performance in recreationally active males.  
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Statement of the Problem  
  CrN will increase exercise performance and related performance indices in a 
dose dependent manner and be equal in effectiveness to CrM.  Furthermore, CrN 
ingestion will not adversely affect hepatorenal function or hemodynamic indices 
following acute and chronic ingestion.  
Purpose of the Study 
The aim was to examine the acute (5 h) hemodynamic (heart rate and blood 
pressure) and hematologic profiles (blood chemistries) for two doses of CrN compared 
to CrM and PL as well as compare their effects on muscle Cr content, body composition 
and anaerobic exercise performance after 28 d of supplementation.  
General Study Overview 
This study was carried out in two trials and both were randomized, double-blind, 
placebo-controlled. In Study 1, in a crossover fashion, we determined acute (5 h) 
hemodynamic (heart rate and blood pressure) and hematologic profiles after the 
administration of four supplements – 1) placebo (PL: 6.5 g dextrose), 2) creatine 
monohydrate (5 g CrM, 1.5 g dextrose), 3) creatine nitrate-lower dose (CrN-L; 1.5 g 
CrN [1 g Cr, 0.5 g nitrate], 5 g dextrose) and 4) creatine nitrate-higher dose (CrN-H; 3 g 
CrN [2 g Cr, 1 g nitrate], 3.5 g dextrose). In Study 2, we determined changes in muscle 
creatine content, body composition, and anaerobic exercise performance after 28 d of 
supplementation. Participants were randomly assigned in counter-balanced order to 1) 
PL (6.5 g dextrose), 2) creatine monohydrate (CrM: 3 g CrM, 0.5 g flavoring, 2 g 
dextrose), 3) CrN-lower dose (1.5 g CrN [1 g Cr, 0.5 g nitrate], 0.5 g flavoring, 3.5 g 
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dextrose), and 4) CrN-higher dose (3 g CrN [2 g Cr, 1 g nitrate], 0.5 g flavoring, 2 g 
dextrose). Study 2 consisted of a loading phase (7 d) and maintenance phase (21 d) of 
supplementation. During the loading phase participants ingest 4 doses/d while the 
maintenance phase consisted of ingesting one dose/d. In other words, participants 
ingested 1) PL (26 g dextrose/d for 7 d and 6.5 g dextrose/d for 21 d), 2) CrM (12 g 
CrM/d for 7 d and 3 g CrM/d for 21 d), 3) CrN-L (6 g CrN/d for 7d and 1.5 g CrN/d for 
21 d) and 4) CrN-H (12 g CrN/d for 7 d and 3 g CrN/d for 21 d ) in a randomized, 
double-blind manner. Muscle Cr, body composition, and blood chemistries were 
assessed at days 0, 7, and 28 to determine acute and chronic effects and safety. 
Anaerobic power variables were assessed and compared between groups using a bench 
press test outfitted with a Tendo FitroDyne Unit and an anaerobic sprint test on a cycle 
ergometer at day 0 and after 28 d of supplementation.    
Hypotheses 
Study 1  
H1: There will be significant differences among groups in plasma creatine 
concentrations.  
H2: There will be significant differences among groups in plasma nitrate 
concentrations. 
H3: There will be no significant differences among groups in markers of 
clinical health. 
H4: There will be no significant difference among groups in heart rate. 
H5:  There will be significant differences among groups in blood pressure. 
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H6:  There will be no significant differences among groups in side effects 
symptoms.  
Study 2 
H7:  There will be a significant difference among groups in plasma creatine 
concentration after 7 and 28 d of supplementation 
H8:  There will be a significant difference among groups in plasma nitrate 
concentration after 7 and 28 d of supplementation  
H9:  There will be a significant difference among groups in muscle creatine 
concentrations after 7 and 28 d of supplementation.  
H10:  There will be no significant difference among groups in body 
composition as measured by dual x-ray absorptiometry (DXA) after 7 and 
28 d of supplementation. 
H11:  There will be a significant difference among groups in upper body power 
as measured by the bench press test after 28 d. 
H12: There will be a significant difference among groups in anaerobic capacity 
as measured by the repeated sprints test on a cycle ergometer after 28 d. 
H13:  There will be no significant difference among groups in markers of 
clinical health and safety after 7 and 28 d of supplementation. 
H14:  There will be no significant difference among groups in side effects 
symptoms after 7, 14, 21, and 28 d of supplementation.      
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 Delimitations 
This study was conducted under the following guidelines: 
1. Thirteen (n=13) recreationally active males ages 18 – 40 y were recruited for 
Study 1. 
2. Forty-eight (n=48) recreationally active males ages 18 – 40 y were recruited 
for Study 2. 
3. Subjects refrained from the consumption of dietary supplements, and/or 
ergogenic aids (excluding daily vitamins and protein supplements) for at least 
three months prior to initiating testing.   
4. Eligible participants took part in a familiarization session during which time 
they were informed of the study protocol, filled out necessary forms 
including an informed consent form. Only those participating in Study 2 
completed a 1 repetition max bench press test and a practice anaerobic sprint 
test on a cycle ergometer.  
5. Participants were advised to maintain a consistent workout regimen 
throughout the duration of the study and recorded all workouts in a workout 
log.  
6. Percutaneous muscle biopsies (only Study 2) were obtained from the vastus 
lateralis at d -1, 7 and 27 and analyzed for muscle creatine content.  
7. Participants refrained from strenuous exercise, alcohol, and non-steroidal 
anti-inflammatory drugs at least 48 h prior to each testing session. 
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8. Participants were fasted for at least 8 hours for Study 1 and fasted for at least 
12 h for Study 2.  
9. Participants performed to their maximal ability on all strength and anaerobic 
sprints tests.  
10.  Participants were instructed to consume all supplements and report any side-
effects in a weekly questionnaire.  
Limitations 
1. The participants were individuals from the Texas A&M University 
community and surrounding fitness facilities that responded to recruitment 
fliers and emails; therefore the selection process was not truly random.  
2. There were some variations in testing times and dietary intake, all efforts 
were made to conduct testing sessions at the same approximate time to 
account for diurnal variations and subjects were instructed to maintain a 
consistent diet throughout the duration of the study.  
3. Motivations and efforts during performance during testing may not have been 
100% at each testing session.   
4. Participants may not have followed the supplementation instructions.  
5. All participants were instructed to maintain a consistent training program and 
keep a workout record. However, exercise habits during the duration of the 
study may have changed and therefore changes in performance may have 
been influenced by the training program rather than the assigned supplement.   
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6. All equipment was calibrated according to manufacturer guidelines and all 
samples were run in duplicate to reduce likelihood or error. However, there 
are innate limitations of the laboratory equipment that were used for data 
collection and analysis.   
Assumptions 
1. Participants followed the protocol that was explained to them during the 
familiarization session.  
2. Participants answered the entrance questionnaires accurately and honestly 
prior to being accepted into the study. 
3. Participants adhered to the supplementation protocol and testing schedule.   
4. All laboratory equipment was calibrated and functioning properly prior to all 
testing sessions.  
5. The population, which the sample was drawn from, was normally distributed.  
6. The variance among the population sample was approximately equal.  
7. The sample was randomly assigned to the different supplement groups. 
8.  Participants maintained a consistent dietary intake and exercise regimen 
throughout the duration of the study. 
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CHAPTER II 
REVIEW OF THE LITERATURE 
 
Introduction 
 Creatine monohydrate (CrM) is the most studied ergogenic aid in the last few 
decades. It continues to be one of the most popular dietary supplements among amateur 
and elite athletes. It is estimated that ~25% of high school athletes and ~45% of male 
division I collegiate athletes consume creatine (Cr) supplements (77, 85, 102). Cr 
supplementation can improve strength, power, and lean body mass when combined with 
resistance training in young (69, 92) and older adults (18, 48). The benefits of Cr 
supplementation have mainly been validated through research involving anaerobic 
exercise. Theoretically Cr supplementation may also benefit endurance exercise via 
increase in glycogen storage (90). To date, CrM is the most researched form of Cr; 
however, novel forms of Cr are created and investigated in hopes of surpassing the 
efficacy of CrM (62). The benefits of Cr supplementation are also being seen in clinical 
research as a therapeutic agent to alleviate symptoms associated with certain in-born 
errors of metabolism, Alzheimer’s, and Parkinson’s disease (19, 111).  
 Cr was discovered as an organic component of meats over 150 years ago by a 
French scientist, Michel Engene Chevreul in 1832 (104). A few years later in 1847, the 
German scientist, Justus von Liebig, identified Cr’s chemical structure as methyl-
guanidino-acetic acid.   In the late 1920s, approximately a century after the discovery of 
Cr, phosphocreatine (PCr) was discovered. In 1981, Sipila et al. (107), treated patients 
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with gyrate atrophy with 1.5 g of Cr/d for one year. One characteristic of gyrate atrophy 
is progressive atrophy of skeletal muscle. Patients ingesting oral Cr supplementation 
reported increased strength and were observed to have increase muscle fiber thickness. 
Cr research was sparse until the 1990s. In 1992, Harris et al. (52) and Greenhaff et al. 
(45), showed the promising effects of Cr supplementation using double-blind, placebo-
controlled investigation. They showed that Cr supplementation increased total creatine 
(TCr) concentration in the muscle, which, in turn, could be responsible for increasing 
muscular performance. Interestingly enough that same year Olympic Gold medalists 
Lindford Christie and Sally Gunnell, both sprint athletes, mentioned using Cr 
supplementation during their training for the Olympics (104).    
 Cr (2-[Carbamimidoyl(methyl)amino]acetic acid) is a nitrogenous amine and a 
natural constituent of meats, that humans can endogenously synthesize from three amino 
acids – glycine, arginine, and methionine (126). The biological synthesis of Cr follows a 
two-step process that involves arginine:glycine amidinotransferase (AGAT) and S-
adenosyl-methionine:N-guanidinoacetate methyltransferase (GAMT). The first step in 
Cr synthesis is catalyzed by AGAT and involves the production of guanidoacetic acid 
and ornithine from glycine and arginine (127, 130). This action mainly takes place in the 
kidneys, but has also noted in the pancreas. In the second step guanidoacetic acid is then 
transferred to the liver where it is methylated by methionine to yield Cr via the action of 
GAMT (130).  Cr is then transported via circulation and stored, primarily in the skeletal 
muscle.  
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 The human body has many different storage sites for Cr, although the primary 
storage site is skeletal muscle. Approximately 95% of TCr is stored in skeletal muscle 
(8). Elevated Cr concentrations are also found in the heart and eyes (130). The brain, 
endothelial cells, and macrophages are known to contain intermediate concentrations of 
Cr, while low concentrations are found in the lungs, spleen, kidney, liver, blood cells, 
and plasma (130). On average, a 70-kg person stores approximately 120 g of TCr in their 
body (122). Some researchers have reported a maximum TCr content of approximately 
160 g (44). Free creatine (FCr) and phosphocreatine (PCr) (the phosphorylated form of 
creatine) are the two components that make up TCr. Approximately 60 – 70% of Cr is 
found as PCr while the other 30 – 40% remains as FCr (127).     
 Although humans can synthesis Cr, dietary sources such as animal products can 
provide significant amounts of Cr. Meats and fish are the primary sources of dietary Cr, 
with raw meat containing the greatest concentration of Cr (3.93 g/kg raw meat) (51).  
However, there is evidence to suggest that the cooking process results in the degradation 
of Cr within the meat (51). Those following a vegetarian diet have lower Cr 
concentrations in the muscle when compared to those consuming an omnivorous diet 
(106). Humans typically endogenously synthesize approximately 1 g of Cr per day, 
while a common omnivorous diet can provide an additional 1 g of Cr (122, 130). The Cr 
pool turn-over rate is approximately 2 g/d and is lost as creatinine (122).  Creatinine is 
the end product of Cr metabolism via a spontaneous, nonenzymatic process. (129).  
Creatinine, once formed, enters the circulatory system, and is eliminated from the body 
through the urine (96).  
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Cr is a high-energy buffer that is a constituent of the phosphagen energy-system, 
which is one of three energy systems that yields adenosine triphosphate (ATP) (39). The 
phosphagen system yields ATP during short, explosive movements lasting up to 30-
seconds (126). This energy system utilizes one catalytic enzyme, creatine kinase. In this 
reversible reaction, creatine kinase can convert adenosine diphosphate (ADP) and PCr to 
Cr and ATP. ATP is vital for muscle movement and without it muscle contraction could 
not occur.  The glycolytic and oxidative phosphorylation systems are energy systems 
that also yield ATP.   
Creatine Supplementation Protocol 
 Various supplementation protocols have been undertaken over the years to 
optimize TCr stores. Harris et al. (52), were the first to demonstrate that 20 g CrM/d 
increased muscle Cr of the quadriceps femoris muscles. Generally, Cr supplementation 
occurs in two phases – the loading phase, followed by a maintenance phase. The initial 
phase of Cr supplementation is referred to as the loading phase, which consists of 
ingesting 20 – 30 g Cr for 5 – 7 d (19, 37, 38, 49, 57, 83, 108, 119, 124). More recent 
recommendations suggest ingesting Cr at 0.3 g/kg body weight/d for at least 3 d (19).  
The loading phase is typically divided into four equal doses distributed evenly 
throughout the day (100).  The maintenance phase typically consists of ingesting a lesser 
amount of Cr.  It is recommended to ingest 3 – 5 g of Cr supplementation to maintain 
elevated TCr stores (19). Alternative dosing strategies recommend ingesting 0.03 g of 
Cr/kg body weight/d during the maintenance phase. Some long-term supplementation 
 14 
 
protocols that  eliminated the loading phase of supplementation have shown increases in 
strength and power (94).   
This supplementation protocol has been shown to increase muscle Cr stores in 
most, but not all studies. Increases in TCr stores by 20 – 40% have been observed in 
those who normally consume relatively less meat, while the increase in TCr is slightly 
less (10 – 20%) in those who regularly consume meats (44). Approximately 20 – 30% of 
subjects do not respond to Cr supplementation (42). Greenhaff et al. (44), suggests that 
some individuals may already have TCr concentrations near the physiological limit and 
thus do not respond to additional Cr supplementation.   
Mechanisms of Action 
 Several theories explain the increased benefits in exercise performance when Cr 
supplementation is combined with resistance training (20, 28, 74, 82). Cr 
supplementation may create a more anabolic environment by influencing hormone 
concentrations and certain proteins vital in the protein synthesis pathway (20, 59).  Cr 
may contain anti-catabolic properties, which can also impact net protein synthesis (93).  
Cr supplementation can increase the ability to perform high-intensity exercise, which 
can lead to greater training adaptations over time (74).  
 In 2005, Deldicque et al. (31), in a double-blind, cross-over study hypothesized 
that Cr (21 g • d-1 • 5 d-1) supplementation would result in an anabolic environment after 
an acute bout of high-intensity resistance exercise. After 5 days of supplementation, 
participants performed 10 sets of 10 leg press repetitions at 70% of 1 repetition 
maximum (1RM). Percutaneous muscle biopsies of the vastus lateralis were collected 
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before exercise and 3 and 24 h post-exercise. Cr supplementation resulted in increased 
expression of mRNA for IGF-I and IGF-II in resting muscle. Furthermore, 
phosphorylated eukaryotic initiation factor-4e binding protein-1 (4E-BP1) was greater in 
the Cr group than in the PL group at 24 h post-exercise.  There were no significant 
differences between treatments in IGF-I, IGF-II, and p70
s6k
 post-exercise, but that may 
have been due to the small number of participants (n=6).  
 In 2008, the same group of researchers later examined the changes in gene 
expression after 5 d of Cr supplementation (21 g • d-1 • 5 d-1) in combination with an 
acute bout of heavy resistance exercise (10 sets of 10 repetitions of one leg extension at 
80% 1RM) (31). Percutaneous muscle biospies of the vastus lateralis were collected 
before, immediately after and 24 h and 72 h after exercise. Cr supplementation increased 
collagen 1 (α1) mRNA by 250% and myosin heavy chain (MHC) mRNA I at rest by 
80%, while MHCII mRNA increased by 70% immediately after exercise.  The increased 
mRNA expression of collagen 1 (α1), MHCI, and MHCII may provide a more anabolic 
environment for skeletal muscle mass accretion.  
A different study compared changes in muscle IGF-I after combining Cr 
supplementation (0.25 g • kg lean body mass • d-1 • 7 d-1[loading phase]; 0.06 g • kg lean 
body mass • d-1 • 49 d-1[maintenance phase]) with an 8-week resistance training program 
(20). Results showed the Cr group had greater concentrations of IGF-1 (78%) when 
compared to PL group (55%), although the increase was not significantly different (p 
=0.06). IGF-I has been of interest as it has been shown to increase protein synthesis and 
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stimulate certain proteins important in the mechanistic target of rapamycin (mTOR) 
pathway, which plays a pivotal role in protein synthesis (2, 31, 53).    
 Cr supplementation has been reported to have anti-catabolic properties.  Parise et 
al. (93), examined the effects of CrM supplementation on protein metabolism in young 
men and women. In a double-blind, placebo-controlled study, participants were 
randomly assigned to ingest CrM (20 g • d-1 • 5 d-1; 5 g • d-1 • 3 – 4 d-1) or PL (glucose 
polymer). Stable isotope leucine infusion was used to measure protein metabolism 
before and after supplementation. Acute CrM supplementation decreased the rate of 
leucine oxidation as well as the rate of leucine appearance in plasma only in men. It was 
not clear why Cr supplementation had anti-catabolic effects in men, but not in women.    
  The available research suggests that Cr supplementation facilitates higher 
intensity exercise performance, which can then lead to greater training adaptations over 
time (74). It is important to note that very little ATP is stored in skeletal muscle (100). 
Stored ATP typically supports a few seconds activity and therefore must be continuously 
replenished by the different energy systems. Under aerobic conditions or low-intensity 
exercise, glycolysis and oxidative phosphorylation, from the breakdown of glycogen, 
blood sugar, and triglycerides are upregulated to resynthesize ATP.  During maximal 
anaerobic conditions or high intensity exercise lasting less than 10 sec, intramuscular 
PCr provides high energy phosphates for ATP resynthesis (8, 100, 106, 120).  PCr serves 
as an energy reservoir ready to yield ATP when immediate energy is needed to support 
human movement. In a reversible reaction catalyzed by creatine kinase, PCr combines 
with adenosine diphosphate (ADP) to yield ATP and Cr.   Some suggest that fatigue 
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from short-term, high intensity exercise results from the inability to sustain ATP 
resynthesis (23). Theoretically, Cr supplementation can be used to maximize TCr 
concentration in the skeletal muscle facilitating higher intensity work. In turn, total work 
and power output may be sustained longer as the increased TCr allows for greater ATP 
resynthesis needed to meet the demands of high intensity exercise. In other words, Cr 
supplementation can result in a greater pool of PCr, which can then yield greater 
amounts of ATP resynthesized.   
Muscular Strength 
 It appears that the earliest Cr-related research involving muscular performance 
dates back to the early 1930s. In 1934, Boothby (24) reported that a glycine-rich diet 
could  delay the onset of muscular fatigue. In 1939, Ray and colleagues (101) 
hypothesized that gelatin, a glycine-rich product, supplementation would results in 
greater TCr concentrations in the muscle, which would in turn improve exercise 
performance. In this study, men were observed to have reduced muscular fatigue after a 
glycine-rich diet. In 1940, Chaikelis (24) examined the effects of glycocoll (glycine) on 
muscular strength in a single-blind, placebo-controlled study. Results indicated that 10-
weeks of glycocoll supplementation increased total strength measures. Later that century 
in 1981, Sipila et al. (107), provided Cr supplementation (1.5 g Cr • d-1) for one year as a 
nutritional therapy for gyrate atrophy. Participants reported increases in strength and one 
participant beat his personal record in the 100-meter sprint by 2 sec.   
Improvements in strengths have been observed after long-term Cr 
supplementation. Vandenburghe et al. (117), examined the effects of Cr supplementation 
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on muscle strength in young women. After being matched by strength and body mass, 
participants followed a supervised, resistance training program for 10 wk while ingesting 
Cr (20 g Cr • d-1 • 4 d-1; 5 g Cr • d-1 • 10-wk-1) supplementation or PL (maltodextrin).  10 
wk of detraining followed the supplementation and resistance training period. Cr 
supplementation promoted 20 – 25% greater strength gains in 1RM of leg press, leg 
extension, and squats. It was also determined that strength gains remained elevated in the 
Cr group than the PL following the 10 wk detraining period.  In an investigation of 
similar length, Pearson and colleagues (94) examined the effects of Cr supplementation 
on collegiate football players. In double-blind fashion, participants received Cr (5 g Cr • 
d
-1 • 10 wk-1) supplementation or PL during a 10-week resistance training program (94).  
Strength increased in bench press, squats, and power clean by approximately 3%, 12%, 
and 6%, respectively. The increase in strength gains were attributed to increases in TCr 
concentrations.  
Longer investigations have also reported improved strength performance after Cr 
supplementation. Volek et al. (120), observed significantly increased bench press and 
squat 1RM after 12-weeks of Cr (25 g Cr • d-1 • 7 d-1; 5 g Cr • d-1 • 11 wk-1) and heavy 
resistance training in young, resistance-trained males. In a different study Volek et al. 
(120),  observed significant increases in bench press (24%) and squat (32%) 
performance with Cr supplementation in conjunction with 12 wk of heavy resistance 
training. The resistance-trained participant were matched according to strength and 
anthropometric measures and in a double-blind manner, were randomly assigned to a Cr 
(25 g Cr • d-1 • 7 d-1; 5 g Cr • d-1 • 11 wk-1) group of PL (powdered cellulose). Becque et 
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al. (10), observed an ~12% increase in arm flexor 1RM after Cr supplementation (20 g 
Cr • d-1 • 5 d-1; 2 g Cr • d-1 • 6 wk-1) during a 6-week resistance training program. The 
greater strength gains associated with Cr supplementation were attributed to an increase 
in TCr, which in turn could lead to greater ATP resynthesis during exercise training.  
Improvements in strength have also been observed with shorter periods of 
supplementation. Brenner et al. (17), reported that creatine supplementation (20 g Cr • d-
1 • 7 d-1; 2 g Cr • d-1 • 28 d-1) significantly improved 1RM bench press strength (17%) 
gain in 16 female college lacrosse players during pre-season training. Earnest et al. (34), 
examined the effects Cr supplementation on strength indices in experienced weight-
trained males. In a double-blind manner participants received Cr (20 g Cr • d-1 • 14 d-1) 
or PL (glucose). The Cr group significantly increased bench press 1RM by 6% and 
bench press repetition (70% of 1RM) by 35%. These increases were not observed in the 
PL group.   
Muscular Power and Work 
 Muscular power is important in many sports, especially in tasks such as striking, 
throwing, and jumping. Cr supplementation has also been observed to increase muscular 
power in conjunction with resistance training. It is unclear why some researchers have 
observed increases in muscular power after Cr supplementation, while others have not 
(26, 113).  
Cr supplementation has been observed to improve upper body power output.  In 
2004, Volek et al. (121), studied the effects of Cr supplementation on muscular 
performance in young, resistance-trained males. In a double-blind, randomized study 
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using Cr (0.3 g Cr • kg body mass-1 • d-1 • 7 d-1; 0.05 g Cr • kg body mass-1 • d-1 • 21 d-1) 
supplementation or PL during 4 wk of resistance training. Power measures included 
ballistic bench press throws and jump squat exercises. Bench press throws were 
significantly greater in the Cr group, but not the PL group. Izquierdo et al. (60), also 
observed increase power output (~20%) during bench press performance after 5 d of Cr 
(20 g Cr • d-1 • 5 d-1) supplementation. No changes in exercise performance were 
observed with PL supplementation. However, some researchers have failed to notice 
differences in upper body power outputs during arm-Wingate tests following short-term 
Cr (20 g Cr • d-1 • 5 d-1) supplementation (41).  
Chronic high-intensity exercise can result in greater exercise performance over 
time; some researchers have observed increases in power output after relatively short 
supplementation periods of Cr supplementation. Tarnopolsky et al. (113), reported 
increased relative (W/kg) and absolute (W) peak power on a cycle ergometer after four 
days of CrM (20 g Cr • d-1 • 4 d-1) in young, recreationally active men and women. In 
this double-blind, cross-over study participants consumed CrM or PL (glucose) and 
performed an anaerobic cycling test consisting of two, 30 sec maximal cycling bouts 
separated by a 4 min rest period. After a similarly short supplementation period, Dawson 
et al. (30), noticed a significant increase in peak power on a cycle ergometer in the Cr 
group when compared to PL. Participants received Cr (20 g Cr • d-1 • 5 d-1) and 
performed repeated sprints (6 x 6 sec sprints, with 30 sec recovery) one and three days 
after Cr supplementation. Cr group performed significantly greater total work (kJ) 
during the repeated sprints. Similarly, Wiroth and coworkers (128) observed a 
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significant increase maximal power and total work in sedentary young and elderly men 
when performing five all-out 10 sec sprints on a cycle ergometer after supplementation 
following Cr (15 g Cr • d-1 • 5 d-1) supplementation.   
Improvements in muscular power have also been observed in elite level athletes.  
After 42 d of Cr (0.3g Cr • kg-1 • d-1 • 42 d-1) supplementation, Kirksey and colleagues 
(71) reported greater gains in vertical jump and power output during sprints on a cycle 
ergometer in Division IAA male and female track and field athletes. Similarly, Jones et 
al. (65), reported that Cr (20 g Cr • d-1 • 5 d-1; 5 g Cr • kg-1 • d-1 • 10 wk-1) 
supplementation improved sprinting performance during a cycle ergometer test (5, 15 
sec sprints with 15 sec recovery) and a sport-specific ice skating task (6 x 80-m sprints) 
in 16 elite ice-hockey players. Bemben et al. (12), investigated the effects of Cr 
supplementation in conjunction with resistance training on body composition in NCAA 
division I football athletes. Participants received Cr (20 g Cr • d-1 • 5 d-1; 5 g Cr • d-1 • 58 
d
-1
), PL (sodium phosphate monohydrate), or no supplementation (control group) during 
preseason training. Peak power and total work on the Wingate test performance 
increased by approximately 20% with Cr supplementation, whereas no significant 
differences were observed in the PL and control group.  
Numerous studies have reported on the performance-enhancing ability of Cr 
using explosive, high intensity exercise. Balsom et al. (6), assigned participants to ingest 
Cr (25 g Cr • d-1 • 6 d-1 + 6 g glucose) or PL (glucose only) before a high intensity cycle 
ergometer protocol consisting of ten, 6 sec bouts (30 sec rest between bouts). With Cr 
supplementation, the difference in sprint performance were noticeable after the forth 
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sprint bout, but were only significantly different after the seventh sprint bout. In a later 
study, the same researchers recruited recreationally active males to perform repeated 
bouts of high intensity exercise on a cycle ergometer before and after Cr (25 g Cr • d-1 • 6 
d
-1
) supplementation (7). The sprint protocol consisted of five, 6 sec sprints (30-sec rest 
between bouts), followed by a 40 sec rest period, then one, 10 sec sprint occurred.  
Following supplementation there were no differences in cycling performance during the 
five, 6 sec sprint; however, the Cr group showed a significantly greater power output 
during the 10 sec sprint bout.  The authors conclude that the ability to maintain a greater 
total power output during the entire cycle ergometer protocol was a direct result of 
significantly greater PCr stores.       
Increases in anaerobic performance in aerobically-trained athletes have also been 
reported. Engelhardt et al. (35), examined triathletes aerobic and anaerobic performance 
on an incremental cycle ergometer test interspersed with high intensity sprints following 
Cr (6 g Cr • d-1 • 5 d-1) supplementation. Aerobic performances during the two, 30 min 
cycling bouts were not affected by Cr supplementation; however, an increase in power 
output was observed during the interval sprints. In a similar study, Vandebuerie et 
al.(116), also examined the effects of Cr (25 g Cr • d-1 • 5 d-1) on sprinting performance 
and endurance capacity in elite cyclist. Participants performed a cycling session for 150 
minutes at their lactate threshold, followed by 5, 10 sec sprints (2 min recovery between 
sprints). Sprint performance in Cr group significantly increased peak and mean power 
output by ~9% for all sprints.  
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Even while following similar supplementation protocols, several studies have 
reported no increases in anaerobic performance. Odland et al. (91), studied the effect of 
Cr supplementation on power output during one 30 sec Wingate test. In a crossover 
design, participants were randomly assigned to Cr (20 g Cr • d-1 • 3 d-1), control (no 
beverage), and PL (beverage only). There were no power output differences during the 
Wingate test between any of the three groups.  
In a different study, Casey et al. (22), recruited nine males subjects to perform 
two bouts of 30 sec sprints on a cycle ergometer before and after Cr (20 g Cr • d-1 • 5 d-1) 
supplementation. There were no significant differences in peak work (J/kg) before and 
after Cr supplementation. Earnest et al. (34), also observed no significant differences in 
peak power during three Wingate tests following Cr (20 g Cr • d-1 • 5 d-1) 
supplementation. Using a greater amount of Cr (30 g Cr • d-1 • 5 d-1) supplementation, 
Snow and colleagues (108) evaluated repeated sprint performance on a cycle ergometer. 
They also reported no differences in sprinting performance. Interestingly, Earnest et al. 
(34), and Casey et al. (22), both reported significant increases in total work following Cr 
supplementation.    
Other researchers have used different testing modalities to observe changes in 
lower body power following Cr supplementation. Claudino et al. (26), examined the 
effect of Cr supplementation on muscular power in professional Brazilian elite soccer 
player. In a double-blind, placebo-controlled study, participants received CrM (20 g Cr • 
d
-1 • 7 d-1; 5 g Cr • d-1 • 6 wk-1) or PL (dextrose) during pre-season training. Lower limb 
power output was determined by observing ground reaction forces during counter-
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movement jumps. Jumping performance was slightly lower in PL group, but the 
difference between groups was not significantly different.   
Body Composition 
 Increases in total body mass and lean body mass have been reported following Cr 
supplementation. In 1940, Chaikelis (24) reported increases in body mass after 
participants supplemented with the Cr precursor, glycine. Many athlete and 
recreationally active individuals desire to improve the lean mass-to-fat mass ratio. 
Increasing lean mass has the potential to improve sports performance. It is well known 
that the muscular strength and power has the potential to predict success in combat 
sports such as Judo, wrestling, and boxing.  
Changes in body composition following Cr supplementation have also been 
reported in National Collegiate Athlete Association (NCAA) football athletes. Kreider et 
al. (75), examined the effects of Cr supplementation on body composition in NCAA 
division IA football players during off-season training. In a double-blind study, 
participants were matched according to total body weight and assigned to ingest Cr 
(15.75 g CrM • d-1 • 28 d-1) or PL (glucose + taurine + disodium phosphate + potassium 
phosphate) for 28 d. It is important to note that the Cr formula contained the same 
ingredients found in PL supplement. Total body mass significantly increased in both 
groups, but total body mass and fat-free mass was significantly greater in Cr group 
following 28 d of supplementation.   
Using a similar cohort, Bemben et al. (12), investigated the effects of Cr 
supplementation in conjunction with resistance training on body composition in NCAA 
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division I football athletes. In a double-blind, placebo-controlled study, participants 
received Cr (20 g Cr • d-1 • 5 d-1; 5 g Cr • d-1 • 58 d-1), PL (sodium phosphate 
monohydrate), or no supplementation (control group) during preseason training (12).  
Total body mass and lean body mass (hydrostatic weighing) were significantly increased 
by approximately 4% in the Cr group, but not in the PL or control group. Furthermore, 
total body water was significantly increased (5%) in the Cr group.    
Different investigations by Volek and colleagues (120) have also reported body 
composition changes following Cr supplementation. Resistance-trained men were 
matched according to physical characteristics and baseline strength parameters before 
commencing Cr (25 g Cr • d-1 • 7 d-1; 5 g Cr • d-1 • 11 wk-1) supplementation and a 12-
week periodized, heavy resistance exercise program. Total body mass was significantly 
greater in Cr group when compared to PL after one-week (1.7 kg) and 12-weeks (5.2 kg) 
of supplementation. Lean body mass was also significantly greater at wk 1 (1.5 kg) and 
wk 12 (4.3 kg) in Cr group when compared to PL. A few years later, Volek et al. (121), 
examined body composition (DXA) following a shorter supplementation period. Young, 
resistance-trained men received Cr (0.3 g Cr • kg body mass-1 • d-1 • 7 d-1; 0.05 g Cr • kg 
body mass
-1 • d-1 • 21 d-1) supplementation or PL during a 4 wk resistance training 
period. The Cr group, when compared to PL, experienced a significant increase in body 
mass (2.5 kg) and lean body mass (LBM) of the legs (1.6 kg). Becque and coworkers 
(11) reported less dramatic changes in body composition examined after 6 wk of Cr (20 
g Cr • d-1 • 5 d-1; 5 g Cr • d-1 • 37 d-1) supplementation. They observed a significant 
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increase in total body mass (2 kg) and lean body mass (1.6 kg) following 
supplementation.     
Aerobic Performance  
 The majority of the literature suggests Cr supplementation is mainly beneficial 
during anaerobic exercise. The research on Cr supplementation and aerobic performance 
is less voluminous. Creatine supplementation does not seem to be as beneficial to 
endurance activity as it is to anaerobic exercise.    
Some researchers postulated that increased PCr concentrations at the end of an 
endurance event could theoretically benefit an athlete performing a final sprint to the 
finish line (54). In a study by Hickner et al. (54), endurance-trained cyclist performed a 
two hour session on a cycle ergometer before and after receiving Cr (3 g Cr • d-1 • 28 d-1) 
supplementation or PL. The two hour cycling session consisted of lower intensity 
cycling (60 – 65% VO2peak) interspersed with high intensity sprints (110% VO2peak). 
Sprinting time performance and power output was not significantly influenced by Cr 
supplementation, although Cr group was found to have significantly greater TCr and PCr 
concentration prior to the cycling bout. Following similar expectations Engelhardt et al. 
(35), examined triathletes aerobic performance on an incremental cycle ergometer test 
interspersed with high intensity sprints following Cr (6 g Cr • d-1 • 5 d-1) 
supplementation. The results indicated that aerobic performance during the two, 30 min 
cycling bouts were not affected by Cr supplementation.   
In a similar study using greater amounts of Cr, Vandebuerie et al. (116), 
examined the effects of Cr (25 g Cr • d-1 • 5 d-1) on endurance capacity in elite cyclist. 
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Participants performed a cycling session for 150 min at their lactate threshold, followed 
by five, 10 sec sprints (2 min recovery between sprints). Endurance performance was not 
influenced by Cr supplementation; however, Cr supplementation increased sprinting 
performance (peak and mean power) in all five sprints. 
Theoretically, Cr supplementation may benefit endurance performance via its 
action on muscle glycogen stores. Nelson et al. (90), observed an significant increase in 
muscle glycogen content when Cr loading preceded carbohydrate loading. Young men 
carbohydrate loaded (6.6 g of carbohydrate/kg) for 3 d, consumed their normal mixed 
diet with Cr supplementation (20 g CrM/d) for 7 d, followed by a second carbohydrate 
loading protocol for three days. The researchers concluded that the Cr-induced increase 
in muscle cell volume allowed for greater glycogen storage. Furthermore, Cr 
supplementation may improve recovery after muscle damage. Cooke et al. (27), reported 
significantly greater isokinetic and isometric knee extension strength after exercise-
induced muscle damage. Participants ingested 0.3 g/kg/d of CrM for 5 d (loading dose) 
and 0.1 g/kg/d for 14 d (maintenance dose). After loading period, participants performed 
an exercise regimen meant to induce muscle damage which consisted of 4 x 10 
eccentric-only repetitions at 120% of their 1RM on leg press, leg extension, and leg 
flexion exercise machine. They observed significantly lower (~84%) plasma creatine 
kinase concentration 48, 72, 96 h, and 7 d after exercise.  
Different Forms of Creatine 
 CrM is the most researched and effective form of Cr supplementation (19). CrM 
first hit consumers in the early 1990s. Since then, novel forms of Cr have appear in the 
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marketplace with claims of being more efficacious than CrM. Novel forms of Cr have 
appeared in salt-form such as creatine pyruvate, creatine citrate, creatine malate, creatine 
phosphate, magnesium creatine, creatine orotate, and Kre-Alkalyn
®
 (1, 28, 86, 97, 98). 
Ester forms of creatine (creatine ethyl ester, creatine gluconate) have also are available. 
The claims of the aforementioned forms of Cr vary greatly. Some claim greater 
solubility in solution and bioavailability, although the bioavailability of CrM is close to 
100% (61). Other manufacturers claim greater shelf life stability although CrM shows 
little quality degradation over several years (62). Furthermore, others claim improved 
efficacy on exercise performance (28, 61).     
Kre-Alkalyn
®, a buffered form of Cr claimed to “enhance the delivery of usable 
creatine to the person taking the supplement, and overcomes the problem caused when 
creatine is converted to creatinine.  The higher the pH, the more creatine a human will 
ingest” (40).  In a recent study, Jagim et al. (63), compared the effects of CrM and Kre-
Alkalyn
®
 on muscle Cr content, body composition, and adaptations to training. In a 
double-blind manner, participants were randomly assigned to ingest CrM (20 g Cr • d-1 • 
7 d
-1
; 5 g Cr • d-1 • 21 d-1), a recommended dose of Kre-Alkalyn® (KA-L; 1.5 g Cr • d-1 • 
28 d
-1
), or Kre-Alkalyn
® with dose equivalent to CrM group (20 g Cr • d-1 • 7 d-1; 5 g Cr • 
d
-1 • 21 d-1). Results indicated that FCr content in muscle significantly increase in all 
group; however, there were greater changes in muscle Cr content with CrM 
supplementation. Furthermore, it was determined that Kre-Alkalyn
® 
did not promote 
greater changes in body composition, strength, or anaerobic performance than CrM 
supplementation.   
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Effervescent creatine citrate claims to have more optimal properties of digestion 
and absorption, thereby allowing greater creatine retention in the body. Greenwood et al. 
(46), examined whole body Cr retention after comparing several forms of Cr 
supplementation, including effervescent creatine citrate. No differences were observed in 
whole body Cr retention between CrM and effervescent creatine citrate; however, the 
group receiving CrM + dextrose was shown to have significantly greater whole body 
retention of Cr.  
 Manufacturers have also attempted to suspend Cr in solution with claims of 
greater transport to the muscle. To test this claim Kreider et al.(73), compared the 
influence of liquid ATP Advantage™ Creatine Serum (CS) and CrM on muscle ATP, 
FCr, PCr, and TCr concentration after 5 d of supplementation. In a randomized and 
double-blind manner, participants were assigned to ingest 5 mL CS (2.5 g of CrM 
equivalent), 5 mL PL, 40 mL CS (20 g of CrM equivalent), 40 mL PL, or 20 g of CrM 
(control). Results indicated that the recommended dose of CS as well as the higher dose 
of CS (8 times greater than recommended dose) is not effective at increasing FCr or PCr 
concentrations. Furthermore, FCr concentration significantly increased only with CrM 
supplementation. According to this study, findings did not support the claims purported 
by the liquid creatine product.   
Some researchers have noticed that salt-forms of Cr dissolve more easily in 
solution than CrM, and therefore there may be a basis for greater uptake when Cr is in its 
salt-form. Jager et al. (61), examined various forms of Cr to determine uptake kinetics.  
Participants, in a balanced cross-over study, ingested isomolar amounts of Cr as creatine 
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monohydrate (CrM; 5 g), tri-creatine citrate (CrC; 6.7 g), or creatine pyruvate (CrPyr; 
7.3 g). Plasma Cr concentrations were significantly greater for CrPyr 1 h after ingestion. 
Mean peak concentrations were found to be significantly greater in CrPyr when 
compared to CrC, but CrPyr was not greater than CrM. The findings may suggest that 
different forms of Cr have slightly different absorption kinetic. Also, it is unclear if the 
kinetics of Cr absorption would influence muscle Cr content and exercise performance 
as neither were performed in this study.      
Creatine ethyl ester (CEE) has also been purported to increase the bioavailability 
of Cr.  In 2009, Spillane et al. (109), examined the effects of CEE supplementation 
during a standardized, resistance training program. Participants ingested CrM (0.3 g Cr • 
kg
-1 • d-1 • 5 d-1; 0.075 g Cr • d-1 • d-1• 42 d-1), CEE (0.3 g Cr • kg-1 •  d-1 • 5 d-1; 0.075 g 
Cr • d-1 • d-1• 42 d-1), or PL for 7 wk. Plasma Cr concentrations were not significantly 
greater with CEE when compared to CrM or PL. Although muscle Cr content increased 
with CrM and CEE, there was no significant difference between the two groups. 
Researchers conclude that CEE was not as effective at increase plasma and muscle Cr 
content when compared to CrM.  Furthermore, CEE did not seem to improve body 
composition or muscular strength and power when compared to CrM supplementation.  
Creatine phosphate (CrP) supplementation appears to have some beneficial 
effects. Peeters et al. (95), examined different forms of Cr on strength, body 
composition, and blood pressure. Resistance-trained participants were matched 
according to strength measured and were then were assigned to ingest CrM (20 g Cr • d-1 
• 3 d-1; 10 g Cr • d-1 • 39 d-1), CrP (20 g Cr • d-1 • 3 d-1; 10 g Cr • d-1 • 39 d-1), or PL. The 
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findings indicated similar increases in 1RM bench press strength, total body mass, and 
lean body in CrM and CrP groups. The increases in 1RM bench press strength, total 
body mass, and lean body mass were greater in CrM when compared to CrP, but the 
differences were not significant. Although CrP supplementation resulted in comparable 
gains in this study others have reported that CrP is more expensive to produce, thus 
making CrM supplementation a more economical choice (19).   
 Creatine nitrate (CrN) is a novel form of Cr that has gained some recent 
attention. A recent study examined the safety profile of CrN (66). Participants were 
randomly assigned to consume either 1 g or 2 g of CrN/d for 28 d.  A complete blood 
and chemistry panel was determined on blood samples collected before and after 
supplementation. Joy et al. (66), reported that all hematological safety markers were 
within normal physiological range following supplementation and therefore, concluded 
CrN supplementation to be safe to consume. Figure 1 shows the chemical structure of 
CrM, while Figure 2 shows the chemical structure of CrN.   
 
 
 
 
 
Figure 1. Chemical Structure of Creatine Monohydrate 
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Figure 2. Chemical Structure of Creatine Nitrate 
 
 
Nitrates and Nitrites 
Inorganic nitrate (NO3
-
) is an ion exhibiting limited synthesis in the body, 
therefore usually obtained from the diet via green leafy vegetables, while nitrites (NO2
-
) 
are also found in food including as processing additives, but to a much lesser degree. 
Dietary sources of nitrates can get metabolized to nitrites.  In turn, nitrates and nitrites 
can serve as precursors to the bioactive compound nitric oxide (NO).  Dietary nitrate and 
nitrites are the main precursor to NO via the nitric oxide-independent pathway, which 
was discovered in 1990 (13, 84). NO is well known for its vasodilatory effect and thus 
its influence on blood pressure (14). The ergogenic aid potential of nitrate 
supplementation lies in its ability to modulate muscle force production, blood flow, and 
mitochondrial respiration (110). Many investigators have relied on sodium nitrate and 
beet root juice (BRJ) to supply dietary sources of nitrates.  
One of the first to investigate nitrate supplementation and its effect on blood 
pressure (BP) was Larsen and colleagues (79). In a randomized, double-blind, crossover 
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study, Larsen et al., examined the effects of sodium nitrate (0.1 mmol • kg-1 • d-1) and PL 
(sodium chloride) on BP in young, healthy volunteers. Researchers found that nitrate 
supplementation did not affect heart rate (HR) or systolic BP (SBP). On the other hand, 
diastolic BP (DBP) and mean arterial pressure were significantly reduced by 3.7 mm Hg 
and 3.2 mm Hg, respectively. Webb et al. (123), also measured BP following nitrate 
supplementation. In an open label, crossover study, participants ingested 0.5 L of BRJ 
(1,395 mg nitrate) or water.  Serial sampling of BP was taken over the course of 6 h and 
again at 24 h post supplementation.  BRJ supplementation resulted in significant increase 
in plasma nitrate concentrations after 30 min and remained elevated for 6 h (peaked at 
1.5 h). Plasma nitrite concentrations were found to be significantly elevated at 3 h and 4 
h post-supplementation. Significant reductions in SBP were observed at 2.5 h (10.4 mm 
Hg), while DBP was significantly reduced at 3 h (8.1 mm Hg) post-supplementation. 
BRJ supplementation was found to have no impact on HR. However, not all 
investigators have reported the same results. Murphy and coworkers (89) administered 
whole beetroot (>500 mg nitrate) to men and women and observed no changes in HR or 
BP 60 min post-administration.   
Changes in endurance performance have been reported in moderately trained 
individuals (78, 81). Larsen et al. (78), reported reduced oxygen consumption and 
improved mechanical efficiency during work rates intensities of 40 – 80% of VO2peak 
with sodium nitrate (0.1 mmol • kg-1 • d-1 • 3 d-1). In a different study, Larsen and 
colleagues (81) reported significantly reduced oxygen consumption at VO2peak after 
nitrate supplementation equivalent to the amount found in 100-300 g of nitrate-rich food.    
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Participants performed incremental exercise to volitional fatigue with arm and leg 
cranking ergometers on two different ergometers after supplementation. It was 
concluded that the increase NO production, via nitrate supplementation, is modulating 
mitochondrial respiration and therefore directly influencing endurance exercise.  
Improvements in mitochondrial respiration were determined as the ratio of oxygen 
consumed per ATP produced.   
Sodium nitrate supplementation was also used in conjunction with endurance 
performance in highly trained individuals. Bescos et al. (15), investigated the impact of 
highly trained cyclist and triathletes ingesting sodium nitrate (10 mg • kg-1) before a 
cycle ergometer test. The exercise test consisted of a submaximal and maximal exercise 
portion. The submaximal exercise bouts, each lasting six minutes, corresponded to 2, 
2.5, 3, and 3.5 W• kg-1 body mass (3 min recovery between bouts). A continuous 
incremental exercise test to exhaustion (maximal exercise) followed the submaximal 
exercise bout. The findings show a significant reduction in VO2peak without influencing 
time to exhaustion or maximal power outputs.   
Other researchers have used beetroot juice as a way to provide supplemental 
nitrates. Bailey et al. (5), have also reported changes in oxygen consumption during 
submaximal exercise following nitrate supplementation. In this double-blind, placebo-
controlled, crossover study participants consumed 500 mL of BRJ (~695 mg nitrate) or 
PL (blackcurrant cordial) for 6 days. Various submaximal and maximal exercise tests 
occurred on the last three days of supplementation. There was a significant reduction in 
systolic blood pressure (-6 mm Hg), but no changes in mean arterial pressure or diastolic 
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blood pressure were observed. Findings suggest a reduction in muscle fractional oxygen 
extraction during submaximal exercise only with BRJ supplementation. Furthermore, 
there appears to be a reduction in oxygen consumption and a concomitant increase in 
time-to-exhaustion with BRJ supplementation.    
Some have investigated the effects of nitrate supplementation in longer duration 
endurance activity. Wilkerson et al. (125), examined the effects of nitrate 
supplementation on time trial performance in well-trained cyclist (influence of acute 
dietary nitrate supplementation on 50 mile time trial performance in well-trained 
cyclist). Participants received a single bolus of 0.5 L of BRJ (~385 mg nitrate) or PL 2.5 
hrs before a 50-mile time trial. BRJ supplementation was found to have no effect on 
systolic, diastolic, or mean arterial blood pressure. Time trial performance was not found 
to be significantly different between groups, although BRJ supplementation results in 
slightly reduced time to completion (BRJ: 136.7 min versus PL: 137.9 min). Similarly, 
mean power output during the trial was no different between groups.  
Most research determining the ergogenic value of nitrate supplementation has 
been completed with aerobic exercise. Additionally, others have examined the effects of 
nitrate supplementation on aerobic exercise under hypoxic conditions. Muggeridge et al. 
(88), investigated the effects of a single dose of BRJ on submaximal and time trial 
performance in simulated altitude (~2500 meters). In a double-blind, crossover study, 
young, amateur cyclist performed 15 min of submaximal cycling at moderate-intensity 
work rate followed by a 16.1 km time trial after ingesting BRJ (310 mg nitrate) or PL 
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supplementation. Finding indicated a significant decrease in oxygen consumption during 
submaximal cycling and improved time-trial performance with BRJ supplementation.   
Vanhatalo et al. (118), hypothesized that nitrate supplementation would 
ameliorate the negative effects of hypoxia on muscle metabolism and oxidative function.  
To test this hypothesis, recreationally active participants performed knee-extension 
exercises under normoxia and hypoxia conditions after nitrate supplementation (~575 
mg nitrate) or PL. Muscle metabolism assessed via phosphorous magnetic resonance 
spectroscopy (
31
P-MRS) showed greater PCr recovery with BRJ supplementation during 
hypoxic conditions. Under hypoxic conditions, BRJ supplementation resulted in a 
significant increase in tolerance during high-intensity knee-extension exercise when 
compared to PL. In support of these findings, Bailey et al., also reported a significant 
reduction (36%) in PCr degradation and a contaminant decline (21%) in inorganic 
phosphate (known to depress contractile function) accumulation during low- and high-
intensity exercise with BRJ (~315 mg nitrate) supplementation (4).   
 Dietary nitrates are found primarily in plant-based foods such as fruits and 
vegetables (56). The dietary approach to stop hypertension (DASH) diet typically 
emphasizes a diet rich in fruits, vegetables, and low-fat dairy products. The DASH diet 
is recommended in national guidelines due to the health benefits associated with a diet 
rich in fruits and vegetables (25). The DASH diet recommends 4 – 5 daily servings each 
of fruits and vegetables. Celery, lettuce, red beetroot, and spinach are known to contain 
very high concentrations of nitrate (>250 mg nitrate/100 g food), while artichokes, 
asparagus, green beans, tomato, and watermelon are known to contain very low 
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concentrations of nitrate (<20 mg nitrate/100 g food) (105). Researchers have reported 
that the daily nitrate concentration of the DASH diet can vary from ~175 to ~1220 mg 
nitrate by consuming low-nitrate or high-nitrate fruits and vegetables (56). Ingesting 
approximately 1220 mg nitrate can be accomplished by consuming the following: 1 cup 
raw spinach, 0.5 cup cooked collard greens, 0.5 cup vegetable juice, 1 medium banana, 
0.25 cup raisins, 1 medium orange, and 0.5 cup pomegranate juice. The World Health 
Organization current acceptable daily intake for dietary nitrate is 0 – 3.7 mg nitrate/kg 
body weight (25).  For a 70 kg individual this equates to approximately 260 mg nitrate.  
Some researchers have criticized the rationale limiting nitrate consumption from plant 
foods (56).       
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CHAPTER III 
METHODS 
 
Experimental Design and Approach to Problem   
A longitudinal research design was employed to assess two different studies.  
Study 1 examined the acute hemodynamic and dose effect of ingesting two doses of 
creatine nitrate (CrN) compared to creatine monohydrate (CrM) and placebo (PL). Study 
2 examined the effects of 28 days of two doses of CrN compared to CrM and PL on 
muscle creatine (Cr) content, body composition, and exercise performance in 
recreationally active males.  
Study 1 – Acute Supplementation  
Independent and Dependent Variables 
Independent variables – The independent variables consisted of 1) Placebo  (PL: 
6.5 g dextrose), 2) Creatine Monohydrate (CrM: 5 g CrM, 1.5 g dextrose), 3) Creatine 
Nitrate-lower dose (CrN-L: 1.5 g CrN [1 g Cr, 0.5 g nitrate], 5 g dextrose), and 4) 
Creatine Nitrate-higher dose (CrN-H: 3 g CrN [2 g Cr, 1 g nitrate], 3.5 g dextrose) 
Dependent variables – The dependent variables include body composition 
(DXA), heart rate (HR), blood pressure, blood chemistries, and side effects 
questionnaire.  
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Study Site 
 All laboratory testing was conducted in the Exercise & Sport Nutrition 
Laboratory. This laboratory is located in the Department of Health and Kinesiology at 
Texas A&M University in College Station, Texas.  
Familiarization 
 Participants were required to have been actively involved in a resistance training 
program for at least six months consisting of upper and lower body training. Participants 
were required to have not had a history of treatment for metabolic disease (e.g., diabetes, 
hypertension, thyroid disease, arrhythmias, and/or cardiovascular disease. Furthermore, 
participants were required to not have currently used prescription medication, a history 
of smoking, or to drink excessively (i.e., 12 alcoholic drinks per week or more). Lastly, 
participants were required to have not had used creatine supplements in the six weeks 
prior to starting the study. Participants meeting entrance criteria were scheduled for 
familiarization session. 
Prior to testing, participants were required to participate in a familiarization 
session in which guidelines of were explained and outlined. Participants were 
familiarized with the study protocol including measurements of body composition 
measurements, heart rate, blood pressure, and blood collection procedures. Information 
related to dietary records and side effect questionnaires were also explained during this 
session. Participants meeting entry criteria were asked to grant consent to continuation in 
the study by signing an informed consent form as approved by the Institutional Review 
Board of Texas A&M University. Once consent was granted, participants were asked to 
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complete a medical history questionnaire which was to be reviewed by a registered 
nurse. After the familiarization session, the participants were scheduled to return to the 
lab for four different testing sessions (i.e., testing session 1 – 4). At each testing session 
the participants received one of four different supplements – 1) PL (6.5 g dextrose), 2) 
CrM (5 g CrM, 1.5 g dextrose), 3) CrN-L (1.5 g CrN [1 g Cr, 0.5 g nitrate], 5 g dextrose) 
or 4) CrN-H (3 g CrN [2 g Cr, 1 g nitrate], 3.5 g dextrose).  
Participants   
Thirteen male participants volunteered to participate in Study 1 (22 ± 5 y, 177.8 
± 7.4 cm, 84.1 ± 18.9 kg). The study was conducted using a double-blind, randomized, 
and crossover design separated by 1 wk. All testing sessions were started at the same 
time of day for each testing session.  
Experimental Design 
Participants were asked to fast for 8 h and refrain from exercise, alcohol, non-
steroidal anti-inflammatory drugs, and high nitrate-containing foods 48 h prior to all 
testing sessions. Participants turned in their food records upon arrival to the lab. Next, 
participants were weighed and body composition was determined via dual energy x-ray 
absorptiometry (DXA) scan. Initial measures (time 0) were assessed, followed by 
supplementation ingestion and serial sampling (0.5, 1, 2, 3, 4, 5 h) post-supplementation. 
The collected measures included HR, blood pressure, and blood samples.  
In a randomized, double-blind, and crossover manner, participants ingested 1) PL 
(6.5 g dextrose), 2) CrM (5 g CrM, 1.5 g dextrose), 3) CrN-L (1.5 g CrN [1 g Cr, 0.5 g 
nitrate], 5 g dextrose) or 4) CrN-H (3 g CrN [2 g Cr, 1 g nitrate], 3.5 g dextrose). 
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HR was determined by palpation of the radial artery using standard procedures 
and blood pressure was also assessed using standard procedures (115). Participants 
provided a fasted blood sample (8 h) via venipuncture, using intravenous (IV) 
catheterization (BD Insyte Autoguard, Bection, Dickinson and Company, Franklin 
Lakes, NJ) from the antecubital vein in the forearm according to standard phlebotomy 
procedures. Blood samples were collected before supplementation (time 0) and 0.5, 1, 2, 
3, 4, 5 h post-supplementation.   
Self-reported side effects questionnaire were completed at each time point 
following supplementation. Dietary intake was not controlled, but participants recorded 
their dietary intake prior to each testing session. Figure 3 outlines the events of Study 1.  
Figure 4 outlines an individual testing session within Study 1. 
Study 1 – Procedures  
Supplementation Protocol 
Participants were assigned in a double-blind, randomized, and crossover fashion 
to ingest 1) PL (6.5 g dextrose), 2) CrM (5 g CrM, 1.5 g dextrose), 3) CrN-L (1.5 g CrN 
[1 g Cr, 0.5 g nitrate], 5 g dextrose) or 4) CrN-H (3 g CrN [2 g Cr, 1 g nitrate], 3.5 g 
dextrose) with at least a 7 d washout period between testing sessions. Subjects consumed 
one serving of the supplement mixed with approximately 8 oz of water. All supplements 
were supplied to the investigator in a double-blind fashion.  Initial measures  
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Figure 4. Study 1 Testing Session Timeline 
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(time 0), followed by supplement ingestion and serial sampling (0.5, 1, 2, 3, 4, 5 h) 
occurred at each testing session. Certificate of analysis from Thermo-Life International 
can be found in appendix E. 
Dietary Records and Analysis 
 After familiarization and prior to baseline testing, participants completed a 
dietary record to include 3 weekdays and 1 weekend day. Participants were asked to 
record all food and beverage consumption except water. Dietary recording then took 
place prior to each successive testing session corresponding to wk 1, 2, 3, and 4. All 
food logs were entered and analyzed by a registered dietitian using dietary analysis 
software (ESHA Food Processor Version 8.6, Salem, OR). 
Body Composition Testing 
 Body composition testing took place at each testing session which corresponds to 
wk 1, 2, 3, and 4. Participants reported to the Exercise and Sport Nutrition Laboratory 
(ESNL) on the assigned testing session day. Prior to testing, participants were asked to 
fast for at least 8 h. Height and weight were recorded to the nearest 0.01 lb and 0.1 in., 
respectively, using a self-calibrating digital scale (Health-O-Meter, Bridgeview, IL, 
USA) in socks or bare feet. Body composition was then determined using dual energy e-
ray absorptiometry (DXA) technology (Hologic Discovery W DXA APEX Systems 
software version 4.0.2, Waltham, MA). Previous studies indicate DXA to be an accurate 
and reliable means to assess changes in body composition (3). For determination of body 
composition, participants removed all metal objects that are known to interfere with 
measurement. Participants were then positioned in the supine position based on 
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manufacture’s guidelines by a trained technician. DXA measurement was then 
performed; taking approximately 6 – 8 min. Analysis was immediately performed by a 
trained technician to determine body composition. Test/retest reliability studies 
performed on male athletes with DXA yielded mean deviation for total bone mineral 
content and total fat-free/soft tissue mass of 0.31-0.45%, with a mean intra-class 
correlation of 0.985 (3). 
Blood Collection 
 Participants abstained from exercise, alcohol, and non-steroidal anti-
inflammatory drugs 48 h prior to each testing session. Participants provided a fasted 
blood sample (8 h) via venipuncture, using intravenous (IV) catheterization (BD Insyte 
Autoguard, Bection, Dickinson and Company, Franklin Lakes, NJ) from the antecubital 
vein in the forearm according to standard phlebotomy procedures. Approximately 20 mL 
of whole blood was collected at each time point (i.e., 0, 0.5, 1, 2, 3, 4, 5 h) in three, pre-
chilled, 10-mL (18 mg K2 ethylene-diaminetera-acetic acid) tubes (BD Hemogard, 
Franklin Lakes, New Jersey). The 10-mL EDTA tubes were pre-chilled on ice and 
immediately placed back on ice after each blood sampling period. Collection tubes were 
centrifuged at 3000 x g for 10 min at 4°C within 3 min of collection. Plasma was 
subsequently extracted and stored at -80°C for later analysis. 
Plasma Creatine and Nitrate Assessment  
Calorimetric assay kits were used to measure plasma Cr (Sigma-Aldrich, St. 
Louis, MO) and plasma nitrate (Cayman Chemical, Ann Arbor, MI) concentrations.  
Test-to-test variability of performing these assays yielded mean coefficient of variation 
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(Cv) values for plasma nitrate (±3.21%) and plasma Cr (±6.66%) with a test/retest 
correlation of r=0.98 and r=0.99 for plasma nitrate and Cr, respectively.  
Hematologic Profile  
Plasma was analyzed for alkaline phosphatase (ALP), aspartate transaminase 
(AST), alanine transaminase (ALT), creatinine, blood urea nitrogen (BUN), creatine 
kinase (CK), lactate dehydrogenase (LDH), glucose, and blood lipids (total cholesterol 
(TCHL), high density lipoprotein [HDL], low density lipoprotein [LDL], triglycerides 
[TG]) using a Cobas
®
 c 111 (Roche Diagnostics, Basel, Switzerland). The Cobas
® 
automated clinical chemistry analyzer was calibrated according to manufacturer 
guidelines. This analyzer has been known to be highly valid and reliable in previously 
published reports (64). The internal quality control for the Cobas c 111 was performed 
using two levels of control fluids purchased from manufacturer to calibrate acceptable 
SD and Cv values for all aforementioned assays. Samples were re-run if the observed 
values were outside control values and/or clinical norms according to standard 
procedures.    
Heart Rate Measurement 
 Resting heart rate was determined at each time point (i.e., 0, 0.5, 1, 2, 3, 4, 5 h) 
by palpitation of the radial artery using standard procedure (115). HR measurement at 
time 0 was performed immediately following the DXA, in the supine position. The 
remaining HR measurements occurred in the seated position prior to blood sampling. 
Trained technicians counted the pulse for 15 sec to determine the number of beats per 
minute.  
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Blood Pressure Measurement 
 Blood pressure was determined at each time point (i.e., 0, 0.5, 1, 2, 3, 4, 5 h) by 
auscultatory method using standard procedure (115). This proceeded immediately after 
determining heart rate. Blood pressure measurement at time 0 was performed in the 
supine position. The remaining blood pressure measurements occurred in the seated 
position prior to blood sampling.   
Side Effect Assessment 
Table 1 presents the side effects questionnaire used.  Participants were given 
questionnaires at each testing session to determine how well participants tolerated 
supplementation; how well participants followed the supplementation protocol; and if 
participants experienced any symptoms as a result of the supplement. Compliance to the 
supplementation protocol was monitored by supplement logs and verbal confirmation.  
The side effect questionnaire was completed immediately after the each of the following 
blood sampling time points (0.5, 1, 2, 3, 4, 5 h). Participants were asked to rank the 
frequency and severity of their symptoms – dizziness, headache, tachycardia, heart 
skipping or palpitations, shortness of breather, nervousness, blurred vision, and unusual 
or adverse effects. Participants were asked to rank their symptoms with 0 (none), 1 
minimal: 1-2/wk), 2 (slight: 3-4/wk), 3 (occasional: 5-6/wk), 4 (frequent: 7-8/wk), or 5 
(severe: 9 or more/wk). We reported frequency and severity ranked greater than or equal 
to 2 (slight: 3-4/wk).  
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Table 1: Study 1: Side Effects Questionnaire 
Time Point 0.5-h 1-h 2-h 3-h 4-h 5-h 
Rate the frequency of the following 
symptoms according to the scale where: 
0 = none 
1 = minimal (1-2 per/wk) 
2 = slight (3-4 per/wk) 
3 = occasional (5-6 per/wk) 
4 = frequent (7-8 per/wk)  
5 = severe (9 or more per/wk) 
      
Dizziness?       
Headache?       
Tachycardia?       
Heart skipping or palpitations?       
Shortness of breath?       
Nervousness?       
Blurred Vision?       
Any other unusual or adverse effects?       
Rate the severity of the following symptoms 
according to the scale where: 
0 = none 
1 = minimal  
2 = slight 
3 = moderate 
4 = severe  
5 = very severe  
      
Dizziness?       
Headache?       
Tachycardia?       
Heart skipping or palpitations?       
Shortness of breath?       
Nervousness?       
Blurred Vision?       
Any other unusual or adverse effects?       
 
 
Study 2 – Chronic Supplementation 
Independent and Dependent Variables 
Independent variables – The independent variables consisted of 1) placebo (PL: 
6.5 g dextrose), 2) creatine monohydrate (CrM: 3 g CrM, 0.5 g flavoring, 2 g dextrose), 
3) CrN-lower dose (1.5 g CrN [1 g Cr, 0.5 g nitrate], 0.5 g flavoring, 3.5 g dextrose), and 
4) CrN-higher dose (3 g CrN [2 g Cr, 1 g nitrate], 0.5 g flavoring, 2 g dextrose).  
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Dependent variables – The dependent variables include muscle Cr content, body 
composition (DXA), blood chemistries, bench press performance, anaerobic sprint 
performance on a cycle ergometer, and side effects questionnaire.  
Study Site 
 All laboratory testing was conducted in the Exercise & Sport Nutrition 
Laboratory.  This laboratory is located in the Department of Health and Kinesiology at 
Texas A&M University in College Station, Texas.  
Familiarization  
 Participants were required to have been actively involved in a resistance training 
program for at least six months consisting of upper and lower body training. Participants 
were required to have not had a history of treatment for metabolic disease (e.g., diabetes, 
hypertension, thyroid disease, arrhythmias, and/or cardiovascular disease. Furthermore, 
participants were required to not have currently used prescription medication, a history 
of smoking, or to drink excessively (i.e., 12 alcoholic drinks per wk or more). Lastly, 
participants were required to have not had used Cr supplements in the 6 wk prior to 
starting the study. Participants meeting entrance criteria were scheduled for 
familiarization session. 
Prior to testing, participants were required to participate in a familiarization 
session in which guidelines of were explained and outlined. Participants were 
familiarized with the study protocol including measurements of body composition 
measurements, blood collection procedures, biopsies, and exercise tests measures.  
Participants also completed a 1 repetition maximum (1RM) bench press test and a 
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practice anaerobic sprint practice test. Strength tests were performed using a standard 
isotonic Olympic bench press according to standard procedures (68). Participants 
followed a standard warm-up consisting of 10 repetitions using 50% of their estimated 
1RM, 5 repetitions using 70% of their estimated 1RM, and 1 repetition using 90% of 
their estimated 1RM. Previous research in our lab on resistance-trained participants have 
yielded a low day-to-day mean coefficients of variation and high reliability for the bench 
press (1.1%, intra-class, r=0.99). Information related to dietary records and side effect 
questionnaires were also explained during this session. Participants meeting entry 
criteria were asked to grant consent to continuation in the study by signing an informed 
consent form as approved by the Institutional Review Board of Texas A&M University.  
Once consent was granted, participants were asked to complete a medical history 
questionnaire which was to be reviewed by a registered nurse. After the familiarization 
session, the participants were scheduled to return to the lab and assigned to a treatment 
group. The four treatment groups were 1) PL (6.5 g dextrose), 2) CrM (3 g CrM, 0.5 g 
flavoring, 2 g dextrose), 3) CrN-L (1.5 g CrN [1 g Cr, 0.5 g nitrate], 0.5 g flavoring, 3.5 
g dextrose), and 4) CrN-H (3 g CrN [2 g Cr, 1 g nitrate], 0.5 g flavoring, 2 g dextrose).  
After the familiarization session participants were scheduled for subsequent testing 
sessions and were asked to start the standardized resistance training program 2 wk prior 
to their next laboratory visit. Exercise testing occurred on d 0 and d 28.   
Participants  
 Forty-eight, recreationally active, males volunteered to participate in Study 2 (21 
± 3 y, 176.8 ± 5.8 cm, 77.4 ± 20.9 kg). All testing sessions were started at the same time 
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of day for each testing session. Participants were asked to follow a standardized 
resistance training program two weeks before their baseline testing session (d 0) and 
continued throughout the remained of the supplementation period. Participants were 
asked not to change their dietary intake throughout the investigative period.   
Experimental Design 
Participants arrived to the laboratory on d -1, 0, 7, 27, and 28; a total of five 
laboratory visits.  A percutaneous muscle biopsy of the vastus lateralis was obtained 
from the participant’s right leg on testing sessions corresponding to d -1, 7, and 27 using 
a modified Bergstrom needle biopsy technique following standard procedures (36). 
Participants were asked to fast for 12 h and refrain from exercise, alcohol, and non-
steroidal anti-inflammatory drugs 48 h prior to d 0, 7, and 28. Participants turned in their 
food records upon arrival to the lab on d 0, 7, and 28. Next, participants were weighed 
and body composition was determined via dual energy x-ray absorptiometry (DXA) 
scan.  Total body water was determined next via bioelectrical impedance analysis (BIA). 
A fasted blood sample was collected after determining body composition. On d 7, 
participants completed the testing session with a muscle biopsy. On d 0 and 28, after the 
blood sample collection, participants continued with the exercise tests, which consisted 
of a bench press test and an anaerobic sprint test.   
After baseline testing (d 0) participants were randomly assigned, in a double 
blind fashion and matched to body weight, to ingested 1) PL (6.5 g dextrose), 2) CrM (3 
g CrM, 0.5 g flavoring, 2 g dextrose), 3) CrN-L (1.5 g CrN [1 g Cr, 0.5 g nitrate], 0.5 g 
flavoring, 3.5 g dextrose), and 4) CrN-H (3 g CrN [2 g Cr, 1 g nitrate], 0.5 g flavoring, 2 
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g dextrose). A side effect questionnaire was completed weekly after the first week of 
supplementation.  Figure 5 outlines the Study 2 timeline. 
Study 2 – Procedures  
Supplementation Protocol  
Participants were assigned in a double-blind and counter-balanced manner to 
ingest of 1) PL (6.5 g dextrose), 2) CrM (3 g CrM, 0.5 g flavoring, 2 g dextrose), 3) 
CrN-L (1.5 g CrN [1 g Cr, 0.5 g nitrate], 0.5 g flavoring, 3.5 g dextrose), and 4) CrN-H 
(3 g CrN [2 g Cr, 1 g nitrate], 0.5 g flavoring, 2 g dextrose). Participants were asked to 
ingest 4 doses per day (at approximately 0800, 1200, 1600, and 2000 h) on d 0 through 7 
(loading phase). During the loading phase participants ingested a total of 1) PL (26 g 
dextrose/d), 2) CrM (12 g CrM+2 g flavoring+8 g dextrose/d), 3) CrN-L (6 g CrN+2 g 
flavoring+14 g dextrose/d), and 4 CrN-H (12 g CrN+2 g flavoring+8 g dextrose/d). 
Thereafter, participants ingested supplements one dose, one time per day (maintenance 
phase) for the remainder of the study (d 8 – 28). During the maintenance phase 
participants ingested a daily total of 1) PL (6.5 g dextrose), 2) CrM (3 g CrM, 0.5 g 
flavoring, 2 g dextrose), 3) CrN-L (1.5 g CrN [1 g Cr, 0.5 g nitrate], 0.5 g flavoring, 3.5 
g dextrose), and 4) CrN-H (3 g CrN [2 g Cr, 1 g nitrate], 0.5 g flavoring, 2 g dextrose). 
All supplements were provided by Nutrabolt International (Bryan, TX).    
Training Protocol and Analysis  
 All participants were required to follow the same resistance training 
routine.  The resistance training routine consisted of exercise 4-d/wk split into two upper 
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Figure 5. Study 2 Timeline 
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and two lower body workouts per week for a total of 6 wk.  The 6 wk training protocol 
was periodized in 3 wk increments consisting of selected exercises for the following 
muscle groups: chest (two exercises for a total of six sets), back (two exercise for a total 
of six sets), shoulders (one exercise for a total of three sets), biceps (one exercise for a 
total of three sets), triceps  (one exercise for a total of three sets), abdominals (one 
exercise for a total of three sets), quadriceps (two exercises for a total of six sets), 
hamstrings (two exercises for a total of six sets), and calves (one exercise for three sets). 
Each exercise consisted of three sets of 10 repetitions (wk 1 – 3) or 8 repetitions (wk 4 – 
6) performed with as much weight as the participant could perform per set.   
Training logs were completed and maintained by each participant. The 
participants recorded the amount of weight lifted during each set on a training log. 
Training sessions were monitored by a training partner or fitness instructor who signed 
off that the session was completed. Total lifting volume was calculated for each subject 
per exercise session and for the entire training program.   
Dietary Records and Analysis 
 Participants recorded all caloric intakes from food and beverages for 4 d prior to 
three labs – d 0, 7, and 28. Participants were asked to record all food and beverage 
consumption except water. After familiarization and prior to the first performance 
testing session (d 0), participants completed a dietary record to include 3 weekdays and 1 
weekend day.  Dietary recording then took place prior to testing on d 7 and 28. All food 
records were entered and analyzed by a registered dietitian using dietary software 
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(ESHA Food Processor Version 8.6, Salem, OR). All participants were instructed to 
maintain their normal mixed diet throughout the training and supplementation period.   
Blood Collection 
 Approximately 20 mL of whole blood was collected at each testing session on d 
0, 7, and 28.  Three, 10-mL (18 mg K2 ethylene-diaminetera-acetic acid) tubes (BD 
Hemogard, Franklin Lakes, New Jersey) were pre-chilled. The 10-mL EDTA tubes were 
pre-chilled on ice and immediately placed back on ice after each blood sampling period. 
Two collection tubes were centrifuged at 3000 x g for 10 min at 4°C within 3 min of 
collection. One collection tube was stored at -4°C for approximately 5 h for complete 
blood count on whole blood. Plasma was subsequently extracted and stored at -80°C for 
later analysis. 
Plasma Creatine and Nitrate Analysis  
Calorimetric assay kits were used to measure plasma Cr (Sigma-Aldrich, St. 
Louis, MO) and plasma nitrate (Cayman Chemical, Ann Arbor, MI) concentrations. 
Test-to-test variability of performing these assays yielded mean Cv values for plasma 
nitrate (±4.46%) and plasma Cr (±4.95%) with a test/retest correlation of r=0.98 and 
r=0.99 for plasma nitrate and Cr, respectively. 
Muscle Biopsies   
A percutaneous muscle biopsy of the vastus lateralis was obtained from the 
participant’s right leg on testing sessions corresponding to d -1, 7, and 27 using a 
modified Bergstrom needle biopsy technique following standard procedures (36). 
Muscle samples were assessed for Cr concentrations.  
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 In the supine position, the region around the biopsy site was shaved and sterilized 
with 3 povidone-iodine swab sticks (Professional Disposables International, Inc, 
Orangeburg, NY). Lidocaine HCl (1%) was injected underneath the skin, followed by an 
injection through the fascia and to the epidermis using a 10 mL syringe to anesthetize the 
biopsy region. After approximately 5 – 10 min a small incision of about 0.5 cm was 
made at the biopsy site using a sterile scalpel (Aspen Surgical, Caldedonia, MI). 
Pressure was usually applied with sterile gauze after the incision was made. A 5mm 
biopsy needle was inserted into the incision and into the ‘belly’ of the vastus lateralis 
muscle. Once the biopsy needle was pushed through the fascia and settled into the 
correct location suction, using 60 mL syringe, a small muscle sample was collected with 
the biopsy needle. The biopsy needle was in the muscle for approximately 5 – 20 sec 
until the procedure was completed.   
 After the biopsy was obtained, the sample was removed from the needle by 
forcing air through the syringe connected to the biopsy needle. The muscle was quickly 
blotted on a sterile cover sponge to remove excess blood and then snap frozen into liquid 
nitrogen. The sample was then stored at -80°C for later analysis.   
 Immediately following the biopsy procedure, pressure was applied for at least 10 
min to the incision site to prevent unwarranted bleeding. After bleeding was thwarted, 
steri-strips (3M Health Care, St. Paul, MN) were applied ensure closure of the incision.  
A tegaderm film (3M Health Care, St. Paul, MN) was placed over the steri-strips, 
followed by gauze and a self-adherent pressure bandage. Participants were provided with 
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a biopsy care kit including multiple steri-strips, tegaderm films, and the contact 
information of the study coordinator. 
Biochemical Analysis for Muscle Creatine  
 Muscle samples were analyzed using mass spectrophotometer for muscle Cr 
concentrations. Samples were analyzed for Cr on methods developed by Harris and 
colleagues (50, 52, 57). The previously stored muscle samples were placed in a vacuum 
centrifuge (Jouan RC1010 SpeedVac Concentrator, Abbott Laboratories, Abbott Park, 
IL) and centrifuged for approximately 4 h. Following the dehydration process, the 
samples were powdered using a mortar and pestle and then placed into pre-weight 
microcentrifuge tubes. Perchloric acid (0.5 M) and 1mM ethylenediaminetetraacetic acid 
(EDTA) solution was used to extract the muscle metabolites. The acid solution was 
added to the microcentrifuge tubes containing the powered muscle. The microcentrifuge 
tube was placed on ice for 15 min while periodically vortexing. Samples were then 
centrifuged at 5,000 rpm for 5 min. The supernatant was transferred into a pre-weighed 
microcentrifuge tube. A 2.1 M KHCO3 basic solution was used to neutralize the 
samples. The samples were then centrifuged a second time at 5,000 rpm for 5 min. The 
supernatant was removed and placed into a label microcentrifuge tube and stored at -
80°C.   
 The samples were allowed to thaw at room temperature while periodically 
vortexing. Extracts were then assayed for Cr concentrations in presence of 50 mM 
imidazole buffer, pH 7.4; 5 mM magnesium chloride; 20 mM potassium chloride; 25 μM 
phosphoenolpyruvate; 200 μM ATP; 45 μM NADH; 1250 U/mL lactate dehydrogenase; 
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2000 U/mL pyruvate kinase. The reagents were individually added into 1.5 mL cuvettes. 
The assay was then carried out using 200 μL buffer, 100 μL potassium chloride, 25 μL 
NADH, 20 μL ATP, 10 μL phosphoenolpyruvate, 2 μL pyruvate kinase, 2 μL  lactate 
dehydrogenase, 150 μL  water, and 100 μL  of muscle extract.  Changes in absorbance 
were recorded with a Beckman Coulter DU 7400 Diode Array Spectrophotometer (Brea, 
California, USA) at a wavelength of 339 nm. 20 μL of creatine kinase (25 U/mg) was 
added after initial reading. The solution was read every 5 min for 20 min for post-
reaction absorbance values. Test-to-test variability of performing these assays yielded 
mean Cv values for muscle Cr (±3.69%) with a test/retest correlation of r=0.946. 
Body Composition Assessment  
Upon arrival to the lab on d 0, 7, and 28, total body mass was measured on a 
calibrated digital scale with a precision of ± 0.02 kg (Health-O-Meter, Bridgeview, IL, 
USA). Next, body composition was determined (excluding cranium) with a Hologic 
4500W DXA (Hologic, Bedford, MA, USA) by using procedures previously described 
(67, 70). A low dose of radiation is used to scan the entire body to determine body 
composition and bone density. The DXA scans regions of the body (limbs, trunk, and 
head) to determine bone mass, fat mass, and fat-free mass within each region. The values 
for each region are subtotaled to determine whole-body composition. Body fat 
percentage was determined by dividing fat mass by the total scanned mass (bone mass, 
fat mass, and fat-free mass). Test/retest reliability studies performed on male athletes 
with DXA yielded mean deviation for total bone mineral content and total fat-free/soft 
tissue mass of 0.31-0.45%, with a mean intra-class correlation of 0.985 (3).  
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Body Water Measurement  
 Total body water was determined immediately after DXA scan using an 
ImpediMed DF50 bioelectrical impedance analysis (ImpediMed, San Deigo, CA). While 
supine, the participant’s hand, wrist, ankle, and foot were properly cleaned with an 
alcohol wipe. Next, four electrodes are then attached to the hand, wrist, ankle and foot.  
The participant’s height, weight, and age information is then added to the BIA device. 
The device then determined total body water, intracellular water, and extracellular water.  
Exercise Testing Session  
Upon arrival to the lab on d 0 and 28, the following tests were conducted in the 
order listed: (1) body mass; (2) body composition; (3) total body water; and (4) donation 
of approximately 20 mL of fasting venous blood from antecubital vein.  After these 
assessments, the participants then began the exercise performance tests. The bench press 
test preceded the anaerobic sprint test. The performance test consisted of two sets of ten 
repetitions at 70% of 1RM. One additional set of repetitions to failure using the same 
load was also performed. Participants had a 2 min rest period between sets. Participants 
were asked to focus on exploding upward during the concentric phase of the lift. Power 
output was measured using a Tendo Fitrodyne (Tendo Sport Machines, Slovak Republic; 
test Cv=2.1%, intra-class, r=0.99). Peak power, average power, and average velocity 
were measured during each repetition of the three sets. 
After completion of the third set, participants rested for approximately 5 min 
before starting the anaerobic sprint test on a Lode Excalibur Sport 925900 cycle 
ergometer (Lode BV, Groningen, The Netherlands). The anaerobic sprint test consisted 
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of the following: three-minute warm up consisted of pedaling at 60 – 70 rpm against a 
resistance of 50 watts (W) for the first minute, 75 W for the second minute, and 100 W 
for the third minute of the warm-up. The six, 6 sec sprints with 30 sec rests in between 
followed immediately after the warm-up period. The sprints were followed by a 3 min 
rest period. The anaerobic sprint test concluded with a 30 sec Wingate test (Figure 6).  
A standardized work rate of 7.5 J/kg/rev was set on the cycle ergometer during 
the sprints and the Wingate test.  The participants were asked to pedal as fast as possible 
prior to application of the workload and sprint at an all-out maximal capacity throughout 
the 6 sec sprints and the 30 sec Wingate test. Test-to-test variability in performing 
repeated Wingate anaerobic capacity tests in our lab have yielded correlation coefficients 
of r=0.98±15% for mean power. Participants practiced the anaerobic sprint test during 
the familiarization session to minimize learning effects during which seat height, pedal 
position, and handlebar height was assessed and recorded.  
Blood Chemistries   
   Plasma was analyzed for ALP, AST, ALT, creatinine, BUN, CK, LDH, glucose, 
and blood lipids (TCHL, HDL, LDL, TG) using a Cobas
®
 c 111 (Roche Diagnostics, 
Basel, Switzerland). The Cobas
® 
automated clinical chemistry analyzer was calibrated 
according to manufacturer guidelines. This analyzer has been known to be highly valid
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Figure 6. Anaerobic Sprint Test on Cycle Ergometer 
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and reliable in previously published reports (64). The internal quality control for the 
Cobas c 111 was performed using two levels of control fluids purchased from 
manufacturer to calibrate acceptable SD and Cv values for all aforementioned assays.  
Samples were re-run if the observed values were outside control values and/or clinical 
norms according to standard procedures. 
Complete blood count with platelet differential were run on whole blood  
(hemoglobin, hematocrit, red blood cell (RBC) counts, MCV, MCH, MCHC, RDW, 
white blood cell (WBC) counts, lymphocytes, granulocytes, and mid-range absolute 
count (MID) using a Abbott Cell Dyn 1800 (Abbott Laboratories, Abbott Park, IL, USA) 
automated hematology analyzer. The internal quality control for Abbott Cell Dyn 1800 
was performed using three levels of control fluids purchased from manufacturer to 
calibrate acceptable SD and Cv values for all whole blood cell parameters. 
Side Effect Assessment   
 The same side effects questionnaires were used during Study 1 and Study 2.  
During Study 2, participants were completed the side effects questionnaire after 7, 14, 
21, and 28 d of supplementation. The questionnaires were completed to determine how 
well participants tolerated supplementation; how well participants followed the 
supplementation protocol; and if participants experienced any symptoms as a result of 
the supplement.  Participants were asked to rank the frequency and severity of their 
symptoms – dizziness, headache, tachycardia, heart skipping or palpitations, shortness of 
breather, nervousness, blurred vision, and unusual or adverse effects. Participants were 
asked to rank their symptoms with 0 (none), 1 minimal: 1-2/wk), 2 (slight: 3-4/wk), 3 
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(occasional: 5-6/wk), 4 (frequent: 7-8/wk), or 5 (severe: 9 or more/wk). Compliance to 
the supplementation protocol was monitored by supplement logs and verbal 
confirmation. After completing the first performance testing session (d 0) the 
participants were given the required supplements and written directions on how to 
properly ingest the supplements during the supplementation period.  
Data Analysis   
 All data were analyzed using the statistical software SPSS 22.0. Study data were 
analyzed using a repeated measured multivariate analysis of variance (MANOVA). 
Delta and percent change values were calculated and used to determine changes from 
baseline which were analyzed by repeated measures analysis of variance (ANOVA). 
Participant baseline demographic data were analyzed using one-way ANOVA. Overall 
MANOVA effects were examined as well as MANOVA univariate group effects for 
certain variables when significant interactions were seen. Greenhouse-Geisser univariate 
tests of within-subjects time and group x time effects and between-subjects univariate 
group effects were reported for each variable analyzed within the MANOVA model. 
Data were considered statistically significant when the probability of type I error was 
0.05 or less and statistical trends were considered when the probability of error ranged 
between p > 0.05 to p < 0.10. Post-hoc LSD pairwise comparisons using Cohen’s d were 
used to determine effect magnitude. When a significant group, treatment and/or 
interaction alpha level was observed, Tukey’s least significant difference (LSD) post-hoc 
analysis was performed to determine where significance was obtained. Data are 
presented as mean ± SD and mean change ± 95% confidence interval as appropriate. 
 64 
 
Prior to initiation of the study, we ran a priori power analysis which indicated a design 
with an N-size of 12 during Study 1 and an N-size of 11 per group during Study 2 would 
provide sufficient power to identify previously reported changes in the independent 
variables. 
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CHAPTER IV 
RESULTS 
 
Study 1 
Subject Demographics  
 Twenty-two participants were initially recruited for Study 1, completed consent 
forms, and participated in the required familiarization session.  However, of the original 
22 participants, 13 completed Study 1 (Figure 7). Seven participants dropped out after 
the familiarization session, six due to time constraints and one due to a pre-existing 
medical condition that excluded them from participating. One participant was dropped 
after being randomized into a treatment group due to missing scheduled testing sessions. 
None of the participants dropped out of the study due to side effects related to the study 
protocol or supplementation. The baseline demographics for the participants are listed in 
Table 2. Of the participants that completed the study, they were on average 23 ± 2 y old, 
177.8 ± 7.4 cm tall, 84.1 ± 18.9 kg, 26.6 ± 5.9 BMI, and a body fat percentage of 17.3 ± 
8.4 %.   
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Table 2. Study 1 - Participant Demographics     
N Age Height  Body Weight BMI Body Fat 
 (yrs) (cm) (kg) 
 
(%) 
            
13 23±2 177.8±7.4 84.1±18.9 26.6±5.9 17.3±8.4 
            
Values are means ± standard deviations (SD).  Data were analyzed by one-
way ANOVA.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 7. Consort Diagram for Study 1 Participation 
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Body Composition  
 Table 3 presents body composition (DXA) data. MANOVA analysis revealed an 
overall Wilks’ Lambda group (p=0.62). Body composition was determined for 
demographic purposes. Univariate analysis revealed no significant differences among 
groups in total body weight, fat mass, lean mass, fat-free mass, and body fat percentage.  
 
 
 
Table 3. Body Composition (DXA)     
Variable  Group Mean±SD Mean Group 
    
 
(SEM) p-level 
Body Weight PL 83.6±18.6 83.6±5.2 0.34 
(kg) CrM 83.7±17.9 83.7±5.0 
 
 
CrN-L 84.1±18.9 84.1±5.3 
 
 
CrN-H 84.1±18.3 84.1±5.1 
 
 
Overall 83.9±17.9     
Fat Mass PL 14.0±10.9 14.0±3.0 0.67 
(kg) CrM 14.2±11.1 14.2±3.1 
 
 
CrN-L 14.3±11.5 14.3±3.2 
 
 
CrN-H 14.1±11.6 14.1±3.1 
 
 
Overall 14.2±10.9     
Fat-Free Mass PL 63.0±8.1 63.0±2.3 0.55 
(kg) CrM 62.8±7.3 62.8±2.0 
 
 
CrN-L 62.9±7.7 62.9±2.1 
 
 
CrN-H 63.4±7.6 63.4±2.1 
 
 
Overall 63.0±7.5     
Body Fat PL 16.8±7.7 16.8±2.1 0.85 
(%) CrM 16.9±8.2 16.9±2.3 
 
 
CrN-L 16.9±8.5 16.9±2.4 
 
 
CrN-H 16.6±8.3 16.6±2.3 
 
  Overall 16.8±7.9     
Values are means ± standard deviations (SD). MANOVA analysis 
revealed overall Wilks' Lambda group effects (p=0.62). 
Greenhouse-Geisser univariate group p-levels are reported.   
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Diet  
 Tables 4 and 5 present absolute and relative, respectively, caloric and 
macronutrient intake data. MANOVA analysis revealed an overall Wilks’ Lambda group 
effect (p=0.78). Univariate analysis showed no significant differences observed among 
groups in absolute or relative caloric or macronutrient intake.    
 
 
 
Table 4. Absolute Dietary Intake and Macronutrient Composition   
Variable  Group Mean±SD Mean  
 
p-level 
      (SEM)    
Calories (kcal/d) PL 2,532±716 2,532±198 Group 0.48 
 
CrM 2,615±769 2,615±213 
  
 
CrN-L 2,408±691 2,408±191 
  
 
CrN-H 2,318±522 2,318±144 
  
 
Overall 2,468±671       
Protein (g/d) PL 129.9±74.7 129.9±20.7 Group 0.89 
 
CrM 130.4±66.6 130.4±18.5 
  
 
CrN-L 124.6±63.5 124.6±17.6 
  
 
CrN-H 126.8±65.5 126.8±17.9 
  
 
Overall 127.9±65.5       
Carbohydrate (g/d) PL 280.6±89.6 280.6±24.8 Group 0.35 
 
CrM 299.3±137.5 299.3±38.1 
  
 
CrN-L 262.8±68.6 262.8±19.0 
  
 
CrN-H 238.9±62.5 238.9±17.3 
  
 
Overall 270.4±94.2       
Fat (g/d) PL 95.6±40.3 95.7±11.2 Group 0.33 
 
CrM 94.5±26.4 94.5±7.3 
  
 
CrN-L 83.5±38.1 83.5±10.6 
  
 
CrN-H 82.4±35.7 82.4±9.9 
  
 
Overall 89.0±35.0   
  Values are means ± standard deviations (SD). MANOVA analysis revealed overall 
Wilks' Lambda group effects (p=0.78). Greenhouse-Geisser univariate group p-levels 
are reported.    
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Table 5. Relative Dietary Intake and Macronutrient Composition   
Variable  Group Mean±SD Mean 
 
p-level 
      (SEM)     
Calories (kcal/kg/d) PL 31.3±10.5 31.3±2.9 Group 0.32 
 
CrM 32.8±12.4 32.8±3.5 
  
 
CrN-L 28.9±7.1 28.9±2.0 
  
 
CrN-H 28.1±6.6 28.1±1.8 
  
 
Overall 30.3±9.4       
Protein (g/kg/d) PL 1.61±0.95 1.61±0.26 Group 0.43 
 
CrM 1.62±0.87 1.62±0.24 
  
 
CrN-L 1.50±0.78 1.50±0.21 
  
 
CrN-H 1.93±2.00 1.93±0.55 
  
 
Overall 1.67±1.22       
Carbohydrate (g/kg/d) PL 3.52±1.36 3.52±0.38 Group 0.26 
 
CrM 3.84±2.35 3.84±0.65 
  
 
CrN-L 3.16±0.68 3.16±0.19 
  
 
CrN-H 2.90±0.78 2.90±0.22 
  
 
Overall 3.36±1.45       
Fat (g/kg/d) PL 1.16±0.52 1.16±0.14 Group 0.24 
 
CrM 1.16±0.35 1.16±0.10 
  
 
CrN-L 0.99±0.38 0.99±0.11 
  
 
CrN-H 0.99±0.41 0.99±0.12 
  
 
Overall 1.07±0.42 
   Values are means ± standard deviations (SD).  MANOVA analysis revealed overall 
Wilks' Lambda group effects (p=0.78). Greenhouse-Geisser univariate group p-levels 
are reported.    
 
 
 
Plasma Creatine and Nitrate  
 Figure 8 shows mean plasma Cr concentration at baseline and 0.5, 1, 2, 3, 4, and 
5 h post-supplementation. Values reported are means ± standard deviation. MANOVA 
analysis revealed overall Wilks’ Lambda group (p<0.001), time (p<0.001), and group x 
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time (p<0.001). Univariate analysis also revealed a significant group, time, and group x 
time interaction (all, p<0.001). Tests of within-subject contrast indicates  
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Values are means ± standard deviations. Values reported are means ± standard deviation.  MANOVA 
analysis revealed overall Wilks’ Lambda group (p<0.001), time (p<0.001), and group x time (p<0.001). 
Greenhouse-Geisser group p-levels are reported. p<0.05 considered significant.  (#) denotes a 
significantly greater plasma Cr concentration with CrM compared to PL, CrN-L, and CrN-H. (ɸ) denotes 
a significantly greater plasma Cr concentration with CrN-H compared to CrN-L and PL.(□) denotes a 
significantly greater plasma Cr concentration with CrN-L compared to PL. (^) denotes significantly 
greater plasma Cr concentration with CrM compared to CrN-L and PL. (◊) denotes significantly greater 
plasma Cr concentration with CrN-H compared to CrN-L.  
Figure 8. Comparison of Plasma Creatine Concentrations After Acute Supplementation 
#, ɸ 
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both a linear (both, p<0.001) and quadratic (both, p<0.001) relationship for overall time 
and group x time interaction. There were no significant differences (p>0.05) in plasma 
Cr concentration among groups at baseline (PL: 76.1±38.3 µM; CrM: 71.6±48.5 µM; 
CrN-L: 64.4±30.3 µM; CrN-H: 89.5±78.1 µM). Plasma Cr concentrations were 
significantly increased (p<0.001) from baseline with CrM and CrN-H at all time-points 
(i.e., 0.5, 1, 2, 3, 4, 5 h). Plasma Cr concentration were significantly greater (p<0.01) at 
0.5, 1, 2, and 3 h post-supplementation with CrN-L compared to baseline, while plasma 
Cr concentration with PL did not significantly change (p>0.05) over time.   
Plasma Cr concentration with CrM was significantly (p<0.001) greater than all 
other groups at 0.5 h (PL: 149.5±149.4 µM; CrM: 949.6±520.8 µM; CrN-L: 
245.5±108.1 µM; CrN-H: 519.8±342.0 µM), 1 h (PL: 285.4±384.4 µM; CrM: 
2,065.9±703.3 µM; CrN-L: 275.1±84.9 µM; CrN-H: 835.0±388.1 µM), 2 h (PL: 
113.9±135.3 µM; CrM: 1319.4±522.2 µM; CrN-L: 173.0±82.8 µM; CrN-H: 
399.8±253.8 µM), 3 h (PL: 90.8±72.8 µM; CrM: 696.2±284.8 µM; CrN-L: 120.4±66.0 
µM; CrN-H: 252.8±172.2 µM), and 4 h (PL: 81.9±57.2 µM; CrM: 398.2±161.5 µM; 
CrN-L: 97.5±57.8 µM; CrN-H: 193.8±153.9 µM) post supplementation. At 5 h post-
supplementation plasma Cr with CrM (267.1±141.4 µM) was only significantly greater 
than CrN-L (100.3±47.5 µM) and PL (89.7±52.9 µM). Plasma Cr with CrN-H was 
significantly greater (p<0.05) than CrN-L and PL at 0.5,1, 2, 3, and 4 h post 
supplementation. At 5 h post-supplementation, plasma Cr concentration was 
significantly (p=0.03) greater with CrN-H compared to CrN-L, but not significantly 
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different than CrM and PL. CrN-L was only significantly greater (p=0.04) than PL at 0.5 
h post-supplementation.   
Figure 9 shows the plasma Cr area under the curve (AUC) after acute 
supplementation. Values reported are means ± standard deviation. MANOVA analysis 
revealed overall Wilks’ Lambda group (p=0.001). Plasma Cr AUC with CrM (5,634.4 ± 
1,949.8 µmol/L) was significantly greater (p<0.05) than PL (1,012.4±1882.2 µmol/L, 
p=0.001), CrN-L (2,342.0±3,133.3 µmol/L, p=0.004), and CrN-H (1,761.7±3,408.8 
µmol/L, p=0.007). Tests of within-subjects contrasts indicates a linear (p<0.001) 
relationship between groups. Plasma Cr AUC values for CrM, CrN-L, and CrN-H were 
457%, 131%, and 74% greater than plasma Cr AUC with PL. There were no significant 
differences in plasma Cr AUC among PL, CrN-L, and CrN-H. Results from the plasma 
Cr analysis provides supporting evidence which fails to reject the null hypothesis of  
hypothesis 1 which stated that there will be significant differences among group in 
plasma Cr concentrations after acute supplementation. 
Figure 10 shows plasma nitrate concentration at baseline and 0.5, 1, 2, 3, 4, and 5 
h post supplementation. Values reported are means ± standard deviation. MANOVA 
analysis revealed overall Wilks’ Lambda group (p<0.001), time (p<0.001), and group x 
time (p<0.001). Univariate analysis revealed significant group (p<0.001), time 
(p<0.001), and group x time (p<0.001) effects. Tests of within subject contrasts indicates 
linear (both, p<0.001) and quadratic (both, p<0.01) relationship for overall time and 
group x time. There were no significant differences (p>0.05) in plasma nitrate 
concentration among groups at baseline (PL: 5.4±3.0 µM; CrM: 4.8±2.5 µM; CrN-L:  
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Values are means ± standard deviations.  MANOVA analysis revealed overall Wilks’ Lambda 
group (p=0.001).   Greenhouse-Geisser group p-levels are reported. (#) denotes a significant 
difference (p<0.05) from PL, CrN-L, and CrN-H.   
 
               Figure 9. Plasma Creatine Area Under the Curve (AUC)  
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Values reported are means ± standard deviation.  MANOVA analysis revealed overall Wilks’ Lambda 
group (p<0.001), time (p<0.001), and group x time (p<0.001). Greenhouse-Geisser group p-levels are 
reported. p<0.05 considered significant. (‡) denotes a significantly greater serum nitrate concentration 
with CrN-H compared to PL, CrM, and CrN-L. (§)  denotes a significantly greater serum nitrate 
concentration with CrN-L compared to PL and CrM.      
 
             Figure 10. Comparison of Plasma Nitrate Concentration 
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6.2±3.9 µM; CrN-H: 5.8±3.9 µM). Plasma nitrate concentrations with CrN-L and CrN-H 
significantly increase (all, p<0.001) at all time-points (i.e., 0.5, 1, 2, 3, 4, 5 h) after 
supplementation compared to baseline. There were no significant changes across time in 
plasma nitrate concentrations with CrM (p>0.05). In PL group, plasma nitrate 
concentrations significantly decrease at 0.5 (p=0.02) and 1 h (p=0.045) compared to 
baseline, increased to near baseline values at 2 h (p=0.85) and 3 h (p=0.59) post 
supplementation, then significantly decrease at 4 h (p=0.008) and 5 h (p=0.003) post 
supplementation.   
Plasma nitrate concentration with CrN-H was significantly (p<0.001) greater 
than all other groups (PL, CrM, and CrN-L) at all post-supplementation time-points – 
0.5 h (PL: 4.9±2.8 µM; CrM: 5.3±2.5 µM; CrN-L: 66.9±14.7 µM; CrN-H: 107.9±35.3 
µM), 1 h (PL: 4.7±2.5 µM; CrM: 5.3±2.5 µM; CrN-L: 66.9±14.7 µM; CrN-H: 
107.9±35.3 µM), 2 h (PL: 5.5±3.1 µM; CrM: 4.8±2.1 µM; CrN-L: 57.0±8.1 µM; CrN-H: 
106.0±14.0 µM), 3 h (PL: 4.9±3.0 µM; CrM: 4.5±1.8 µM; CrN-L: 51.4±8.0 µM; CrN-H: 
83.1±14.2 µM), 4 h (PL: 3.9±1.8 µM; CrM: 4.0±1.6 µM; CrN-L: 47.7±7.8 µM; CrN-H: 
83.1±14.2 µM), and 5 h (PL: 3.6±1.6 µM; CrM: 3.9±1.4 µM; CrN-L: 43.2±7.3 µM; CrN-
H: 80.1±10.9 µM). Plasma nitrate concentration with CrN-L was significantly greater 
than CrM (all, p<0.001) and PL (all, p<0.001) at all post supplementation time-points. 
There were no significant differences between CrM and PL in plasma nitrate 
concentration at any post-supplementation time-point.      
Figure 11 shows the plasma nitrate AUC after acute supplementation. Values 
reported are means ± standard deviation.  MANOVA analysis revealed overall Wilks’ 
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Lambda group (p=0.01).  Plasma nitrate AUC for CrN-H (1988.2±1618.8 µmol/L) was 
significantly greater (p<0.05) than CrM (48.0±73.1µmol/L, p=0.001) and PL (51.4±83.4  
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Values are means ± standard deviations. MANOVA analysis revealed overall Wilks’ Lambda group (p=0.01).  
Greenhouse-Geisser group p-levels are reported. (§) denotes a significant difference (p<0.05) from CrM and 
PL. 
 
Figure 11. Plasma Nitrate Area Under the Curve (AUC) 
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µmol/L, p=0.001), but not significantly different than CrN-L (898.8±1688.9 µmol/L, 
p=0.10). Test of within-subjects contrast indicates a quadratic (p=0.002) relationship 
between groups. Plasma nitrate AUC for CrN-L and CrN-H were 1649%, and 3771% 
greater, respectively, compared to plasma nitrate AUC for PL. Plasma nitrate AUC for 
CrM was 6% less than plasma nitrate AUC for PL; however, difference was not 
significant (p=0.91). Although there was a trend towards greater plasma nitrate AUC 
with CrN-L there was no significant difference compared to PL (p=0.10) or CrM 
(p=0.09). The results from the plasma nitrate analysis provides supporting evidence 
which fails to reject the null hypothesis of  hypothesis 2 which stated that there will be 
significant differences among groups in plasma nitrate concentrations after acute 
supplementation. 
Hematologic Profile   
 Table 6 presents plasma lipids. MANOVA analysis revealed overall Wilks' 
Lambda group (p=0.002), time (p<0.001), and group x time (p=0.10). Univariate 
analysis revealed no significant time effects were observed for TCHL (p=0.06), TCHL: 
HDL ratio (p=0.09), and LDL (p=0.06). Although changes from baseline were not 
statistically significant among groups across time (p=0.06), the Cohen’s d effect size 
indicates a large effect size in the increase (1.2 – 3.7%) in TCHL at 0.5 h (1.2%, 
d=1.49), 1 h (2.6%, d=1.47), 2 h (1.9%, d=1.51), 3 h (3.7%, d=1.55), 4 h (3.7%, d=1.57), 
and 5 h (2.6%, d=1.54) post supplementation. Similarly, although change from baseline 
were not statistically significant among groups across time (p=0.09) the
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Table 6. Plasma Lipids                     
Marker  Group Time (hours) Mean    
 N  0 0.5 1 2 3 4 5 (SEM)  p-level 
TCHL 11 PL 153.8±28.4 156.2±31.1 161.0±31.8 162.5±32.9 164.5±31.2 164.6±36.7 165.0±36.1 161.1±8.9 Group 0.59 
(mg/dl) 13 CrM 156.8±29.3 157.2±29.3 160.7±34.3 157.2±31.4 159.3±30.4 160.3±32.8 160.2±28.3 158.8±8.4 Time 0.06 
 13 CrN-L 154.5±27.6 154.2±28.0 155.7±31.7 156.0±27.8 158.6±28.9 158.5±26.8 159.5±27.9 156.7±7.5 G x T 0.77 
 11 CrN-H 158.3±30.0 163.2±27.0 162.3±32.6 159.9±26.9 163.9±32.6 162.9±26.8 163.5±27.9 162.0±7.5 
  
  Overall 155.9±28.1 157.7±28.2 159.9±31.8 158.9±29.1 161.6±31.0 161.6±30.2 160.0±29.4 
   
HDL 11 PL 55.8±15.3 58.2±15.6 58.8±17.4 59.9±16.1 61.0±15.7 61.6±17.0 62.2±17.9 59.6±4.5 Group 0.29 
(mg/dl) 13 CrM 53.9±17.1 54.1±16.7 55.6±18.4 55.1±17.2 56.0±17.1 56.9±17.6 56.4±18.8 55.4±4.8 Time 0.001 
 13 CrN-L 51.0±14.1 50.8±15.6 51.2±15.0 52.1±14.9 53.8±14.5 54.9±15.2 55.3±15.8 52.7±4.1 G x T 0.64 
 11 CrN-H 52.9±17.5 54.7±17.0 54.2±16.8 54.2±17.3 55.4±16.9 55.2±16.3 55.4±17.7 54.6±4.6 
  
  Overall 53.4±15.7 54.5±16.0 55.0±16.7 55.4±16.2* 56.6±15.8* 57.1±16.3* 57.3±17.3* 
   
TCHL:HDL  11 PL 2.93±0.84 2.85±0.84 2.92±0.85 2.87±0.83 2.85±0.83 2.82±0.83 2.81±0.83 2.86±0.23 Group 0.40 
Ratio 13 CrM 3.14±0.92 3.11±0.91 3.10±0.88 3.03±0.77 3.02±0.81 3.00±0.80 3.07±0.93 3.07±0.24 Time 0.09 
(mg/dl) 13 CrN-L 3.27±1.16 3.30±1.15 3.26±1.02 3.21±1.03 3.16±1.02 3.11±1.04 3.10±1.02 3.20±0.29 G x T 0.62 
 11 CrN-H 3.33±1.43 3.31±1.40 3.30±1.37 3.31±1.49 3.26±1.40 3.30±1.51 3.31±1.47 3.31±0.39 
  
  Overall 3.16±1.09 3.14±1.08 3.14±1.03 3.11±1.05 3.07±1.02 3.06±1.06 3.07±1.07 
   
LDL 11 PL 94.0±26.3 96.5±27.6 98.1±28.1 100.1±29.1 102.4±32.6 102.5±32.3 102.2±32.0 99.4±8.1 Group 0.72 
(mg/dl) 13 CrM 99.1±25.6 99.0±24.1 102.5±27.7 101.1±24.7 102.0±23.7 103.8±26.5 102.5±22.9 101.4±6.8 Time 0.06 
 13 CrN-L 97.2±23.0 97.1±22.4 98.8±24.0 100.0±22.4 102.4±23.1 102.6±21.6 104.4±22.5 100.4±6.1 G x T 0.67 
 11 CrN-H 102.7±27.1 105.3±25.8 105.0±29.8 104.1±26.6 101.5±43.7 106.0±27.0 105.4±25.8 104.3±7.5 
  
  Overall 98.3±25.0 99.5±24.6 101.1±26.8 101.4±25.1 102.1±30.9 103.7±26.4 103.6±25.3 
   
TG 11 PL 79.2±26.2 82.1±27.9 78.8±24.8 73.9±23.5 72.6±21.0 71.8±22.1 71.1±22.6 75.6±6.2 Group 0.60 
(mg/dl) 13 CrM 90.7±33.1 88.1±34.1 86.6±30.9 76.2±27.3 72.5±25.9 73.7±27.2 68.9±22.6 79.6±7.2 Time 0.01 
 13 CrN-L 88.3±36.9 94.5±37.9 90.6±34.7 79.4±25.3 75.4±20.4 73.2±18.3 72.8±17.9 82.0±7.1 G x T 0.66 
 11 CrN-H 79.4±25.6 86.1±34.1 81.8±29.1 73.0±18.3 70.9±19.5 71.9±19.4 70.2±20.3 76.2±5.4 
  
  Overall 84.45±30.37 87.7±33.0 84.5±29.5 75.6±23.3* 72.9±21.2* 72.6±21.4* 70.8±20.4* 
   
Values are means ± standard deviations.  MANOVA analysis revealed overall Wilks' Lambda group (p=0.002), time (p<0.001), and group x time (p=0.10). Greenhouse-
Geisser time and group x time (G x T) interaction p-levels are reported with univariate group p-levels. (*) denotes a significant (p<0.05) difference from baseline.   
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Cohen’s d for TCHL:HDL ratio indicates a small effect size decrease (all, -2.2% from 
baseline across time at 0.5 h (d=0.06), 1 h (d=0.07), 2 h (d=0.06), 3 h (d=0.07), 4 h 
(d=0.06), and 5 h (d=0.06) h post supplementation. Furthermore, changes from baseline 
were not statistically significant among groups across time for LDL (p=0.06) the 
Cohen’s d for LDL indicates a small effect size increase (1.3 – 5.5%) increase across 
time at 0.5 h (, 1.3%, d=0.05), 1 h (2.9%, d=0.11), 2 h (3.2%, d=0.13), 3 h (3.9%, 
d=0.14), 4 h (5.5%, d=0.21), and 5 h (5.4%, d=0.21) post-supplementation. There were 
significant time effects were observed for HDL (p=0.001) and TG (p=0.007). Test of 
within-subjects contrast indicates a linear increase (p<0.001) in HDL from baseline after 
2 h post-supplementation, while TG linearly (p=0.01) decreased from baseline after 2 h 
post-supplementation. There were no significant group x time interaction for TCHL 
(p=0.77), HDL (p=0.64), TCHL: HDL ratio (p=0.62), LDL (p=0.67), and TG (p=0.66).   
Table 7 presents clinical markers of health. There were significant overall group 
(p=0.002) and time effects (p<0.001), while there were no significant overall group x 
time effects (p=0.10) observed. Univariate analysis revealed no significant time effects 
for AST (p=0.12), CK (p=0.06), and LDH (p=0.40). While changes from baseline were 
not statistically significant among groups across time for CK (p=0.06), the Cohen’s d 
indicates a small effect size change (-5.5 – 1.9%) at 0.5 h (1.9%, d=0.01), 1 h (1.7%, 
d=0.01), 2 h (-2.5%, d=0.02), 3 h (-2.4%, d=0.02), 4 h (-5.5%, d=0.04), and 5 h (-5.2%, 
d=0.03) post-supplementation. There were significant time effects for ALP (p<0.001), 
ALT (p=0.001), BUN (p<0.001), BUN:Creatinine ratio (p<0.001), and glucose 
(p=0.009). A test of within-subject contrast indicates a linear (p<0.01)  
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Table 7. Study 1: Health Markers 
      
      
Marker 
 
Group Time (hours) Mean 
  
 
N 
 
0 0.5 1 2 3 4 5 (SEM) 
 
p-level 
ALP 11 PL 7.9±6.5 11.5±8.0 11.9±8.8 13.3±9.1 13.9±9.9 14.3±9.4 16.9±14.1 12.8±2.2 Group 0.23 
(U/L) 13 CrM 14.7±9.1 15.9±11.7 15.9±10.4 16.8±12.9 20.5±14.4 25.4±15.3 24.6±14.9 19.1±2.9 Time 0.001 
 13 CrN-L 12.3±9.3 16.3±10.3 20.3±10.8 18.7±11.5 21.7±10.9 20.6±10.2 22.8±10.5 18.9±2.0 G x T 0.65 
 11 CrN-H 12.8±8.1 17.5±9.5 16.1±8.2 17.2±11.2 16.2±9.7 17.2±15.6 20.1±18.1 16.7±2.5  
 
  Overall 11.9±8.5 15.3±9.95* 16.0±9.8* 16.5±11.1* 18.1±11.5* 19.4±12.4* 21.1±14.5* 
 
 
 
ALT 11 PL 19±8.2 19.5±9.1 20.2±9.6 19.6±8.5 20.2±9.7 20.3±9.3 20.2±9.3 19.9±2.5 Group 0.70 
(U/L) 13 CrM 20.3±7.3 20.5±7.7 21.4±7.8 21.1±8.4 21.1±8.4 21.0±7.9 21.2±8.7 20.9±2.2 Time 0.001 
 13 CrN-L 20.1±7.7 20.63±8.4 20.7±8.5 20.8±8.1 21.3±8.2 21.0±8.3 21.1±8.0 20.8±2.3 G x T 0.66 
 11 CrN-H 21.2±8.5 21.3±8.3 21.5±8.7 21.9±8.6 21.1±8.5 22.6±8.8 22.7±8.8 21.9±2.4  
 
  Overall 20.2±7.8 20.5±8.2 21.0±8.5* 20.8±8.2* 21.2±8.5* 21.2±8.4* 21.3±8.5* 
 
 
 
AST 11 PL 24.7±4.9 23.8±5.3 25.1±4.7 25.4±5.8 25.5±5.8 25.2±6.2 25.5±6.1 25.1±1.5 Group 0.40 
(U/L) 13 CrM 25.9±7.9 26.5±8.8 27.1±8.9 26.0±9.1 26.3±8.8 26.5±8.6 27.0±9.5 26.5±2.4 Time 0.12 
 13 CrN-L 24.1±6.1 24.6±6.3 23.9±5.9 24.7±6.1 24.8±5.3 24.3±5.6 24.6±5.4 24.4±1.6 G x T 0.64 
 11 CrN-H 28.0±15.6 28.8±16.3 28.7±16.4 28.8±14.8 29.6±15.2 28.9±14.8 29.8±16.0 28.9±4.3  
 
  Overall 25.7±9.4 25.9±10.0 26.2±9.9 26.2±9.5 26.6±9.5 26.2±9.4 26.7±10.0 
 
 
 
CK 11 PL 260±222 264±231 266±219 262±210 259±211 253±200 247±193 2589±59 Group 0.40 
(U/L) 13 CrM 160±220 262±222 263±212 240±207 249±195 242±189 237±185 251±56 Time 0.06 
 13 CrN-L 265±275 270±273 272±287 267±271 266±273 256±250 255±252 264±74 G x T 0.51 
 11 CrN-H 490±931 505±958 497±940 475±864 470±863 453±809 470±894 480±248  
 
  Overall 319±505 325±518 324±509 311±472 311±470 301±441 302±479 
 
 
 
LDH 11 PL 168±40 158±24 170±27 172±26 169±22 171±30 171±27 168±6 Group 0.08 
(U/L) 13 CrM 168±21 164±31 168±31 162±23 164±28 165±31 172±29 166±7 Time 0.39 
 13 CrN-L 146±25 165±31 155±19 161±23 160±18 158±22 159±18 158±5 G x T 0.40 
 11 CrN-H 169±36 179±42 183±40 167±47 196±74 176±32 180±27 179±9   
  Overall 163±32 167±33 169±31 166±31 172±43 168±29 170±26 
 
  
Values are means ± standard deviations.  MANOVA analysis revealed overall Wilks' Lambda group (p=0.002), time (p<0.001), and 
group x time (p=0.10). Greenhouse-Geisser time and group x time (G x T) interaction p-levels are reported with univariate group p-
levels. (*) denotes a significant (p<0.05) difference from baseline. 
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Table 7. Continued              
Marker  Group Time (hours) Mean   
 N  0 0.5 1 2 3 4 5 (SEM)  p-level 
BUN 11 PL 14.4±4.8 14.0±4.2 14.0±4.3 13.4±4.5 13.2±4.2 12.8±4.1 12.3±3.8 13.4±1.2 Group 0.28 
(mg/dl) 13 CrM 15.2±5.0 14.8±4.6 14.6±4.7 13.7±4.5 13.4±4.3 13.1±4.3 12.6±4.0 13.9±1.2 Time 0.001 
 13 CrN-L 13.5±4.8 13.0±4.5 12.8±4.5 12.2±4.1 12.1±4.1 11.6±3.8 11.4±3.8 12.4±1.2 G x T 0.76 
 11 CrN-H 14.6±5.1 14.5±5.22 14.1±4.9 13.7±5.1 13.2±4.6 12.9±4.3 12.7±4.3 13.7±1.3   
  Overall 14.4±4.8 14.1±4.6* 13.9±4.6* 13.6±4.5* 12.9±4.2* 12.6±4.1* 12.3±3.9* 
 
  
Creatinine 11 PL 1.00±0.15 0.99±0.16 0.99±0.15 0.98±0.15 0.98±0.15 0.98±0.17 0.95±0.14d 0.98±0.04ψ Group 0.001 
(mg/dl) 13 CrM 0.99±0.18 1.04±0.17 1.04±0.19 1.01±0.19 0.99±0.17 0.99±0.17 1.00±0.17 1.01±0.05ǂ Time 0.001 
 
13 CrN-L 1.01±0.19 1.08±0.18a 1.09±0.17a,b 1.05±0.16a 
1.05±0.17
a 
1.02±0.18a 1.01±1.16 1.05±0.05 G x T 0.001 
 
11 CrN-H 1.05±0.14a 1.11±0.15a,b 1.17±0.14a,b,c 1.12±0.16a,b,c 
1.06±0.16
a 
1.03±0.13a 1.02±0.14 1.08±0.04 
  
  Overall 1.01±0.16 1.06±0.17* 1.07±0.17* 1.04±0.17* 1.02±0.16 1.00±0.16 0.99±0.15 
 
  
BUN:Creatinine 11 PL 14.4±4.2 14.2±4.1 14.3±4.1 13.7±3.9 13.5±3.6 13.1±3.4 12.9±3.2 13.8±1.0 Group 0.11 
(mg/dl) 13 CrM 15.3±4.3 14.5±4.3 14.2±3.9 13.7±4.1 13.6±4.2 13.4±4.1 12.7±3.5 13.9±1.1 Time 0.001 
 13 CrN-L 13.7±5.4 12.2±4.6 11.9±4.6 11.8±4.3 11.8±4.4 11.7±4.1 11.5±4.0 12.1±1.2 G x T 0.08 
 11 CrN-H 14.0±4.8 13.2±4.6 12.0±3.9 12.3±4.0 12.6±3.9 12.5±3.8 12.5±3.9 12.7±1.1   
  Overall 14.4±4.6 13.5±4.4* 13.1±4.2* 12.9±4.1* 12.9±3.9* 12.7±3.8* 12.4±3.6* 
 
  
Glucose 11 PL 95.8±10.3 103.0±10.4 92.1±8.0 92.2±5.5 91.5±4.0 85.9±26.1 91.9±4.3 93.2±2.2 Group 0.33 
(mg/dl) 13 CrM 96.3±9.9 85.3±27.0 91.4±6.0 89.8±5.1 91.4±5.4 91.6±5.6 91.2±4.9 91.0±1.8 Time 0.01 
 13 CrN-L 96.3±5.5 102.6±8.1 94.1±5.9 91.8±6.5 91.2±6.8 92.9±6.7 92.1±6.2 94.4±1.6 G x T 0.12 
 11 CrN-H 94.7±7.5 96.1±6.4 91.4±6.2 91.1±4.0 90.6±5.4 91.3±4.2 83.8±25.3 91.3±1.5 
  
  Overall 95.8±8.3 96.7±16.5 91.4±6.3* 91.2±5.3* 91.2±5.4* 90.4±13.8* 89.8±13.5* 
   
Values are means ± standard deviations.  MANOVA analysis revealed overall Wilk's Lambda group (p=0.002), time (p<0.001), and group x time 
(p=0.10). Greenhouse-Geisser time and group x time (G x T) interaction p-levels are reported with univariate group p-levels. p<0.05 considered 
significant. (*) denotes a significant difference from baseline. (ǂ) denotes a significant difference from CrN-H. (ψ) denotes a significant difference 
from CrN-L and CrN-H. (a) denotes a significant difference from PL. (b) denotes a significant difference from CrM. (c) denotes a significant 
difference from CrN-L. (d) denotes a significant difference from CrM, CrN-L, and CrN-H. 
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relationship with ALP, ALT, BUN, BUN:Creatine ratio, and glucose across time. No 
significant group x time interactions were observed for ALP (p=0.65), ALT (p=0.66), 
AST (p=0.64), CK (p=0.51), LDH (p=0.40), BUN (p=0.76), BUN:Creatinine ratio 
(p=0.08), and glucose (p=0.12). Significant time (p=0.001) and group x time effects 
(p=0.001) were only observed for creatinine. A test of within-subject contrast indicates 
linear and quadratic time (p<0.01) and group x time (p<0.01) relationships for 
creatinine. Hematologic results provide supporting evidence which fails to reject the null 
hypothesis of hypothesis 3 which states that there will be no significant differences 
among groups in markers of clinical health after acute supplementation.   
Hemodynamic Profile  
Table 8 shows heart rate (HR), systolic blood pressure (SBP), and diastolic blood 
pressure (DBP) data to acute supplementation for each group. MANOVA analysis 
revealed overall Wilks' Lambda group (p=0.23), time (p=0.005), and group x time 
(p=0.26). Univariate analysis revealed were no significant time (p= 0.15) or group x time 
effects (p=0.56) for HR. Additionally, there were also no significant time (p=0.29) or 
group x time effects (p=0.11) for DBP. Significant differences in SBP were observed 
across time (p=0.02) with no significant group x time interactions (p=0.39). SBP at 0 h 
was significantly (p<0.05) greater than SBP at 0.5 h and 1 h post supplementation. SBP 
at 1 h was significantly (p<0.01) different than SBP at 0, 2, 3, 4, and 5 h post-
supplementation. Tests of within-subjects contrasts indicates a cubic (p=0.02) 
relationship in changes in SBP across time. The results from the hemodynamic analysis 
provides supporting evidence which fails to reject the null hypothesis of hypothesis 4  
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Table 8. Heart Rate and Blood Pressure Response               
Variable  Group Time (hours) Mean 
      0 0.5 1 2 3 4 5 (SEM)   p-level 
HR PL 59.7±8.2 60.1±7.4 58.8±7.7 57.2±5.3 58.0±7.4 54.8±6.4 56.0±7.3 57.8±1.3 Group 0.23 
 
CrM 63.8±11.8 60.9±5.7 59.9±8.2 58.2±7.0 56.3±6.8 59.6±8.8 58.5±10.0 59.6±1.7 Time 0.15 
 
CrN-L 60.0±8.4 57.9±8.3 58.8±9.0 56.3±6.0 56.3±6.0 56.9±5.7 55.1±5.9 57.3±1.5 G x T 0.59 
 
CrN-H 59.1±9.0 56.7±7.4 57.9±5.8 58.6±3.8 58.0±4.1 56.8±4.7 57.5±3.8 58.2±1.1 
  
 
Overall 60.7±9.4 59.6±7.1 58.8±7.6 57.6±5.6 57.2±6.1 57.0±6.6 56.8±7.0       
SBP PL 114.8±6.2 113.9±5.6 112.6±4.9 116.5±6.7 116.0±4.8 117.2±8.5 115.5±5.2 115.2±1.4 Group 0.37 
 
CrM 114.6±5.1 112.6±4.4 112.2±4.2 114.9±5.3 112.9±6.1 113.1±5.8 114.9±3.8 113.6±1.1 Time 0.02 
 
CrN-L 115.9±6.1 113.1±4.1 111.9±5.2 113.5±6.9 114.6±6.9 114.62±5.0 112.5±3.5 113.7±1.1 G x T 0.39 
 
CrN-H 115.4±6.7 114.2±5.5 111.4±6.6 112.5±6.0 113.5±6.2 113.7±9.7 114.2±7.0 113.5±1.7 
  
 
Overall 115.2±5.9 113.4±4.8* 112.0±5.1* 114.4±6.3 114.3±6.0 114.7±7.5 114.3±5.0       
DBP PL 73.1±6.6 71.9±7.5 72.2±6.6 72.3±7.3 73.1±6.6 74.0±5.5 72.3±5.7 72.7±1.4 Group 0.66 
 
CrM 70.3±6.6 71.5±7.8 72.5±4.1 73.9±5.4 72.8±6.0 73.9±5.0 74.5±4.0 72.8±1.2 Time 0.29 
 
CrN-L 72.2±6.5 73.5±5.4 71.9±6.1 75.5±5.4 74.3±6.2 74.5±4.6 73.1±4.1 73.6±1.2 G x T 0.18 
 
CrN-H 73.1±7.9 77.1±4.8 73.9±6.5 74.5±5.2 73.7±6.1 72.2±7.9 72.9±4.8 73.9±1.4 
  
 
Overall 72.2±6.8 73.5±6.7 72.6±5.8 74.0±5.8 73.5±6.0 73.6±5.8 73.2±4.6 
   
Values are means ± standard deviations.  HR=Heart rate, SBP=systolic blood pressure, DBP=diastolic blood pressure.  MANOVA analysis revealed 
overall Wilks' Lambda group (p=0.23), time (p=0.005), and group x time (p=0.26).  Greenhouse-Geisser time and group x time (G x T) interaction p-
levels are reported with univariate group p-levels. (*) denotes a significant (p<0.05) difference from baseline.  
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which stated there will be no significant difference among groups in heart rate after 
acute supplementation. Furthermore, there is also supporting evidence to reject 
hypothesis 5 which stated there will be significant differences among groups in blood 
pressure after acute supplementation.   
Side Effects  
 Tables 9 and 10 present frequency and severity, respectively, of symptoms 
reported. A MANOVA analysis was run on side effects questionnaire to assess changes 
in symptoms which include frequency and severity of dizziness, headache, tachycardia, 
heart skipping or palpitations, shortness of breath, nervousness, blurred vision, and any 
other unusual or adverse effects. Participants were asked to rank their symptoms with 0 
(none), 1 minimal: 1-2/wk), 2 (slight: 3-4/wk), 3 (occasional: 5-6/wk), 4 (frequent: 7-
8/wk), or 5 (severe: 9 or more/wk). Some participants reported minimal to slight in side 
effects such as dizziness (PL: N=1 at 2 h; CrM: N=1 at 0.5 h, N=1 at 2 h, N=1 at 3 h; 
CrN-L: N=1 at 0.5 h; CrN-H: N=1 at 2 h, N=1 at 4 h), headaches (CrN-L: N=1 at 0.5 h, 
N=1 at 1 h, N=1 at 2 h, N=1 at 3 h, N=1 at 4 h, N=1 at 5 h; CrN-H: N=1 at 0.5 h), 
tachycardia (PL: N=1 at 2 h; CrM: N=1 at 1 h; CrN-L: N=0; CrN-H: N=0), nervousness 
(PL: N=1 at 0.5 h; CrM: N=1 at 0.5 h, N=1 at 1 h; CrN-L: N=0; CrN: N=0), and blurred 
vision (PL: N=0; CrM: N=1 at 0.5 h; CrN-L: N=1 at 0.5 h; CrN-H: N=1 at 2 h, N=1 at 3 
h, N=1 at 4 h, N=1 at 5 h) during the supplementation period. MANOVA analysis 
revealed an overall Wilks’ Lambda group (p=0.45), time (p=0.24), and group x time 
(p=0.47). Additionally, univariate analysis revealed no time (p=0.45) or group x time 
interaction (p=0.36) observed among treatment groups. The greatest ranking reported 
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Table 9. Study 1: Side Effects - Frequency of Symptoms 
    
      
Symptoms  Group Time (hours) Mean   
 N  0.5 1 2 3 4 5 (SEM)  p-level 
Dizziness 11 PL 0.00±0.00 0.00±0.00 0.08±0.28 0.00±0.00 0.00±0.00 0.00±0.00 0.01±0.01 Group 0.12 
 13 CrM 0.08±0.28 0.00±0.00 0.08±0.28 0.08±0.28 0.00±0.00 0.00±0.00 0.05±0.02 Time 0.14 
 13 CrN-L 0.08±0.28 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.03±0.02 G x T 0.25 
 11 CrN-H 0.00±0.00 0.00±0.00 0.08±0.28 0.00±0.00 0.08±0.28 0.00±0.00 0.01±0.01  
 
  Overall 0.04±0.19 0.04±0.19 0.00±0.00 0.00±0.00 0.00±0.24 0.08±0.24       
Headache 11 PL 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 Group 0.37 
 13 CrM 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.03±0.03 Time 0.26 
 13 CrN-L 0.08±0.28 0.08±0.28 0.08±0.28 0.08±0.28 0.08±0.28 0.08±0.28 0.04±0.04 G x T 0.58 
 11 CrN-H 0.08±0.28 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00  
 
  Overall 0.04±0.19 0.00±0.14 0.04±0.14 0.02±0.14 0.00±0.14 0.00±0.28       
Tachycardia 11 PL 0.00±0.00 0.00±0.00 0.08±0.28 0.00±0.00 0.00±0.00 0.00±0.00 0.01±0.01 Group 0.10 
  13 CrM 0.00±0.00 0.15±0.38 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.05±0.03 Time 0.28 
 13 CrN-L 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.03±0.02 G x T 0.30 
 11 CrN-H 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00  
 
  Overall 0.00±0.00 0.08±0.00 0.04±0.19 0.00±0.14 0.00±0.14 0.02±0.14       
Heart Skipping or 11 PL 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 Group 0.08 
Palpitations 13 CrM 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.04±0.02 Time 0.26 
 13 CrN-L 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 G x T 0.26 
 11 CrN-H 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00  
 
  Overall 0.04±0.00 0.00±0.00 0.00±0.00 0.02±0.00 0.00±0.00 0.00±0.00       
Shortness of Breath 11 PL 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.03±0.02 Group 0.22 
 13 CrM 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.01±0.01 Time 0.50 
 13 CrN-L 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 G x T 0.41 
 11 CrN-H 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00   
  Overall 0.00±0.00 0.02±0.00 0.02±0.00 0.00±0.00 0.00±0.00 0.02±0.00       
Nervousness 11 PL 0.08±0.28 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.03±0.03 Group 0.69 
 13 CrM 0.23±0.44 0.08±0.28 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.01±0.01 Time 0.25 
 13 CrN-L 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.01±0.01 G x T 0.46 
 11 CrN-H 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.01±0.01  
 
  Overall 0.00±0.27 0.00±0.33 0.06±0.14 0.02±0.14 0.02±0.00 0.00±0.00       
Blurred Vision 11 PL 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.01±0.01 Group 0.73 
 13 CrM 0.08±0.28 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.01±0.01 Time 0.33 
 13 CrN-L 0.08±0.28 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.03±0.03 G x T 0.39 
 11 CrN-H 0.00±0.00 0.00±0.00 0.08±0.00 0.08±0.28 0.08±0.28 0.08±0.28 0.03±0.03   
  Overall 0.00±0.19 0.00±19 0.06±0.00 0.02±0.00 0.02±0.14 0.00±0.14       
Any other unusual  11 PL 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.01±0.01 Group 0.34 
or adverse effects 13 CrM 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 Time 0.34 
 13 CrN-L 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 G x T 0.34 
 11 CrN-H 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.01±0.01   
    Overall 0.02±0.00 0.00±00 0.00±0.00 0.00±0.00 0.02±0.00 0.00±0.00       
Values are mean ± standard deviation.  MANOVA analysis revealed overall Wilks' Lambda group (p=0.45), time (p=0.24), and group x 
time (p=0.47).  Greenhouse-Geisser time and group x time (G x T) interaction p-levels are reported with univariate group p-levels. 
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Table 10. Study 1: Side Effects - Severity of Symptoms 
   
      
Symptoms  Group Time (hours) Mean   
 N  0.5 1 2 3 4 5 (SEM)  p-level 
Dizziness 11 PL 0.00±0.00 0.00±0.00 0.08±0.28 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 Group 0.34 
 13 CrM 0.08±0.28 0.00±0.00 0.08±0.28 0.08±0.28 0.00±0.00 0.00±0.00 0.01±0.01 Time 0.34 
 13 CrN-L 0.08±0.28 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.01±0.01 G x T 0.34 
 11 CrN-H 0.00±0.00 0.00±0.00 0.08±0.28 0.00±0.00 0.08±0.28 0.00±0.00 0.00±0.00  
 
  Overall 0.02±0.14 0.02±0.14 0.00±0.14 0.00±0.14 0.00±0.00 0.00±0.00       
Headache 11 PL 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 Group 0.51 
 13 CrM 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.01±0.01 Time 0.44 
 13 CrN-L 0.08±0.28 0.08±0.28 0.15±0.56 0.15±0.56 0.08±0.28 0.15±0.56 0.03±0.03 G x T 0.34 
 11 CrN-H 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.01±0.01  
 
  Overall 0.02±0.14 0.00±0.28 0.02±0.14 0.04±0.14 0.00±0.14 0.00±0.28       
Tachycardia 11 PL 0.00±0.00 0.00±0.00 0.08±0.28 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 Group 0.45 
  13 CrM 0.00±0.00 0.08±0.28 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 Time 0.50 
 13 CrN-L 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.01±0.01 G x T 0.34 
 11 CrN-H 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.03±0.03  
 
  Overall 0.00±0.00 0.00±0.00 0.02±0.00 0.00±0.00 0.02±0.00 0.02±0.00       
Heart Skipping or 11 PL 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 Group 0.34 
Palpitations 13 CrM 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 Time 0.34 
 13 CrN-L 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 G x T 0.34 
 11 CrN-H 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.01±0.01  
 
  Overall 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.02±0.00 0.00±0.00       
Shortness of Breath 11 PL 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 Group 0.51 
 13 CrM 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 Time 0.46 
 13 CrN-L 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.01±0.01 G x T 0.36 
 11 CrN-H 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.01±0.01   
  Overall 0.02±0.00 0.02±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00       
Nervousness 11 PL 0.08±0.28 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 Group 0.51 
 13 CrM 0.00±0.60 0.08±0.28 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 Time 0.50 
 13 CrN-L 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.01±0.01 G x T 0.36 
 11 CrN-H 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.01±0.01  
 
  Overall 0.02±0.00 0.00±0.00 0.00±0.00 0.02±0.00 0.00±0.00 0.00±0.00       
Blurred Vision 11 PL 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 Group 0.45 
 13 CrM 0.08±0.28 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 Time 0.42 
 13 CrN-L 0.08±0.28 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.03±0.03 G x T 0.35 
 11 CrN-H 0.00±0.00 0.00±0.00 0.08±0.28 0.08±0.28 0.08±0.28 0.08±0.28 0.01±0.01   
  Overall 0.00±0.14 0.00±0.14 0.02±0.14 0.00±0.14 0.00±0.14 0.04±0.14       
Any other unusual 11 PL 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 Group 0.34 
or adverse effects 13 CrM 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 Time 0.34 
 13 CrN-L 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 G x T 0.34 
 11 CrN-H 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.01±0.01   
    Overall 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.02±0.00 0.00±0.00       
Values are mean ± standard deviation.  MANOVA analysis revealed overall Wilks' Lambda group (p=0.45), time (p=0.24), and group 
x time (p=0.47).  Greenhouse-Geisser time and group x time (G x T) interaction p-levels are reported with univariate group p-levels. 
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was 2, which was used by one participant to indicate the severity of his nervousness 0.5 
h after ingesting CrM as well as to indicate the severity of his headache at 2, 3, and 5 h 
after consuming CrN-L. There were no symptoms ranked with 3, 4, or 5 in frequency or 
severity by any participant. Results of the side effects questionnaire analysis provide 
evidence which accepts the null hypothesis of hypothesis 5 which stated that there will 
be no significant difference among groups in side effect symptoms in frequency or 
severity after acute supplementation. 
Study 2 
Participant Demographics  
 Seventy-one participants were initially recruited for Study 2 and completed 
consent forms, and participated in the required familiarization session. However, of the 
original 71 participants, 48 completed (21.3 ± 3.4 y old, 176.8 ± 5.8 cm tall, 80.5 ± 13.8 
kg, 25.8 ± 3.8 BMI, and a body fat percentage of 17.8 ± 5.9 %) the 28 d research study 
(Figure 12).  Twenty-three participants dropped out after the familiarization, 22 of them 
due to time constraints and one due to apprehension of the muscle biopsy procedure. 
Fifty-three participants were randomized to the four treatment groups. Twelve were 
initially randomized to the placebo group, but one participant was dropped due to missed 
scheduled laboratory visits. Fifteen were initially randomized to the creatine 
monohydrate group. Four participants dropped out of this group, one due to missed 
scheduled laboratory visits, one developed abdominal pains after the second day of 
supplementation, one due to a family emergency, and one withdrew due to time  
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Figure 12. Consort Diagram for Study 2 Participation 
Assessed for eligibility 
and consented (n=71) Excluded (n=23):  
* Decided to withdraw after 
familiarization session (n=22) 
* Decided to withdraw after 
first biopsy (n=1) 
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Dropped 
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keep 
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PL 
 (n=11) 
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(n=15) 
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(n=13) 
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supplementation (n=4) due 
to: 
* Missed scheduled 
appointment (n=1) 
* Developed abdominal 
pain, as a result of kidney 
stone after second day of 
supplementation (n=1) 
* Family emergency (n=1) 
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constraint (n=1) 
CrM  
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(n=13) 
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constraints. There were no withdraws from either creatine nitrate group.  Table 11 
represents participant demographics.  
 
 
 
Table 11. Study 2 - Participant Demographics       
Group 
 
PL CrM CrN-L CrN-H p-level 
 
N 11 11 13 13   
Age (yrs) 
 
21.2±3.7 21.6±2.5 20.7±1.9 21.5±4.8 0.93 
Height (cm) 
 
177.8±7.2 177.3±4.7 175.0±7.1 177.5±3.9 0.63 
Body Weight (kg) 77.3±11.8 81.7±13.2 71.9±9.7 90.8±13.4^ 0.002 
BMI 
 
24.3±2.5 25.8±3.6 23.6±2.7 28.9±4.2^ 0.001 
Body Fat (%) 17.8±6.9 16.7±4.0 13.2±5.4 19.2±6.0 0.06 
Values are means ± standard deviations (SD).  Data were analyzed by one-way ANOVA. (^) 
denotes a significant difference (p<0.05) from creatine nitrate (CrN-L) and placebo (PL).  
 
 
Compliance, Training and Diet  
 Five of the forty-eight participants reported not supplementing on schedule based 
on the completed supplement checklist and verbal confirmation.  90% of the participants 
supplemented on schedule and exhibited 100% compliance based on the completed 
supplement checklist and verbal confirmation. The 10% that did not supplement on 
schedule reported taking the missed dose(s) within 1 -2 days. Two participants in CrN-H 
group each missed the ingestion of 6 g CrN-H (12 g CrN-H total) on schedule. Two 
participants in CrN-L group missed scheduled supplementation; one participant missed 3 
g CrN-L, while the other participant missed 12 g CrN-L. In the CrM group one 
participant missed the ingestion of 3 g CrM on schedule.    
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Table 12 shows the training volumes for upper and lower body lifts throughout 
Study 2. A one-way ANOVA analysis was run to examine differences among the four 
groups.  Results indicate no statistically significant differences among groups in total 
upper body training volume (p=0.78) or lower body training volume (p=0.49) 
 
 
 
 
 
 
 
 
 
 
 
 
Tables 13 and 14 present absolute and relative, respectively, caloric 
macronutrient intake for each treatment group. MANOVA analysis revealed overall 
Wilks' Lambda group (0.38), time (p=0.24), and group x time (p=0.12). Univariate 
analysis showed no significant group x time effects in absolute and relative 
macronutrient intake.   
 
 
Table 12. Training Volume   
Group Upper Body (kg) p-level 
PL 117,048±21,951 0.78 
CrM 104,017±33,926 
 
CrN-L 108,505±37,207 
 
CrN-H 108,596±23,708 
 
  Lower Body (kg)   
PL 121,285±24,295 0.49 
CrM 101,966±27,299 
 CrN-L 123,718±47,215 
 CrN-H 117,038±38,939  
Values are means ± standard deviations. Training volume 
variables were analyzed by one-way ANOVA.  
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Table 13. Absolute Caloric and Macronutrient Intake       
Variable  Group Day Mean  
      0 7 28 (SEM)   p-level 
Calories PL 2,179±490 2,225±701 2,170±858 2,191±151 Group 0.98 
(kcal/d) CrM 2,258±400 2,254±473 2,303±405 2,272±151 Time 0.38 
 
CrN-L 2,282±689 2,149±656 2,395±575 2,275±139 G x T 0.89 
 
CrN-H 2,234.5±447 2,125±831 2,389±600 2,250±138 
  
 
Overall 2,240±509 2,184±664 2,321±613       
Protein  PL 113.4±42.4 114.0±41.0 104.9±41.7 110.8±9.1 Group 0.96 
(g/d) CrM 112.3±31.0 114.9±24.5 113.3±24.9 113.5±9.1 Time 0.74 
 
CrN-L 101.8±33.46 106.1±44.5 123.5±41.7 110.5±8.3 G x T 0.40 
 
CrN-H 120.7±36.4 109.8±33.1 118.6±40.2 116.4±8.3 
  
 
Overall 112.0±35.5 111.0±35.9 115.6±37.6       
Carbohydrate  PL 233.1±91.1 234.4±99.1 231.5±121.3 233.0±23.5 Group 0.94 
(g/d) CrM 215.3±46.0 236.2±83.5 220.6±74.5 224.1±23.5 Time 0.23 
 
CrN-L 273.4±94.3 224.5±104.5 235.9±67.8 224.6±21.6 G x T 0.31 
 
CrN-H 254.9±92.1 224.7±85.1 223.0±74.8 234.3±21.6 
  
 
Overall 245.9±84.5 229.5±90.8 227.9±83.4       
Fat  PL 74.1±23.6 88.9±39.2 82.5±42.0 81.8±9.7 Group 0.70 
(g/d) CrM 97.2±17.8 90.1±24.9 92.3±21.4 93.2±9.7 Time 0.41 
 
CrN-L 83.1±40.5 87.9±38.6 101.5±38.2 90.8±8.9 G x T 0.64 
 
CrN-H 94.7±46.5 95.4±55.3 101.1±44.4 97.1±8.9 
    Overall 87.4±35.2 90.7±40.4 94.9±37.5       
Values are means ± standard deviations.  MANOVA analysis revealed overall Wilks' Lambda group (0.38), time 
(p=0.24), and group x time (p=0.117).  Greenhouse-Geisser time and group x time (G x T) interaction p-levels are 
reported with univariate group p-levels.   
 
 
Plasma Creatine and Nitrate  
Figure 13 presents plasma Cr concentrations at day 0, 7 and 28 d.  A MANOVA 
analysis was run to assess plasma creatine concentrations. MANOVA analysis revealed 
overall Wilks’ Lambda group (p=0.03), time (p<0.001), and group x time (p=0.01).  
Univariate analysis showed that mean plasma Cr concentrations significantly increased 
over time (140±223 µM, 75±197 µM, p<0.001) with significant  
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Table 14. Relative Caloric and Macronutrient Intake       
Variable  Group Day Mean  
      0 7 28 (SEM)   p-level 
Calories  PL 28.8±7.2 28.8±8.7 28.4±10.5 28.7±2.1 Group 0.13 
(kcal/kg/d) CrM 28.4±8.1 27.9±7.2 28.7±7.9 28.4±2.1 Time 0.37 
 
CrN-L 32.0±9.1 30.1±9.4 32.9±6.1 31.7±1.9 G x T 0.94 
 
CrN-H 25.3±7.4 23.4±8.7 26.5±7.8 25.1±1.9 
  
 
Overall 28.6±8.1 27.5±8.7 29.2±8.3       
Protein  PL 1.53±0.71 1.48±0.54 1.38±0.52 1.46±0.13 Group 0.67 
(g/kg/d) CrM 1.40±0.43 1.44±0.46 1.42±0.51 1.42±0.13 Time 0.77 
 
CrN-L 1.43±0.46 1.46±0.53 1.69±0.55 1.53±0.12 G x T 0.39 
 
CrN-H 1.38±0.58 1.24±0.45 1.33±0.51 1.31±0.12 
  
 
Overall 1.44±0.53 1.40±0.49 1.46±0.53       
Carbohydrate  PL 3.08±1.23 3.08±1.36 3.03±1.45 3.06±0.33 Group 0.25 
(g/kg/d) CrM 2.67±0.63 2.90±0.98 2.74±1.03 2.77±0.33 Time 0.15 
 
CrN-L 3.87±1.42 3.22±1.69 3.29±0.97 3.46±0.30 G x T 0.33 
 
CrN-H 2.93±1.31 2.52±1.01 2.49±0.96 2.65±0.30 
  
 
Overall 3.16±1.26 2.93±1.29 2.89±1.12       
Fat  PL 0.975±0.32 1.13±0.48 1.08±0.56 1.07±0.13 Group 0.76 
(g/kg/d) CrM 1.23±0.36 1.11±0.35 1.15±0.35 1.17±0.13 Time 0.57 
 
CrN-L 1.14±0.50 1.20±0.47 1.37±0.38 1.24±0.12 G x T 0.54 
 
CrN-H 1.11±0.76 1.07±0.64 1.12±0.50 1.11±0.12 
  
 
Overall 1.12±0.52 1.13±0.49 1.19±0.45 
   
Values are means ± standard deviations.  MANOVA analysis revealed overall Wilks' Lambda group (0.38), time 
(p=0.24), and group x time (p=0.12). Greenhouse-Geisser time and group x time (G x T) interaction p-levels are 
reported with univariate group p-levels.   
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Values are means ± standard deviations.  MANOVA analysis revealed overall Wilks’ Lambda 
group (p=0.03), time (p<0.001), and group x time (p=0.01).  Greenhouse-Geisser time and group 
x time (G x T) interaction p-levels are reported with univariate group p-levels. p<0.05 considered 
significant. (¥) denotes a significant difference between creatine monohydrate (CrM) and creatine 
nitrate-lower dose (CrN-L) at day 0 (baseline).  (†) denotes a significantly greater Cr 
concentration with CrM compared to CrN-L, CrN-H, and PL at day 7.  
 
Figure 13. Comparison of Plasma Creatine Concentration with Chronic Supplementation 
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group x time interactions (PL: 12±73 µM, 19±97 µM; CrM: 340±354 µM, 66±66 µM; 
CrN-L: 97±129 µM, 75±69 µM; CrN-H: 121±125 µM, 132±360 µM, p<0.001) after 7 
and 28 d of supplementation. Tests of within-subject contrasts indicates a linear (p=0.02) 
and quadratic (p=0.001) relationship over time, while only indicating quadratic 
(p=0.006) group x time relationship in plasma Cr concentration. Percent change in 
plasma Cr from baseline was greatest for CrM (205%) compared to the other groups 
(PL: 9.4%, CrN-L: 133%, CrN-H: 101%) after 7 d of supplementation. Although there 
were no significant difference in plasma Cr concentrations at 28 d of supplementation, 
concentrations were significantly greater than baseline (PL: 15%, CrM: 40%, CrN-L: 
103%, CrN-H: 110%) values. The results of the plasma Cr analysis provide evidence 
which fails to reject hypothesis 7 which states there will be significant differences 
between groups in plasma Cr concentration after 7 and 28 d of supplementation.  
Figure 14 presents plasma nitrate concentrations at day 0, 7 and 28 d.  A 
MANOVA analysis was run to assess plasma nitrate concentrations. MANOVA analysis 
revealed an overall Wilks’ Lambda group (p<0.001), time (p<0.001), and group x time 
(p<0.001). Univariate analysis showed a significant time effect (34.2±43.1 µM, 7.8±18.8 
µM, p<0.001) with significant group x time interactions (PL: 0.6±3.6 µM, 4.4±15.9 µM; 
CrM: -1.1±2.6 µM, -0.4±2.8 µM; CrN-L: 59.2±29.8 µM, 8.3±13.7 µM; CrN-H: 
67.7±47.8 µM, 17.3±28.4 µM, p<0.001) after 7 and 28 d of supplementation, 
respectively. There was a significant increase after 7 d of supplementation only with 
CrN-L and CrN-H. Tests of within-subject contrasts indicates a linear (p=0.007) and 
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quadratic (p<0.001) relationship across time, while only indicating a quadratic (p<0.001) 
group x time relationship in plasma nitrate concentration. Plasma nitrate concentration 
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Figure 14. Serum Nitrate Concentration.  
Values are means ± standard deviations.  MANOVA analysis revealed an overall Wilks’ Lambda group 
(p<0.001), time (p<0.001), and group x time (p<0.001). Greenhouse-Geisser time and group x time (G x T) 
interaction p-levels are reported with univariate group p-levels. p<0.05 considered significant. (§) denotes a 
significant difference with CrN-L and CrN-H compared to CrM and PL at day 7. (Ø) denotes a significantly 
greater concentration with CrN-H compared to CrM  at day 28. 
§ 
Ø 
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 increase by 1057% and 1574% with CrN-L and CrN-H, respectively, after 7 d of 
supplementation. There was only a significant difference (p<0.001) between CrM and 
CrN-H after 28 d of supplementation. However, plasma nitrate concentrations were 
increased by 98%, 148% and 400% with PL, CrN-L, and CrN-H, respectively. The 
results of the plasma nitrate analysis provides evidence which fails to reject hypothesis 8 
which states that there will be significant difference among groups in plasma nitrate 
concentration after 7 and 28 d of supplementation. 
Muscle Creatine Concentration  
Table 15 presents muscle free creatine (FCr) concentration data. An ANCOVA 
analysis with baseline muscle FCr as a covariate was run on all muscle FCr data. The 
covariate allows for the statistical model to consider the continuous independent variable 
(i.e., baseline muscle Cr concentration), which is not part of the experimental 
manipulation, into the statistical equation. Including this covariate also explains more 
within-group variance and improves the statistical power the analysis. Additionally, 
including a covariate in the statistical model helps reduce the occurrence of regression to 
the mean. The values listed in Table 16 are expressed in mmol • kg-1 DW and are 
presented as means ± standard deviations. ANCOVA analysis revealed overall Wilks' 
Lambda group (p<0.001), time (p<0.001), and group x time (p<0.001). Univariate 
analysis revealed a significant time effects (p=0.013) for mean muscle free Cr 
concentration for all groups over time 37.2±6.8, 38.5±9.0, 37.9±8.8 mmol • kg-1 DW for 
d 0, 7, and 28, respectively. Additionally, there was a significant group x time effects 
(p<0.001) in mean muscle FCr concentration after 7 and 28 d of supplementation. Tests 
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of within-subject contrasts indicates linear relationships for time (p=0.013) and group x 
time (p=<0.001).  
 
 
 
Table 15.  Muscle Free Creatine Concentration           
Marker 
 
Group Day Mean 
  
 
N 
 
0 7 28 (SEM) 
 
p-level 
Creatine  11 PL 34.9±6.3 33.8±6.0 33.2±5.4 35.6±1.0
ǂ
 Group 0.001 
(mmol/kg DW) 13 CrM 36.9±5.1 44.1±7.0a,c 45.8±5.6a,d 42.5±0.9^ Time 0.01 
 
13 CrN-L 35.8±6.6 32.5±4.2 32.3±5.6 34.5±0.9
ǂ
 G x T 0.001 
 
11 CrN-H 40.6±8.0 43.7±10.6a,c 40.9±9.9c 39.2±0.9 
     Overall 37.2±6.8 38.5±9.0* 37.9±8.8*       
Values are means ± standard deviations.  ANCOVA analysis revealed overall Wilks' Lambda group (p<0.001), 
time (p<0.001), and group x time (p<0.001). Greenhouse-Geisser time and group x time (G x T) interaction p-
levels are reported with univariate group p-levels. p<0.05 considered significant. (ǂ) denotes a significant 
difference from CrN-H.  (^) denotes a significant difference from CrN-L and PL.  (a) denotes a significant 
difference from PL. (c) denotes a significant difference from CrN-L. (d) denotes a significant difference  from 
CrN-L and CrN-H. (*) denotes a significant difference from baseline.  
 
 
Figure 15 presents percent changes in muscle FCr concentration. ANCOVA 
analysis revealed overall Wilks' Lambda group (p<0.001), time (p<0.001), and group x 
time (p<0.001). Univariate analysis showed that after d 7 of supplementation there was a 
significant percent increase in muscle FCr concentration in CrM (p<0.001) and CrN-H 
(p=0.003) by 20.2±16.4% and 8.5±18.5 %, respectively. However, percent change was 
not significantly different between CrM and CrN-H (p=0.40) at d 7. At d 7, percent 
change in muscle FCr was significantly greater with CrM compared to PL (-0.4±25.6%, 
p=0.02) and CrN-L (-6.8±18.9%, p=0.002). There were no significant differences in 
percent change in muscle FCr among PL, CrN-L, and CrN-H after 7 d of 
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supplementation. After 28 d of supplementation, muscle FCr concentrations increased by 
25.7±19.3% with CrM, which was significantly greater when compared to CrN-L (-
8.5±16.1 %, p<0.001), CrN-H (1.2±19.1 %, p=0.002), and PL (-4.2±8.9 %, p<0.001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Values are means ± standard deviations.  ANCOVA analysis revealed overall Wilks' Lambda 
group (p<0.001), time (p<0.001), and group x time (p<0.001). Greenhouse-Geisser time and 
group x time (G x T) interaction p-levels are reported with univariate group p-levels. p<0.05 
considered significant. (^) denotes a significantly greater Cr concentrations with CrM and 
CrN-H compared to CrN-L and PL at d 7.  (†) denotes a significantly greater Cr concentration 
with CrM compared to CrN-L, CrN-H, and PL at d 28.  (◊) denotes a significantly greater Cr 
concentration with CrN-H compared to CrN-L at d 28.  
 
Figure 15. Percent Change in Muscle Creatine Concentration 
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Percent change with CrN-H was significantly greater (p=0.02) at 28 days of 
supplementation when compared to CrN-L (p=0.002).  There were no significant 
difference (p=0.52) in percent change in muscle FCr between CrN-L and PL. Tests of 
within-subjects contrast indicates a linear (p=0.02) and quadratic (p=0.01) relationship in 
percent change over time, while indicating a linear (p<0.001) group x time relationship.   
Figure 16 represents mean muscle FCr concentration, 95% CI, and individual 
responses supplementation at d 7 (A) and d 28 (B). The values listed in this figure are 
expressed in mmol • kg-1 DW. ANCOVA analysis revealed overall Wilks' Lambda group 
(p<0.001), time (p<0.001), and group x time (p<0.001). Univariate analysis revealed a 
significant increase in muscle FCr concentration with CrM [mean±SEM] (7.1±1.9 
mmol• kg-1 DW, 95% CI, 3.1, 11.1) and CrN-H (4.7±1.9 mmol • kg-1 DW, 95% CI, 0.9, 
8.4) after 7 d of supplementation. There was a significant decrease in muscle FCr 
concentrations with CrN-L (-4.0±1.8 mmol • kg-1 DW, 95% CI, - 7.6, -0.3) and no 
significant change in muscle FCr with PL (-2.1±2.0 mmol • kg-1 DW, 95% CI, -6.2, 1.9) 
after 7 d of supplementation. After 28 d of supplementation, muscle FCr concentrations 
were only significantly elevated from baseline with CrM (8.9±1.7 mmol • kg-1 DW, 95% 
CI, 5.5, 12.2). There was no significant change from baseline with CrN-H (1.5±1.6 
mmol • kg-1 DW, 95% CI, -1.7, 4.6) and PL (-2.4±1.7 mmol • kg-1 DW, 95% CI, -5.8, 
1.0) after 28 d of supplementation. Muscle FCr concentration was significantly 
decreased from baseline with CrN-L (-4.0±1.5 mmol • kg-1 DW, 95% CI, -7.0, -0.9).   
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Figure 16. Mean, 95% CI, and Individual Responses to Treatment at Day 7 (A) and Day 28 (B). 
ANCOVA analysis revealed overall Wilks' Lambda group (p<0.001), time (p<0.001), and group x 
time (p<0.001). Greenhouse-Geisser time and group x time (G x T) interaction p-levels are reported 
with univariate group p-levels.  p<0.05 considered significant.  (^) denotes a significantly greater 
change in Cr concentrations with CrM and CrN-H compared to CrN-L and PL at d 7.  (†) denotes a 
significantly greater change in Cr concentration with CrM compared to CrN-L, CrN-H, and PL at d 28.  
(◊) denotes a significantly greater change in Cr concentration with CrN-H compared to CrN-L at d 28. 
◊ 
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After 7 d of supplementation FCr concentrations with CrM were significantly 
greater than CrN-L (p=0.001) and PL (p=0.009), but not significantly different than 
CrN-H (p=0.17). Additionally, FCr concentrations with CrN-H were significantly 
greater than CrN-L (p=0.03), but not significantly different than PL (p=0.15) after 7 d of 
supplementation. There were no significant differences between CrN-L and PL (p=0.44). 
At 28 d of supplementation FCr concentrations with CrM were significantly greater than 
CrN-L (p<0.001), CrN-H (p=0.001), and PL (p<0.001). Although there was a trend 
towards a significant difference between CrN-H and CrN-L (p=0.096), there were no 
significant differences between other treatment groups after 28 d of supplementation. 
Tests of within-subject contrasts indicates linear relationships for time (p=0.013) and 
group x time (p=<0.001). The results of the muscle Cr analysis provide evidence which 
fails to reject hypothesis 9 which stated that there will be significant differences among 
groups in muscle Cr concentration after 7 and 28 d of supplementation.  
Body Composition  
  Table 16 displays the results from all body composition analysis. A MANOVA 
analysis was run to examine changes in body in body composition variables which 
included body weight (kg), fat mass (kg), fat-free mass (kg), and percentage of body fat 
and total body water (BIA). MANOVA analysis revealed overall Wilk's Lambda group 
(p=0.20), time (p=0.15), and group x time (p=0.37). Univariate analysis showed a 
significant increase in body weight in all groups over time (0.29±1.04 kg, 0.74±1.33 kg, 
p=0.002) with no significant group x time interaction observed among groups (PL 
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Table 16. Body Composition           
Variable  
 
Group Day Mean 
    N   0 7 28 (SEM)   p-level 
Body Weight 11 PL 77.3±11.9 77.6±12.1 77.4±12.7 77.4±3.7
ǂ
 Group 0.003 
(kg) 11 CrM 81.7±13.2 82.4±13.4 82.6±14.0 82.2±3.7 Time 0.002 
 
13 CrN-L 72.0±9.7 72.2±9.9 72.7±10.0 72.3±3.4
ǂ
 G x T 0.29 
 
13 CrN-H 90.8±13.4 90.8±13.2 92.0±14.3 91.2±3.4 
  
  
Overall 80.5±13.8 80.8±13.8 81.3±14.5*       
Fat Mass 11 PL 12.7±6.3 12.6±6.3 12.7±6.3 12.7±1.8 Group 0.02 
(kg) 11 CrM 12.9±5.3 13.0±5.5 13.2±5.2 13.0±1.8 Time 0.17 
 
13 CrN-L 8.9±4.7 8.7±4.6 9.1±4.7 8.9±1.6
ǂ
 G x T 0.90 
 
13 CrN-H 16.5±6.9 16.2±6.4 16.6±7.4 16.5±1.6 
  
  
Overall 12.8±6.4 12.6±6.2 12.9±6.4       
Fat-Free Mass 11 PL 58.1±8.0 58.5±8.0 58.3±8.3 58.3±2.4
ǂ
 Group 0.01 
(kg) 11 CrM 62.4±8.7 62.5±8.8 62.9±9.2 62.6±2.4 Time 0.02 
 
13 CrN-L 56.9±7.4 57.4±7.3 57.3±7.3 57.2±2.2
ǂ
 G x T 0.50 
 
13 CrN-H 67.4±8.1 67.7±8.2 68.5±8.2 67.9±2.2 
  
  
Overall 61.3±8.9 61.6±8.9 61.9±9.2*       
Body Fat 11 PL 17.8±6.9 17.1±6.7 17.2±6.7 17.4±1.7 Group 0.07 
(%) 11 CrM 16.7±4.0 16.8±4.3 16.8±3.7 16.8±1.7 Time 0.24 
 
13 CrN-L 13.1±5.4 12.8±5.2 13.2±5.2 13.1±1.5
ǂ
 G x T 0.78 
 
13 CrN-H 19.2±5.9 18.7±5.5 18.8±6.3 18.9±1.5 
  
  
Overall 16.7±6.0 16.4±5.8 16.5±5.9       
Total Body Water 11 PL 51.3±4.5 50.6±5.1 52.5±6.9 51.5±1.3 Group 0.18 
(%) 11 CrM 51.4±3.3 50.8±3.7 49.4±8.4 50.5±1.3 Time 0.64 
 
13 CrN-L 52.9±4.6 54.1±5.1 52.7±4.2 53.2±1.2 G x T 0.47 
 
13 CrN-H 50.6±6.5 48.8±4.1 49.0±4.7 49.5±1.2 
  
  
Overall 51.6±4.8 51.1±4.8 50.9±6.2 
   
Values are means ± standard deviation. MANOVA analysis revealed overall Wilk's Lambda group (p=0.20), 
time (p=0.15), and group x time (p=0.37).   Greenhouse-Geisser time and group x time (G x T) interaction p-
levels are reported with univariate group p-levels.  (*) denotes a significant (p<0.05) difference from baseline. 
(ǂ) denotes a significant (p<0.05 difference from CrN-H.  
 
0.30±0.87 kg, 0.15±1.24 kg; CrM: 0.63±0.81 kg, 0.89±1.46 kg; CrN-L: 
0.28±1.28 kg, 0.69±1.23 kg; CrN-H: 1.17±1.38 kg, p=0.29) after 7 and 28 d of 
supplementation, respectively. Tests of within-subjects contrast indicates a linear 
(p<0.001) change in body weight over time.  
There were no significant differences over time for fat mass (-0.16±0.77, 
0.10±0.86 kg, p=0.17) and no group x time interactions were observed (PL: -0.08±0.74 
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kg, 0.04±0.81 kg; CrM: 0.09±0.23 kg; CrN-L: -0.22±0.58 kg, 0.14±0.42 kg; CrN-H: -
0.38±0.89 kg, 0.01±1.16 kg, p=0.90) after 7 and 28 d of supplementation, respectively.  
Fat-free mass significantly increased over time for all groups (0.30±1.22 kg, 0.56±1.30 
kg, p=0.02) with no significant group x time interaction effects observed among groups 
(PL: 0.33±1.40 kg, 0.19±0.99 kg; CrM: 0.09±0.85, 0.53±1.50; CrN-L: 0.36±1.26 kg, 
0.32±1.04 kg; CrN-H: 0.39±1.42 kg, 1.13±1.53 kg, p=0.49) after 7 and 28 d of 
supplementation, respectively. Tests of within-subjects contrast indicates a linear 
(p=0.006) change in fat-free mass over time.   
No significant differences were observed over time in body fat percent for all 
groups (-0.33±1.38%, -0.19±1.36%, p=0.24) and no significant group x time interactions 
were observed among groups (PL: -0.62±2.28%, -0.54±2.02%; CrM: 0.09±1.15%, 
0.11±1.22%; CrN-L: -0.37±0.91%, 0.07±0.61%; CrN-H: -0.41±0.96%, -0.42±1.37%, 
p=0.78) after 7 and 28 d of supplementation, respectively.  Total body water expressed 
as a percentage of body weight was not significantly difference over time for any group 
(-0.45±4.11%, -0.66±5.65%, p=0.64) with no significantly group by time interactions 
observed among groups (PL: -0.69±2.60%, -1.98±8.70%; CrM: -0.57±1.82%, -
0.25±2.95%; CrN-L: 1.15±5.42%, -1.57±5.40%; CrN-H: -1.75±4.88%, 1.25±4.62%, 
p=0.47) after 7 and 28 d of supplementation, respectively. The results of the body 
composition analysis provide evidence which fails to rejects the null hypothesis of 
hypothesis 10 which states there will be no significant differences among groups in body 
composition as measured by DXA after 7 and 28 d of supplementation.  
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Bench Press Performance and Anaerobic Sprint Test  
Table 17 presents bench press performance and power output during the third 
bench press set. Participants performed three sets of bench press using a load equivalent 
to 70% of their 1 repetition max (1RM). One participant from the CrM group was 
omitted from the statistical analysis as he was unable to perform the bench press test at d 
28 due to a shoulder injury that occurred outside the study. The first two sets consisted 
of ten repetitions each. The third set consisted of maximal repetitions performed.  
Workload was calculated by multiplying weight by repetitions completed during the 
third set.  Peak power, average power, and average velocity were measured by a Tendo 
Fitrodyne.  
MANOVA analysis revealed overall Wilks' Lambda group (p=0.24), time 
(p<0.001), and group x time (0.37). Univariate analysis showed a significant time effects 
for all variables (maximum repetitions, workload, peak power, average power, average 
velocity, all p<0.001) with no group x time interaction observed for any variable 
(maximum repetitions [p=0.55], workload [p=0.10], peak power [p=0.57], average 
power [p=0.82], average velocity [p=0.74]). The percent change in maximum repetitions 
with 70% of 1RM increased by 35.5%, 20.5%, 19.0%, and 26.9% with CrN-H, CrN-L, 
PL, and CrM, respectively after supplementation; however, there were no significant 
differences in maximum repetitions among groups after supplementation. After 28 of 
supplementation, workload with CrN-H was significantly greater than CrN-L (p=0.045) 
and PL (p=0.02), but not significantly greater than CrM (p=0.44). Percent change in 
workload was 35.4±27.7%, 20.5±31.0%, 19.0±23.6%, 26.9±19.4% for CrN-H, CrN-L,  
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Table 17. Bench Press (Set) - Maximum Repetition Performance     
Variable  N Group Day 
         0 28 Mean (SEM)   p-level 
Max Reps 11 PL 10.8±2.9 13.0±4.8 11.9±1.2 Group 0.83 
 
10 CrM 12.0±5.5 15.0±7.1 13.5±1.3 Time 0.001 
 
13 CrN-L 11.9±2.7 14.0±3.7 13.0±1.1 G x T 0.55 
 
13 CrN-H 11.5±3.6 14.8±3.7 13.2±1.1 
  
 
 
Overall 11.6±3.7 14.2±4.7*       
Workload 11 PL 1474±374 1753±549 1614±216 Group 0.17 
(wt x reps) 10 CrM 1827.±926 2255±1122 2041±227 Time 0.001 
 
13 CrN-L 1617±491 1877±535 1746±199 G x T 0.10 
 
13 CrN-H 1927±830 2517±867 2221±199 
  
 
 
Overall 1714±688 2105±824*       
Peak Power  11 PL 426±101 443±107 434±27 Group 0.10 
(W) 10 CrM 453±114 522±120 487±28 Time 0.001 
 
13 CrN-L 440±76 481±88 461±24 G x T 0.57 
 
13 CrN-H 492±95 553±98 523±24 
  
 
 
Overall 454±96 501±108*       
Average Power 11 PL 358±88 382±93 370±27
ǂ
 Group 0.03 
(W) 10 CrM 424±121 456±105 440±28 Time 0.001 
 
13 CrN-L 372±70 396±73 384±25
ǂ
 G x T 0.82 
 
13 CrN-H 451±92 489±90 470±25 
  
 
 
Overall 402±98 432±97*       
Average Velocity 11 PL 0.50±0.09 0.53±0.11 0.52±0.03 Group 0.10 
(m/s) 10 CrM 0.55±0.09 0.62±0.11 0.59±0.03 Time 0.001 
 
13 CrN-L 0.61±0.83 0.65±0.12 0.63±0.03 G x T 0.74 
 
13 CrN-H 0.54±0.11 0.61±0.15 0.58±0.03 
  
 
 
Overall 0.56±0.10 0.61±0.13* 
   
Values are means ± standard deviations.  MANOVA analysis revealed overall Wilks' Lambda group (p=0.24), 
time (p<0.001), and group x time (0.37).  Greenhouse-Geisser time and group x time (G x T) interaction p-
levels are reported with univariate group p-levels. (*) denotes a significant difference (p<0.05) from baseline. 
(ǂ) denotes a significant difference (p<0.05) from CrN-H.   
 
 
PL, and CrM, respectively. Similarly, average power was significantly greater with CrN-
H when compared to CrN-L (p=0.01) and PL (p=0.006), but not significantly greater 
than CrM (p=0.39). Percent change in average power was 9.3±10.1%, 7.7±13.8%, 
7.2±12.2%, and 9.3±8.7% for CrN-H, CrN-L, PL, and CrM, respectively. Peak power 
was significantly greater with CrN-H after 28 d of supplementation compared to PL 
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(p=0.01). There were no significant differences in peak power between CrM and CrN-L 
(p=0.36) or PL (p=0.09) after 28 days of supplementation. Percent change in peak power 
after supplementation was 16.2±29.6%, 9.7±12.0%, 6.4±21.5%, and 16.7±16.7% for 
CrN-H, CrN-L, PL, and CrM, respectively. After 28 d of supplementation, average 
velocity was significantly greater with CrN-L when compared to PL (p=0.03), but not 
significantly greater than CrM (p=0.58) and CrN-H (p=0.46). Percent change in average 
velocity post-supplementation was 14.2±28.8%, 7.2±14.4%, 7.4±16.4%, and 
12.9±11.9% for CrN-H, CrN-L, PL, and CrM, respectively. Tests of within-subjects 
contrasts indicates a linear (p<0.001) change in maximum repetition, workload, peak 
power, average power, and average velocity after supplementation. The results of the 
bench press performance analysis provide evidence which rejects hypothesis 11 which 
stated that there will be a significant difference among groups in bench press 
performance after 28 d of supplementation.  
Table 18 shows the overall results for the anaerobic capacity observed for each 
group. A MANOVA analysis was run on order to assess changes in anaerobic capacity 
variables. MANOVA analysis revealed overall Wilks' Lambda group (p=0.25), time 
(p=0.41), and group x time (p=0.40). Univariate analysis showed no significant time or 
group x time effects for mean power, peak power and total work.   
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Table 18. Anaerobic Sprint Capacity           
Variable 
 
Group Day 
 
    N   0 28 Mean (SEM)   p-level 
Mean Power (W) 10 PL 680±177 683±150 681±37
ǂ
 Group 0.04 
 
11 CrM 684±129 721±142 702±35 Time 0.19 
 
13 CrN-L 671±125 709±107 690±32
ǂ
 G x T 0.41 
 
13 CrN-H 808±91 798±61 803±32 
  
  
Overall 714±140 731±121     
 Peak Power (W) 10 PL 1,490±390 1,487±340 1,488±100 Group 0.17 
 
11 CrM 1,548±352 1,611±441 1,580±94 Time 0.16 
 
13 CrN-L 1,497±270 1,565±278 1,531±87 G x T 0.85 
 
13 CrN-H 1,739±276 1,784±307 1,761±87 
  
  
Overall 1,575±326 1,617±349     
 Total Work (J) 10 PL 6,006±967 6,232±919 6,119±373 Group 0.49 
 
11 CrM 6613±918 6,887±745 6,750±356 Time 0.17 
 
13 CrN-L 6,761±1618 6,818±1291 6,789±327 G x T 0.94 
 
13 CrN-H 6,716±1533 6,884±1495 6,800±327 
  
  
Overall 6,553±1322 6,728±1172 
 
  Values are means ± standard deviations. MANOVA analysis revealed overall Wilks' Lambda group 
(p=0.25), time (p=0.41), and group x time (p=0.40). Greenhouse-Geisser time and group x time (G x T) 
interaction p-levels are reported with univariate group p-levels. (ǂ) denotes a significant (p<0.05) 
difference from CrN-H.  
 
 
Tables 19, 20, and 21 show peak power, mean power, and total work, 
respectively, during each sprint in the anaerobic sprint test. MANOVA analysis revealed 
overall Wilks' Lambda group (p=0.25), time (p=0.41), and group x time (p=0.40). 
Univariate analysis showed a significant time effects for mean power only at sprint 1 
(p=0.03) and sprint 3 (both, p=0.02) after supplementation. 
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Table 19. Peak Power - Individual Sprints         
Variable 
 
Group Day Mean 
 
   N   0 28 (SEM)   p-level 
Sprint: 1 10 PL 1,527±411 1,554±403 1,553±114 Group 0.05 
(W) 11 CrM 1,589±484 1,670±542 1,629±114 Time 0.13 
 
13 CrN-L 1,609±310 1,718±341 1,663±105 G x T 0.94 
 
13 CrN-H 1,903±328 2,021±503 1,962±105 
  
  
Overall 1,668±411 1756±472       
Sprint: 2 10 PL 1,787±594 1,677±451 1,736±123 Group 0.62 
(W) 11 CrM 1,800±468 1,819±476 1,810±123 Time 0.98 
 
13 CrN-L 1,653±299 1,712±318 1,682±113 G x T 0.66 
 
13 CrN-H 1,869±455 1,907±500 1,888±113 
  
  
Overall 1,772±444 1,783±435       
Sprint: 3 10 PL 1,458±399 1,605±471 1,529±112 Group 0.14 
(W) 11 CrM 1,661±378 1,710±540 1,685±112 Time 0.12 
 
13 CrN-L 1,558±405 1,687±290 1,637±103 G x T 0.85 
 
13 CrN-H 1,880±365 1,906±453 1,893±103 
  
  
Overall 1,658±405 1,735±442       
Sprint: 4 10 PL 1,568±426 1,461±304 1,502±95 Group 0.27 
(W) 11 CrM 1,508±319 1,673±473 1,590±95 Time 0.56 
 
13 CrN-L 1,593±344 1,585±256 1,589±87 G x T 0.26 
 
13 CrN-H 1,737±301 1,797±399 1,767±87 
  
  
Overall 1,608±346 1,638±375       
Sprint: 5 10 PL 1,415±368 1,380±305 1,382±95 Group 0.11 
(W) 11 CrM 1,499±406 1,508±426 1,504±95 Time 0.37 
 
13 CrN-L 1,425±359 1,588±320 1,507±87 G x T 0.47 
 
13 CrN-H 1,703±344 1,735±304 1,719±87 
  
  
Overall 1,517±376 1,566±354       
Sprint: 6 10 PL 1,320±349 1,356±374 1,315±91 Group 0.16 
(W) 11 CrM 1,450±360 1,523±385 1,486±91 Time 0.21 
 
13 CrN-L 1,357±322 1,384±351 1,370±83 G x T 0.95 
 
13 CrN-H 1,552±263 1,639±304 1,596±83 
  
  
Overall 1,425±325 1,481±360       
Wingate Test 10 PL 1,352±313 1,372±269 1,334±96 Group 0.32 
(W) 11 CrM 1,329±427 1,374±482 1,351±96 Time 0.79 
 
13 CrN-L 1,253±285 1,279±296 1,266±88 G x T 0.86 
 
13 CrN-H 1,525±364 1,478±329 1,502±88 
      Overall 1,367±354 1376±349       
Values are means ± standard deviations.  MANOVA analysis revealed overall Wilks' 
Lambda group (p=0.25), time (p=0.41), and group x time (p=0.40).  Greenhouse-Geisser 
time and group x time (G x T) interaction p-levels are reported with univariate group p-
levels.  
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Table 20. Mean Power - Individual Sprints         
Variable 
 
Group Day Mean 
 
   N   0 28 (SEM)   p-level 
Sprint: 1 10 PL 793±186 822±194 803±44 Group 0.06 
(W) 11 CrM 813±194 822±195 817±44 Time 0.03 
 
13 CrN-L 826±123 864±124 845±41 G x T 0.84 
 
13 CrN-H 949±103 974±114 961±41 
  
  
Overall 850±160 876±165*       
Sprint: 2 10 PL 793±196 806±190 791±42 Group 0.18 
(W) 11 CrM 811±145 851±203 831±42 Time 0.81 
 
13 CrN-L 803±144 813±105 808±39 G x T 0.32 
 
13 CrN-H 937±136 891±92 914±39 
  
  
Overall 840±161 842±149       
Sprint: 3 10 PL 699±216 738±172 706±40
ǂ
 Group 0.05 
(W) 11 CrM 706±135 798±153 752±40 Time 0.02 
 
13 CrN-L 693±184 765±118 729±37
ǂ
 G x T 0.20 
 
13 CrN-H 867±124 851±79 859±37 
  
  
Overall 745±178 791±134*       
Sprint: 4 10 PL 690±198 660±162 660±38 Group 0.15 
(W) 11 CrM 681±138 749±115 715±38 Time 0.81 
 
13 CrN-L 664±141 712±107 688±35 G x T 0.10 
 
13 CrN-H 818±118 753±177 785±35 
  
  
Overall 716±157 721±143       
Sprint: 5 10 PL 655±181 633±138 627±36
ǂ
 Group 0.008 
(W) 11 CrM 650±131 701±184 675±36
ǂ
 Time 0.41 
 
13 CrN-L 619±154 669±120 644±33
ǂ
 G x T 0.55 
 
13 CrN-H 797±108 792±101 795±33 
  
  
Overall 683±157 703±145       
Sprint: 6 10 PL 640±188 635±149 624±39
ǂ
 Group 0.03 
(W) 11 CrM 638±141 635±164 636±39
ǂ
 Time 0.45 
 
13 CrN-L 595±191 641±126 618±36
ǂ
 G x T 0.76 
 
13 CrN-H 755±99 777±102 766±36 
  
  
Overall 659±165 676±145       
Wingate Test 10 PL 484±122 483±112 473±31 Group 0.56 
(W) 11 CrM 487±116 485±130 486±31 Time 0.82 
 
13 CrN-L 493±109 496±99 494±28 G x T 0.97 
 
13 CrN-H 530±94 542±102 536±28 
  
    Overall 500±108 503±109       
Values are means ± standard deviations.  MANOVA analysis revealed overall Wilks' 
Lambda group (p=0.25), time (p=0.41), and group x time (p=0.40).  Greenhouse-Geisser 
time and group x time (G x T) interaction p-levels are reported with univariate group p-
levels. (*) denotes a significant difference from baseline. (ǂ) denotes a significant difference 
(p<0.05) from CrN-H.  
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Table 21. Total Work - Individual Sprints         
Variable 
 
Group Day Mean 
 
   N   0 28 (SEM)   p-level 
Sprint: 1 10 PL 5796±652 5,601±725 5,737±345 Group 0.66 
(J) 11 CrM 6,148±831 6,360±889 6,254±345 Time 0.06 
 
13 CrN-L 6,075±1425 6,350±1225 6,212±317 G x T 0.08 
 
13 CrN-H 5,856±1478 6,068±1509 5,962±317 
  
  
Overall 5,972±1163 6,115±1161*       
Sprint: 2 10 PL 5,677±580 5,565±880 5,672±318 Group 0.80 
(J) 11 CrM 5,999±892 6,090±793 6,044±318 Time 0.73 
 
13 CrN-L 5,820±1374 5,905±1296 5,863±292 G x T 0.70 
 
13 CrN-H 6,108±1462 5,878±1222 5,993±292 
  
  
Overall 5,911±1147 5,869±1071       
Sprint: 3 10 PL 4,694±986 5,265±811 5,056±312 Group 0.45 
(J) 11 CrM 5,294±814 5,594±621 5,444±312 Time 0.04 
 
13 CrN-L 5,226±1514 5,392±1154 5,309±287 G x T 0.54 
 
13 CrN-H 5,659±1437 5,705±1161 5,682±287 
  
  
Overall 5,249±1260 5,499±970*       
Sprint: 4 10 PL 4,574±760 4,719±843 4,722±283 Group 0.46 
(J) 11 CrM 4,985±761 5,121±708 5,053±283 Time 0.84 
 
13 CrN-L 5,254±1305 4,809±1314 5,031±260 G x T 0.41 
 
13 CrN-H 5,263±1295 5,309±1068 5,286±260 
  
  
Overall 5,049±1093 5,001±1027       
Sprint: 5 10 PL 4,352±952 4,731±1144 4,618±292 Group 0.74 
(J) 11 CrM 4,856±716 4,877±536 4,867±292 Time 0.57 
 
13 CrN-L 5,014±1313 4,867±1133 4,941±269 G x T 0.64 
 
13 CrN-H 4,918±1215 4,985±1283 4,951±269 
  
  
Overall 4,809±1089 4,873±1044       
Sprint: 6 10 PL 4,297±1024 4,252±1042 4,341±303 Group 0.57 
(J) 11 CrM 4,749±761 4,850±513 4,800±303 Time 0.70 
 
13 CrN-L 4,776±1311 4,846±1105 4,811±279 G x T 0.98 
 
13 CrN-H 4,721±1228 4,774±1294 4,748±279 
  
  
Overall 4,653±1099 4,701±1040       
Wingate Test 10 PL 12,650±3177 13,495±2775 13,466±968 Group 0.37 
(J) 11 CrM 14,259±4680 15,315±2138 14,787±968 Time 0.16 
 
13 CrN-L 15,161±4171 15,553±3500 15,357±891 G x T 0.98 
 
13 CrN-H 14,490±4355 15,473±4079 14,981±891 
  
    Overall 14,230±4127 15,037±3271       
Values are means ± standard deviations.  MANOVA analysis revealed overall Wilks' Lambda 
group (p=0.25), time (p=0.41), and group x time (p=0.40).    Greenhouse-Geisser time and group x 
time (G x T) interaction p-levels are reported with univariate group p-levels. (*) denotes a 
significant difference from baseline.  
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There was also a time effects for total work at sprint 3 (p=0.04). Tests of within-subjects 
contrast indicated a linear change in mean power at sprint 1 (p=0.03) and sprint 3 
(p=0.02) and total work at sprint 3 (p=0.04). No other time effects observed for any 
variable during the anaerobic sprint test. There was no group x time interactions for peak 
power, mean power, or total work during any sprint of the anaerobic sprint test. 
Although changes from baseline were not statistically significant between groups across 
time (p=0.06), the Cohen’s d effect size indicates a small significant increase in total 
work at sprint 1 (d=0.12) after supplementation. The results of the anaerobic sprint test 
provide evidence which rejects hypothesis 12 which states there will be differences 
among groups in anaerobic capacity as measured by repeated sprints on a cycle 
ergometer after 28 d of supplementation.  
Clinical Chemistry Panels  
 Table 22 presents whole blood markers assessed during Study 2. MANOVA 
analysis revealed overall Wilks' Lambda (p=0.32), time (p=0.03), and group x time 
(p=0.76). Univariate analysis revealed no significant time or group by time effect for any 
whole blood marker. While changes from baseline were not statistically significant 
between groups across time (p=0.09), the Cohen’s d indicates a small to moderate effect 
size decrease across time in RBC count after supplementation.   
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Table 22. Study 2: Whole Blood Markers           
Markers 
 
Group Day Mean 
  
 
N 
 
0 7 28 (SEM) 
 
p-level 
MCV 11 PL 92.2±3.1 91.6±3.7 91.6±3.8 91.8±1.3 Group 0.79 
(fL) 13 CrM 92.9±3.9 93.6±3.9 93.6±4.7 93.4±1.3 Time 0.47 
 
13 CrN-L 91.6±3.7 91.7±4.0 92.2±4.2 91.9±1.2 G x T 0.49 
 
11 CrN-H 93.2±2.9 93.4±3.1 88.6±17.7 91.7±1.2 
  
  
Overall 92.5±3.4 92.6±3.7 91.5±9.8 
   MCH 11 PL 30.3±1.7 30.4±1.2 30.9±2.3 30.6±0.3 Group 0.45 
(pg/cell) 13 CrM 30.5±1.3 31.1±1.4 30.9±2.6 30.9±0.3 Time 0.23 
 
13 CrN-L 30.5±1.6 31.5±2.0 31.3±2.2 31.1±0.3 G x T 0.92 
 
11 CrN-H 31.2±0.8 31.2±1.3 31.5±1.2 31.3±0.3 
  
  
Overall 30.7±1.4 31.1±1.5 31.2±2.0 
   MCHC 11 PL 32.9±1.1 33.2±1.7 33.7±1.8 33.3±0.4 Group 0.40 
(g/dl) 13 CrM 32.8±0.7 33.2±1.5 33.1±1.9 33.1±0.4 Time 0.53 
 
13 CrN-L 33.3±0.7 34.4±3.3 33.9±1.7 33.9±0.3 G x T 0.66 
 
11 CrN-H 33.5±0.7 33.5±1.6 32.2±5.9 33.1±0.3 
  
  
Overall 33.1±0.8 33.6±2.2 33.2±3.4 
   RBCDW 11 PL 13.2±0.5 13.1±0.9 13.±0.3 13.1±0.1 Group 0.02 
(%) 13 CrM 13.5±0.9 13.7±0.9 13.9±0.8 13.7±0.1# Time 0.11 
 
13 CrN-L 13.3±0.6 13.4±0.6 13.5±0.7 13.3±0.1 G x T 0.66 
 
11 CrN-H 12.8±0.6 13.2±0.6 13.1±0.4 13.0±0.1 
  
  
Overall 13.2±0.7 13.3±0.8 13.4±0.7 
   Platelet Count 11 PL 206±36 188±32 208±69 200±4 Group 0.35 
(x103/µl) 13 CrM 234±56 225±91 255±50 238±4 Time 0.56 
 
13 CrN-L 218±69 183±50 194±68 198±3 G x T 0.39 
 
11 CrN-H 220±60 412±713 224±58 285±3 
  
  
Overall 219±56 256±376 219±64 
   Values are means ± standard deviations.  MANOVA analysis revealed overall Wilks' Lambda (p=0.32), time 
(p=0.03), and group x time (p=0.76).  Greenhouse-Geisser time and group x time (G x T) interaction p-levels 
are reported with univariate group p-levels. (#) denotes a significant difference (p<0.05) from CrN-H and PL.  
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Table 22. Continued         
Markers 
 
Group Day Mean 
  
 
N 
 
0 7 28 (SEM) 
 
p-level 
WBC 11 PL 6.2±1.7 5.3±1.5 6.2±1.1 5.9±0.4 Group 0.72 
(x103/µl) 13 CrM 6.0±1.7 6.6±1.3 6.4±1.3 6.3±0.4 Time 0.58 
 
13 CrN-L 6.2±1.6 5.9±1.8 5.4±1.3 5.9±0.3 G x T 0.18 
 
11 CrN-H 5.9±1.4 5.5±1.6 6.1±1.6 5.8±0.3 
  
  
Overall 6.1±1.6 5.8±1.6 6.0±1.4 
   RBC 11 PL 5.2±0.8 5.0±0.8 4.8±0.6 5.0±0.1 Group 0.25 
(x106/µl) 13 CrM 5.3±0.6 5.6±1.0 5.1±0.8 5.3±0.1 Time 0.09 
 
13 CrN-L 5.0±0.5 5.1±01.0 4.9±0.7 5.0±0.1 G x T 0.65 
 
11 CrN-H 5.5±0.8 5.1±0.5 5.1±0.5 5.2±0.1 
  
  
Overall 5.3±0.7 5.2±0.8 5.0±0.6 
   Hematocrit 11 PL 47.7±7.1 46.0±8.2 44.0±4.5 45.9±1.8 Group 0.16 
(%) 13 CrM 49.5±6.7 52.5±9.7 47.6±8.4 49.9±1.8 Time 0.51 
 
13 CrN-L 46.2±5.5 47.1±10.3 44.8±7.1 46.0±1.7 G x T 0.44 
 
11 CrN-H 51.2±7.8 47.5±5.2 51.7±15.4 50.1±1.7 
  
  
Overall 48.7±6.9 48.2±8.6 47.1±10.1 
   Hemoglobin 11 PL 15.7±2.5 15.3±2.7 14.8±1.2 15.3±0.9 Group 0.17 
(g/dl) 13 CrM 16.3±2.1 20.1±10.2 15.7±2.8 17.3±0.9 Time 0.63 
 
13 CrN-L 15.4±2.1 16.1±3.1 15.2±2.3 15.6±0.8 G x T 0.19 
 
11 CrN-H 17.2±2.7 15.9±1.4 18.7±9.5 17.2±0.8 
      Overall 16.1±2.4 16.8±5.5 16.2±5.4       
Values are means ± standard deviations.  MANOVA analysis revealed overall Wilks' Lambda 
(p=0.32), time (p=0.03), and group x time (p=0.76).  Greenhouse-Geisser time and group x time (G x 
T) interaction p-levels are reported with univariate group p-levels.  
 
Table 23 presents biological markers of health. MANOVA analysis revealed 
overall Wilks' Lambda (p=0.32), time (p=0.03), and group x time (p=0.76) Univariate 
analysis revealed a significant time effects for creatinine (p<0.001). Tests of within-
subject contrasts indicated a linear (p=0.001) change over time. There was a trend 
towards a significant time effect for BUN:Creatinine ratio (p=0.07) and alanine 
aminotransferase (ALT) (p=0.06). However, there was no significant group x time 
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effects for any biological health marker. Although changes from baseline were not 
statistically significant between groups across time for BUN:Creatinine ratio (p=0.07) 
and ALT (p=0.06), the Cohen’s d indicates a small effect change across time in 
BUN:Creatinine ratio and ALT after supplementation.  
 
 
Table 23. Study 2: Health Markers           
Marker 
 
Group Day Mean 
 
 
 
N 
 
0 7 28 (SEM) 
 
p-level 
ALP 11 PL 11.2±14.6 10.5±10.7 12.4±10.9 11.4±3.0 Group 0.44 
(U/L) 13 CrM 11.4±9.5 12.0±10.4 11.0±7.8 11.5±3.0 Time 0.36 
 
13 CrN-L 15.5±11.4 16.2±11.9 19.5±15.9 17.1±2.7 G x T 0.85 
 
11 CrN-H 12.1±7.1 13.6±6.1 14.3±11.7 13.3±2.7 
 
 
  
Overall 12.7±10.7 13.2±9.9 14.5±12.2 
  
 
ALT 11 PL 27.2±8.6 30.2±13.8 32.1±30.6 29.9±4.2 Group 0.24 
(U/L) 13 CrM 28.9±16.6 25.1±10.0 32.7±22.9 21.2±3.9 Time 0.06 
 
13 CrN-L 21.3±6.7 19.9±4.4 22.4±6.7 21.2±3.9 G x T 0.70 
 
11 CrN-H 28.7±13.2 30.0±15.7 36.8±23.2 31.8±3.9 
 
 
  
Overall 26.4±11.9 26.2±12.2 30.9±22.1 
  
 
AST 11 PL 31.2±13.3 30.1±11.6 29.5±13.4 30.3±2.7 Group 0.90 
(U/L) 13 CrM 28.3±10.2 26.4±7.7 32.5±12.3 29.1±2.7 Time 0.56 
 
13 CrN-L 26.0±7.0 30.6±25.3 26.0±6.0 27.5±2.5 G x T 0.47 
 
11 CrN-H 26.4±5.9 28.7±7.0 32.0±7.6 29.0±2.5 
 
 
  
Overall 27.8±9.2 29.0±14.8 29.9±10.1 
  
 
CK 11 PL 252±128 294±399 206±161 251±82 Group 0.79 
(U/L) 13 CrM 288±169 345±319 409±373 346±82 Time 0.35 
 
13 CrN-L 283±169 480±987 243±136 335±75 G x T 0.56 
 
11 CrN-H 284±171 350±203 425±287 352±75 
 
 
  
Overall 277±157 371±565 321±265 
  
 
LDH 11 PL 226±180 167±29 157±33 184±14 Group 0.93 
(U/L) 13 CrM 185±62 172±38 184±48 180±14 Time 0.20 
 
13 CrN-L 175±50 173±41 166±28 171±12 G x T 0.23 
 
11 CrN-H 173±29 176±30 182±38 177±12 
 
 
    Overall 188±95 172±34 172±38       
Values are means ± standard deviations. MANOVA analysis revealed overall Wilks' Lambda (p=0.32), time (p=0.03), 
and group x time (p=0.76).  Greenhouse-Geisser time and group x time (G x T) interaction p-levels are reported with 
univariate group p-levels.  
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Table 23. Continued            
Marker 
 
Group Day Mean 
 
 
 
N 
 
0 7 28 (SEM) 
 
p-level 
BUN 11 PL 16.3±3.6 15.6±5.2 15.7±4.9 15.8±1.2 Group 0.64 
(mg/dl) 13 CrM 15.3±5.5 15.2±4.9 16.3±6.1 15.6±1.2 Time 0.48 
 
13 CrN-L 14.9±3.8 13.3±3.9 13.5±4.6 13.9±1.1 G x T 0.64 
 
11 CrN-H 14.6±3.2 14.8±2.7 15.7±5.8 15.0±1.1 
 
 
  
Overall 15.2±4.0 14.7±4.2 15.2±5.3 
  
 
Creatinine  11 PL 1.18±0.26 1.19±0.33 1.15±0.27 1.18±0.09 Group 0.97 
(mg/dl) 13 CrM 1.15±0.46 1.26±0.36 1.23±0.39 1.21±0.09 Time 0.001 
 
13 CrN-L 1.09±0.25 1.21±0.31 1.23±0.31 1.18±0.81 G x T 0.12 
 
11 CrN-H 1.12±0.18 1.15±0.23 1.20±0.23 1.16±0.08 
 
 
  
Overall 1.13±0.29 1.20±0.30* 1.20±0.29* 
  
 
BUN:Creatinine 11 PL 14.2±3.7 13.9±6.8 13.6±3.1 13.9±1.2 Group 0.78 
(mg/dl) 13 CrM 13.7±3.6 12.8±5.3 14.0±6.1 13.5±1.2 Time 0.07 
 
13 CrN-L 14.1±4.2 11.4±3.8 11.3±3.4 12.3±1.1 G x T 0.13 
 
11 CrN-H 13.3±3.8 13.3±3.3 13.4±4.8 13.3±1.1 
 
 
  
Overall 13.84±3.73 12.82±4.82 13.01±4.45      
Glucose 11 PL 102.0±18.6 102.1±15.3 94.9±12.6 99.7±3.4 Group 0.74 
 
13 CrM 97.5±13.9 99.7±15.1 100.4±16.8 99.2±3.4 Time 0.70 
 
13 CrN-L 96.1±8.5 96.1±7.9 96.4±17.9 96.2±3.1 G x T 0.27 
 
11 CrN-H 97.1±9.4 93.2±5.2 96.0±9.4 95.4±3.1 
  
  
Overall 98.0±12.7 97.5±11.5 96.8±14.2 
   
Values are means ± standard deviations.  MANOVA analysis revealed overall Wilks' Lambda (p=0.32), time 
(p=0.03), and group x time (p=0.76).  Greenhouse-Geisser time and group x time (G x T) interaction p-levels are 
reported with univariate group p-levels. (*) denotes a significant difference from baseline.  
 
 
 Table 24 presents plasma lipids.  A MANOVA analysis was run to assess plasma 
lipid concentrations.  MANOVA analysis revealed overall Wilks' Lambda (p=0.32), time 
(p=0.03), and group x time (p=0.76). Univariate analysis showed no significant time 
effects or group x time interaction for any variable presented. The results of the markers 
of clinical health and safety analysis provide evidence which fails to reject the null 
hypothesis of hypothesis 13 which stated there will be no significant differences among 
groups in markers of clinical health and safety after 7 and 28 d of supplementation.  
 116 
 
 
Table 24. Plasma Lipids 
  
      
Marker 
 
Group Day Mean 
  
 
N 
 
0 7 28 (SEM) 
 
p-level 
TCHL 11 PL 165.1±33.4 161.5±38.8 164.6±38.8 163.7±9.1 Group 0.19 
(mg/dl) 13 CrM 174.4±25.5 175.4±27.8 183.4±41.1 177.7±9.1 Time 0.38 
 
13 CrN-L 151.9±35.8 149.7±29.5 150.0±37.5 150.5±8.4 G x T 0.83 
 
11 CrN-H 162.7±25.1 155.9±23.8 160.7±29.1 159.8±8.4 
  
  
Overall 163.0±30.5 160.0±30.7 163.9±37.4 
   HDL 11 PL 49.2±11.4 50.6±10.2 50.3±12.8 50.0±3.8 Group 0.62 
(mg/dl) 13 CrM 51.8±15.2 54.7±15.5 55.2±17.4 53.9±3.8 Time 0.36 
 
13 CrN-L 48.6±15.7 48.3±15.1 47.9±12.8 48.3±3.5 G x T 0.85 
 
11 CrN-H 46.7±10.7 47.2±12.3 48.7±10.6 47.5±3.5 
  
  
Overall 49.0±13.1 50.0±13.4 50.3±12.8 
   TCHL:HDL 11 PL 3.5±0.7 3.2±0.6 3.3±0.6 3.3±0.3 Group 0.82 
(mg/dl) 13 CrM 3.7±1.5 3.5±1.3 3.7±1.6 3.6±0.3 Time 0.24 
 
13 CrN-L 3.3±0.8 3.3±1.0 3.3±1.1 3.3±0.3 G x T 0.74 
 
11 CrN-H 3.6±0.8 3.5±0.9 3.4±0.9 3.5±0.3 
  
  
Overall 3.5±1.0 3.4±1.0 3.4±1.1 
   LDL 11 PL 93.4±23.4 91.7±29.6 95.8±34.6 93.6±8.6 Group 0.34 
(mg/dl) 13 CrM 103.8±33.3 106.6±33.5 112.2±49.0 107.5±8.5 Time 0.36 
 
13 CrN-L 86.3±22.6 84.8±23.7 87.3±28.7 86.1±7.9 G x T 0.88 
 
11 CrN-H 95.2±25.0 93.4±22.9 94.3±28.4 94.3±7.9 
  
  
Overall 94.4±26.1 93.7±27.7 96.8±35.5 
   TG 11 PL 109.1±52.5 98.2±36.9 94.2±19.1 100.5±10.7 Group 0.63 
(mg/dl) 13 CrM 114.5±60.6 93.1±30.9 112.0±42.6 106.5±10.7 Time 0.16 
 
13 CrN-L 87.5±43.2 90.7±49.1 85.8±30.7 88.0±9.8 G x T 0.69 
 
11 CrN-H 104.8±47.1 85.6±39.2 97.2±49.8 95.9±9.8 
  
  
Overall 103.3±50.2 91.6±39.0 96.8±37.8 
   Values are means ± standard deviations.  MANOVA analysis revealed overall Wilks' Lambda (p=0.32), time (p=0.03), 
and group x time (p=0.76). Greenhouse-Geisser time and group x time (G x T) interaction p-levels are reported with 
univariate group p-levels.  
 
 
Side Effects 
Tables 25 and 26 present frequency and severity, respectively, of symptoms 
reported. MANOVA analysis was run on side effects questionnaire to assess changes in 
symptoms which include frequency and severity of dizziness, headache, tachycardia, 
heart skipping or palpitations, shortness of breath, nervousness, blurred vision, and any   
 117 
 
Table 25. Study 2: Side Effects - Frequency of Symptoms             
Symptoms N Group Day 
         7 14 21 28 Mean (SEM)   p-level 
Dizziness 11 PL 0.09±0.30 0.91±0.30 0.18±0.40 0.09±0.30 0.11±0.09 Group 0.32 
 
11 CrM 0.18±0.60 0.27±0.47 0.36±0.92 0.27±0.65 0.27±0.09 Time 0.37 
 
13 CrN-L 0.00±0.00 0.08±0.28 0.23±0.60 0.08±0.28 0.10±0.09 G x T 0.81 
 
13 CrN-H 0.08±0.28 0.08±0.28 0.00±0.00 0.00±0.00 0.04±0.09 
  
 
 
Overall 0.08±0.35 0.13±0.33 0.19±0.57 0.10±0.37       
Headache 11 PL 0.27±0.47 0.18±0.40 0.27±0.47 0.18±0.40 0.23±0.14 Group 0.22 
 
11 CrM 0.36±0.67 0.46±0.69 0.46±0.93 0.36±0.67 0.41±0.14 Time 0.74 
 
13 CrN-L 0.23±0.43 0.31±0.85 0.23±0.60 0.23±0.60 0.25±0.13 G x T 0.94 
 
13 CrN-H 0.27±0.47 0.00±0.00 0.00±0.00 0.00±0.00 3.5E-17±0.13 
  
 
 
Overall 0.21±0.46 0.23±0.59 0.23±0.59 0.19±0.49       
Fast or Racing 11 PL 0.00±0.00 0.09±0.30 0.27±0.65 0.36±0.92 0.18±0.22 Group 0.64 
Heart Rate 11 CrM 0.27±0.65 0.36±0.81 0.46±1.0 0.36±0.81 0.36±0.22 Time 0.38 
 
13 CrN-L 0.31±0.48 0.23±0.44 0.15±0.38 0.15±0.38 0.21±0.20 G x T 0.31 
 
13 CrN-H 0.46±1.2 0.54±1.1 0.54±1.1 0.54±1.1 0.52±0.20 
  
 
 
Overall 0.27±0.74 0.31±0.72 0.35±0.81 0.35±0.81       
Heart Skipping or  11 PL 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 2.1E-17±0.13 Group 0.63 
Palpitations 11 CrM 0.09±0.30 0.18±0.60 0.27±0.90 0.18±0.60 0.18±0.13 Time 0.67 
 
13 CrN-L 0.00±0.00 0.08±0.28 0.00±0.00 0.00±0.00 0.02±0.12 G x T 0.29 
 
13 CrN-H 0.23±0.83 0.15±0.55 0.15±0.55 0.15±0.55 0.17±0.12 
  
 
 
Overall 0.10±0.42 0.10±0.42 0.10±0.51 0.08±0.40       
Shortness of Breath  11 PL 0.00±0.00 0.00±0.00 0.09±0.30 0.00±0.00 0.02±0.15 Group 0.62 
 
11 CrM 0.09±0.30 0.09±0.30 0.09±0.30 0.09±0.30 0.09±0.15 Time 0.34 
 
13 CrN-L 0.08±0.28 0.00±0.00 0.00±0.00 0.00±0.00 0.02±0.14 G x T 0.49 
 
13 CrN-H 0.31±1.12 0.23±0.83 0.23±0.83 0.23±0.83 0.25±0.14 
  
 
 
Overall 0.13±0.61 0.08±0.45 0.10±0.47 0.08±0.45       
Nervousness 11 PL 0.00±0.00 0.09±0.30 0.09±0.30 0.00±0.00 0.05±0.15 Group 0.72 
 
11 CrM 0.18±0.40 0.27±0.47 0.27±0.47 0.27±0.47 0.25±0.15 Time 0.35 
 
13 CrN-L 0.15±0.55 0.08±0.28 0.08±0.28 0.08±0.28 0.10±0.14 G x T 0.38 
 
13 CrN-H 0.15±0.55 0.23±0.83 0.23±0.83 0.23±0.83 0.21±0.14 
  
 
 
Overall 0.13±0.44 0.17±0.52 0.17±0.52 0.15±0.50       
Blurred Vision 11 PL 0.00±0.00 0.00±0.00 0.09±0.30 0.00±0.00 0.02±0.06 Group 0.27 
 
11 CrM 0.18±0.40 0.18±0.60 0.18±0.40 0.09±0.30 0.16±0.06 Time 0.33 
 
13 CrN-L 0.08±0.28 0.08±0.28 0.08±0.28 0.00±0.00 0.06±0.06 G x T 0.92 
 
13 
CrN-H 0.00±0.00 0.00±0.00 0.00±0.00 
0.00±0.00 
-3.3E-
18±0.06   
 
 
Overall 0.06±0.24 0.06±0.32 0.08±0.28 0.02±0.14       
Any other unusual  
11 
PL 
0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 
-2.5E-
17±0.14 
Group 0.13 
or adverse effects 11 CrM 0.55±1.51 0.46±1.21 0.46±1.21 0.18±0.40 0.41±0.14 Time 0.36 
 
13 CrN-L 0.15±0.55 0.00±0.00 0.00±0.00 0.00±0.00 0.04±0.13 G x T 0.72 
 
13 
CrN-H 0.00±0.00 0.00±0.00 0.00±0.00 
0.00±0.00 
-5.3E-
19±0.13   
 
 
Overall 0.17±0.78 0.10±0.59 0.10±0.59 0.04±0.20 
   
Values are means ± standard deviations. MANOVA analysis revealed an overall Wilks’ Lambda group 
(p=0.11), time (p=0.35), and group x time (0.34). Greenhouse-Geisser time and group x time (G x T) 
interaction p-levels are reported with univariate group p-levels.   
  
 118 
 
 
Table 26. Study 2: Side Effects - Severity of Symptoms             
Variable  N Group Day 
         7 14 21 28 Mean (SEM)   p-level 
Dizziness 11 PL 0.09±0.30 0.09±0.57 0.18±0.40 0.09±0.30 0.11±0.11 Group 0.27 
 
11 CrM 0.09±0.30 0.64±1.02 0.18±0.40 0.18±0.40 0.27±0.11 Time 0.28 
 
13 CrN-L 0.00±0.00 0.08±0.28 0.39±0.96 0.30±1.11 0.19±0.10 G x T 0.16 
 
13 CrN-H 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.10 
  
 
 
Overall 0.42±0.20 0.19±0.57 0.19±0.57 0.15±0.62       
Headache 11 PL 0.64±1.21 0.18±0.40 0.55±1.04 0.36±0.92 0.43±0.21 Group 0.30 
 
11 CrM 0.55±1.04 0.36±0.67 0.55±0.82 0.55±0.82 0.50±0.21 Time 0.23 
 
13 CrN-L 0.54±1.05 0.46±1.20 0.39±0.96 0.31±0.85 0.42±0.19 G x T 0.79 
 
13 CrN-H 0.08±0.28 0.00±0.00 0.00±0.00 0.00±0.00 0.02±0.19 
  
 
 
Overall 0.44±0.94 0.25±0.73 0.35±0.81 0.29±0.74       
Fast or Racing 11 PL 0.00±0.00 0.09±0.30 0.09±0.30 0.09±0.30 0.07±0.17 Group 0.41 
Heart Rate 11 CrM 0.09±0.30 0.09±0.30 0.18±0.60 0.09±0.30 0.11±0.17 Time 0.77 
 
13 CrN-L 0.39±0.65 0.23±0.43 0.15±0.38 0.15±0.37 0.23±0.16 G x T 0.17 
 
13 CrN-H 0.31±0.85 0.46±0.96 0.46±0.97 0.46±0.96 0.42±0.16 
  
 
 
Overall 0.21±0.58 0.23±0.59 0.23±0.63 0.21±0.58       
Heart Skipping or  11 PL 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 2.8E-17±0.10 Group 0.60 
Palpitations 11 CrM 0.18±0.40 0.09±0.30 0.18±0.60 0.09±0.30 0.14±0.10 Time 0.74 
 
13 CrN-L 0.00±0.00 0.08±0.27 0.00±0.00 0.00±0.00 0.02±0.10 G x T 0.49 
 
13 CrN-H 0.15±0.55 0.15±0.55 0.15±0.55 0.15±0.55 0.15±0.10 
  
 
 
Overall 0.08±0.34 0.08±0.34 0.08±0.40 0.06±0.32       
Shortness of Breath  11 PL 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 5.6E-17±0.16 Group 0.61 
 
11 CrM 0.09±0.30 0.09±0.30 0.18±0.60 0.18±0.60 0.14±0.16 Time 0.46 
 
13 CrN-L 0.08±0.28 0.00±0.00 0.00±0.00 0.00±0.00 0.02±0.14 G x T 0.39 
 
13 CrN-H 0.31±1.11 0.23±0.83 0.23±0.83 0.23±0.83 0.25±0.14 
  
 
 
Overall 0.13±0.61 0.08±0.45 0.10±0.51 0.10±0.51       
Nervousness 11 PL 0.00±0.00 0.27±0.90 0.27±0.90 0.00±0.00 0.14±0.17 Group 0.49 
 
11 CrM 0.18±0.40 0.55±1.04 0.46±0.93 0.55±1.04 0.43±0.17 Time 0.400 
 
13 CrN-L 0.23±0.83 0.15±0.55 0.08±0.28 0.08±0.28 0.12±0.15 G x T 0.30 
 
13 CrN-H 0.15±0.55 0.27±0.90 0.15±0.55 0.15±0.55 0.15±0.15 
  
 
 
Overall 0.15±0.55 0.25±0.72 0.23±0.69 0.19±0.61       
Blurred Vision 11 PL 0.00±0.00 0.00±0.00 0.27±0.65 0.00±0.00 0.07±0.08 Group 0.31 
 
11 CrM 0.27±0.64 0.09±0.30 0.27±0.65 0.18±0.60 0.21±0.08 Time 0.13 
 
13 CrN-L 0.08±0.28 0.00±0.00 0.15±0.55 0.00±0.00 0.06±0.07 G x T 0.76 
 
13 CrN-H 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 1.3E-17±0.07 
  
 
 
Overall 0.08±0.35 0.02±0.14 0.17±0.60 0.04±0.29       
Any other unusual  11 PL 0.09±0.30 0.00±0.00 0.00±0.00 0.00±0.00 0.02±0.10 Group 0.05 
or adverse effects 11 CrM 0.18±0.40 0.27±0.65 0.46±1.21 0.45±0.93 0.34±0.10 Time 0.77 
 
13 CrN-L 0.23±0.83 0.00±0.00 0.00±0.00 0.00±0.00 0.06±0.09 G x T 0.57 
 
13 CrN-H 0.00±0.0 0.00±0.00 0.00±0.00 0.00±0.00 -2.2E18±0.09 
  
 
 
Overall 0.13±0.49 0.06±0.32 0.10±0.59 0.10±0.47 
   
Values are means ± standard deviations. MANOVA analysis revealed an overall Wilks’ Lambda group 
(p=0.11), time (p=0.35), and group x time (p=0.34).  Greenhouse-Geisser time and group x time (G x T) 
interaction p-levels are reported with univariate group p-levels.   
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other unusual or adverse effects. MANOVA analysis revealed an overall Wilks’ Lambda 
group (p=0.11), time (p=0.35), and group x time (0.34). Univariate analysis revealed no 
significant time (p=0.35) or group x time (p=0.34) effects for frequency or severity of 
reported symptoms.     
Herein we report the weekly occurrence of a symptom ranking of 2 or greater on 
a 0 – 5 ranking scale with each treatment group. In the PL group, participants reported 
headache/severity=3 (N=2) during wk 1, nervousness/severity=3 (N=1) during wk 2, 
tachycardia/frequency=2 (N=1), headache/severity=2 (N=1), nervousness/severity=3 
(N=1), and blurred vision/severity=3 (N=1) during wk 3, and fast or racing heart 
rate/frequency=3 (N=1) during wk 4.  
In CrM group, participants reported headache/frequency=2 (N=1), fast or racing 
heart rate/frequency=2 (N=1), adverse effect/frequency=5 (N=1), headache/severity=1 
(N=1), blurred vision/severity=2 (N=1) during wk 1, headache/frequency=2 (N=1), 
tachycardia/frequency=2 (N=2), heart skipping or palpitations/frequency=2 (N=1), 
blurred vision/frequency=2 (N=1), adverse effect/severity=4 (N=1), headache/severity=2 
(N=1), nervousness/severity=2 and 3 (N=2), adverse effect/severity=2 (N=1) during 
week 2, dizziness/frequency=3 (N=1), headache/frequency=3 (N=1), 
tachycardia/frequency=2 and 3 (N=2), heart skipping or palpitations/frequency (N=1), 
adverse effect/frequency=4 (N=1), headache/severity=2 (N=2), tachycardia/severity=2 
(N=1), heart skipping or palpitations/severity=2 (N=1), shortness of breath/severity=2 
(N=1), blurred vision/severity=2 (N=1), and adverse effect/severity=4 (N=1) during 
week 3, and dizziness/frequency=2 (N=1), headache/frequency=2 (N=1), 
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tachycardia/frequency=2 (N=1), headache/frequency=2 (N=1), tachycardia/frequency=2 
(N=1), headache/severity=2 (N=2), shortness of breath/severity=3 (N=1), 
nervousness/severity=3 (N=1), blurred vision/severity=2 (N=1), and adverse 
effect/severity=3 (N=1) during wk 4.  
In CrN-L group participants reported nervousness/frequency=2 (N=1), adverse 
effect/frequency=2 (N=1), headache/severity=2 (N=2), headache/severity=3 (N=3), 
tachycardia/severity=2 (N=1), nervousness/severity=3 (N=1) during week 1, 
headache/frequency=3 (N=1) and headache/severity=2 (N=1) and 4 (N=1) during week 
2, dizziness/frequency=2 (N=1), headache/frequency=2 (N=1), dizziness/severity=2 
(N=1) and 3 (N=1), headache/severity=2 (N=1) and 3 (N=1), and blurred 
vision/severity=2 (N=1) during wk 3, and headache/frequency=2 (N=1), 
dizziness/severity=4 (N=1), headache/severity=3 (N=1) and adverse effect/severity 
(N=1). 
In CrN-H group participants reported fast or racing heart/frequency=2 (N=1) and 
4 (N=1), heart skipping or palpitation/frequency=3 (N=1), shortness of 
breath/frequency=4 (N=1), tachycardia/severity=3 (N=1), heart skipping or 
palpitations/severity=2 (N=1), shortness of breath/severity=4 (N=1), 
nervousness/severity=2 (N=1) during wk 1, tachycardia/frequency=2 (N=2) and 3 
(N=1), heart skipping or palpitations/frequency=2 (N=1), shortness of 
breath/frequency=3 (N=1), nervousness/frequency=3 (N=1), fast or racing 
heart/severity=2 (N=1) and 3 (N=1), shortness of breath/severity=3 (N=1), heart 
skipping or palpitations/severity=2 (N=1), and nervousness/severity=2 (N=1) during wk 
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2, tachycardia/frequency=2 (N=2) and 3 (N=1), heart skipping or 
palpitation/frequency=2 (N=1), shortness of breath/frequency=3 (N=1), 
nervousness/frequency=3 (N=1), tachycardia/severity=2 (N=1) and3 (N=1), heart 
skipping or palpitations/severity=2 (N=1), shortness of breath/severity=3 (N=1), and 
nervousness/severity=2 (N=1) during wk 3, and fast or racing heart/frequency=2 (N=2) 
and 3 (N=1), heart skipping/frequency=2 (N=1), shortness of breath/frequency=3 (N=1), 
nervousness/frequency=3 (N=1), fast or racing heart/severity=2 (N=1) and 3 (N=1), 
heart skipping or palpitation/severity=2 (N=1), shortness of breath/severity=3 (N=1), 
and nervousness/severity=2 (N=1) during wk 4. The results of the side effects 
questionnaire analysis provides evidence which accepts the null hypothesis of hypothesis 
14 which states there will be no significant differences between groups in side effects 
symptoms after 7, 14, 21, and 28 d of supplementation.   
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CHAPTER V 
DISCUSSION AND CONCLUSIONS 
 
Creatine and nitrate are popular supplements amongst those wishing to improve 
exercise performance; yet have not been investigated together. We examined creatine 
nitrate (CrN) at a recommended dose (CrN-L) and twice the recommended (CrN-H) 
compared to creatine monohydrate (CrM) and a placebo (PL). The purpose of this study 
was to examine the acute safety and chronic efficacy of a lower dose of CrN (CrN-L: 6 g 
CrN-L/d for 7 d and 1.5 g CrN-L/d for 21 d), or a higher dose of CrN (CrN-H: 12 g CrN-
H/d for 7 d and 3 g CrN-H/d for 21 d) compared to CrM (CrM: 20 g CrM/d for 7 d and 5 
g CrM for 21 d) and PL (26 g dextrose/d for 7 d and 6.5 g/d for 21 d) on muscle creatine 
retention, body composition, strength, anaerobic capacity and markers of clinical health.   
Our findings refute the current marketing claims indicating that CrN is 10 times more 
effective than CrM, the gold standard form of creatine. The results of the present study 
show that creatine nitrate supplementation is safe; however, neither dose of CrN was 
more effective than CrM in enhancing muscle creatine storage, improving body 
composition, upper body strength, or anaerobic capacity.     
Study 1 
  We observed significant changes in plasma creatine and nitrate after acute 
supplementation – CrM (5 g CrM, 1.5 g dextrose), CrN-L (1 g Cr, 0.5 g Nitrate, 5 g 
dextrose, CrN-H (2 g Cr, 1 g Nitrate, 3.5 g dextrose). We observed no significant 
differences among groups in baseline plasma creatine concentrations. Peak plasma Cr 
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concentrations were greatest with CrM, followed by CrN-H, then CrN-L. There were no 
significant changes in plasma Cr with PL. Peak plasma Cr concentrations occurred after 
1 h of ingestion of one dose of supplementation and seemed unaffected by the form of 
Cr. Plasma Cr area under the curve (AUC) was significantly greater with CrM compared 
to all other groups, while no significant differences in plasma Cr AUC were observed 
among PL, CrN-L, and CrN-H. Other researchers have reported similar time-to-peak 
concentrations. Jager et al. (61), examined changes in plasma Cr concentrations for 8-hrs 
after supplementation with CrM, tri-creatine citrate (CrC), and creatine pyruvate 
(CrPyr). Plasma Cr concentrations peaked 1 h post supplementation regardless of the 
form of Cr. Peak plasma Cr concentrations at 1 h post supplementation were reported to 
be significantly greater with CrPyr when compared to CrC and CrM.  
Changes in plasma nitrate concentration appear to be dose-dependent. Plasma 
nitrate concentrations with CrN-H were significantly greater than all groups at all time-
points (0.5, 1, 2, 3, 4, 5-hr) during acute supplementation. Although, significantly lesser 
than CrN-H, plasma nitrate concentration with CrN-L was significantly greater than 
CrM and PL at all time-points.  Peak plasma nitrate concentration was achieved 1 h post 
supplementation. Others have also noticed similar time-to-peak plasma nitrate 
concentrations. Cortas et al. (29), reported peak plasma nitrate concentration after 40-
minutes of supplementation with 0.47 mmol nitrate • kg (~2 g nitrate for 70 kg person).  
Bartholomew et al. (9), also observed plasma nitrate concentrations peak after 30 – 60 
minutes of supplementation with 25, 50, 100, and 170 mg potassium nitrate.  AUC for 
plasma nitrate for CrN-H were significantly greater compared to CrM and PL, but not 
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significantly different than CrN-L. This suggests that CrN-L and CrN-H are 
bioequivalent; however, plasma nitrate concentrations were measured over a finite 
period of time. AUC calculations would need to be extrapolated infinitely to determine 
accurate bioequivalence.    
Several studies have reported on the effects of nitrate supplementation on blood 
pressure (BP) and heart rate (79, 89, 123). We observed a significant decrease (~3 mm 
Hg) in systolic blood pressure (SBP) in all groups 1-hr after ingestion of 
supplementation with no significant differences observed among groups, while 
observing no significant changes in diastolic blood pressure (DBP) and heart rate (HR).  
Larsen et al. (79), reported no change in SBP after administering 0.1 mmol • kg • d-1 
(~430 mg nitrate for a 70 kg person) for three days. Similarly, Murphy and colleagues 
(89) failed to observed a change in BP 1 h post-consumption of 200 g beetroot 
consumption (≥ 500 mg nitrate). On the other hand, Webb et al. (123), observed a ~10 
mm Hg decrease in systolic blood pressure 2.5 h after ingestion of 0.5 L (~1,400 mg 
nitrate) of beetroot juice (BRJ). Our findings for DBP changes in response to 0.5 g (CrN-
L) and 1 g (CrN-H) of dietary nitrate are in agreement with some, but not all. Murphy et 
al. (89), who reported no significant change in DBP after the consumption of 200 g 
beetroot (≥500 mg nitrate). Conversely, Larsen et al. (79) and Webb et al., (89, 123) 
both observed a decrease in DBP of 3.7 and 8.1 mm Hg after ~430 mg (70 kg body 
weight at 0.1 mmol • kg • d-1) and 1,400 mg nitrate supplementation, respectively. 
Similarly, Larsen (79) and Webb (89, 123) failed to observe a significant change in HR 
after nitrate supplementation. In Study 1 we provided 0.5 g nitrate (CrN-L) and 1 g 
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(CrN-H) nitrate during Study 1 and found no evidence that CrN reduced blood pressure 
or affects HR in comparison to PL or CrM. Additionally, no participant had hypotensive 
response (SBP<90 mm Hg, DBP<60 mm Hg) to either dose of CrN studied.  It is 
possible that doses greater than those prescribed in this study are required to affect blood 
pressure.  
The nitrate doses provided in this study (0.5 – 1 g nitrate) are within the range 
recommended by national guidelines (25). Dietary nitrates are found primarily in plant-
based foods such as fruits and vegetables (56). Therefore, the dietary approach to stop 
(DASH) diet, which recommends 4 – 5 servings of fruits and vegetables, is often 
prescribed as a nutritional therapy to reduce blood pressure. Celery, lettuce, red beetroot, 
and spinach are known to contain very high concentrations of nitrate (>250 mg 
nitrate/100 g food), while artichokes, asparagus, green beans, tomato, and watermelon 
are known to contain very low concentrations of nitrate (<20 mg nitrate/100 g food) 
(105). Researchers have reported that the daily nitrate concentration of the DASH diet 
can vary from ~175 mg to ~1220 mg nitrate by consuming low-nitrate or high-nitrate 
fruits and vegetables (56).       
Plasma creatinine concentrations among groups were within normal 
physiological ranges for healthy, young males, although we observed significant 
interactions among groups. Creatinine significantly increased from baseline among all 
groups from 0.5 h to 2 h post-supplementation, then decrease back to baseline values 
thereafter. Creatinine concentration with CrN-L and CrN-H were significantly greater 
than PL at 0.5, 1, 2, 3, and 4 h, while only being significantly greater than CrM  0.5, 1, 
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and 2 h post-supplementation. Since creatinine is the end product of creatine metabolism 
via a spontaneous, nonenzymatic process it is reasonable to expect an increase in plasma 
creatinine after introducing exogenous creatine supplementation (129). With the 
exception of plasma creatinine, we observed no significant group x time interaction for 
any other blood marker in Study 1.   
All blood markers were within normal physiologic ranges with the exception of 
ALP.  At baseline, plasma ALP concentrations for all groups (11.9±8.5 U/L) were 
slightly below normal physiologic ranges of 30 – 100 (103). Although plasma ALP 
concentrations significantly increase over time among all groups, it remained below 
(15.5 – 21.1 U/L) normal physiologic ranges throughout the 5 h study period.  Some 
may argue that the CK values for CrN-H are consistently above (453 – 504 U/L) normal 
clinical ranges of 50 – 398 U/L (112); however, athletic populations are known to 
regularly have greater CK concentrations than their sedentary counterparts. Mougios 
(87) examined the CK concentration of 483 male athletics from various sport 
backgrounds. A plasma CK reference interval of 82 - 1083 U/L was calculated for all 
male athletes, with football players (183 players) having an upper reference interval of 
1492 U/L for plasma CK.    
Although there were no significant group x time interactions for any blood lipid 
marker, we observed HDL significantly increased by 7 %, while TG significantly 
decreased by 16% at 5 h post-supplementation among all groups.  Others have also 
reported change in blood lipids with Cr supplementation (33, 75). Kreider et al. (75) 
reported a ~15% increase in HDL  in NCAA division IA football players after 28 d of Cr 
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supplementation (15.75 g Cr • d-1 • 28 d-1). In the same study, Kreider and coworkers 
(75) also observed a 13% decrease in very low-density lipoprotein and 7% reduction in 
TCHL: HDL ratio. Earnest et al., also reported a significant reduction in TG by 
approximately 23% after 4 and wk of Cr supplementation (20 g Cr • d-1 • 5 d-1; 10 g Cr • 
day
-1 • 51 d-1) (33).  Conversely, Earnest and colleagues observed no significant changes 
in HDL cholesterol after the Cr supplementation period.  
Creatine supplementation has repeatedly been shown to have minimally 
significant side-effects with no major impact on health markers (19), while a nitrate-rich 
diet is suggested to a beneficial influence on health (16). Although minor side-effects 
were reported in Study 1 there were no significant difference observed among groups or 
in the pattern and/or severity of the few symptoms reported. Symptom frequency and 
severity were evenly distributed among all groups, including PL group.   
Study 2  
CrN is a novel form of creatine-salt although many other forms of creatine salts 
already exist in the market place. Creatine-salts are typically developed due to the 
chemical properties of creatine (Cr). Cr, with a base dissociation constant (pKb) of 
11.08,  is a weak base and as a result can only form salt solutions with strong acids with 
an acid dissociation constant (pKa) of less than 3.98 (62). In the gastric environment 
CrN with a pKa of 3.8 would dissociate into its parent compounds, Cr and nitrate. As 
soon as CrN made contact with the gastric environment (up to 0.1 M hydrochloric acid, 
and sodium and potassium chloride), nitrate would be displaced by the excess of 
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chloride to yield creatine hydrochloride. The dissociation of Cr involves the hydrolysis 
of carboxyl groups (62), which is where the nitrate anion would be attached.   
Pandit et al. (72), reported creatine nitrate (CrN) to be more soluble than creatine 
monohydrate (CrM) under various experimental conditions. They observed an increased 
solubility in CrN compared to CrM and buffered creatine (BC) in water at room 
temperature as well as in pH 2.5 buffer at room temperature and 37° C.  CrN was 
approximately 10-fold more soluble than CrM and BC under all three conditions.  Some 
claim that enhancing product solubility can enhance bioavailability and rate of 
absorption, which, in turn, results in increased creatine uptake and storage in the muscle 
(72). This claim of greater bioavailability is made despite previous research showing the 
absorption and bioavailability of CrM near 100% (32, 61, 62).  
This is the first study to measure muscle Cr concentration after CrN 
supplementation. Our study failed to show greater Cr retention with CrN-L (6 g CrN-L/d 
for 7 d and 1.5 g CrN for 21 d) or CrN-H (12 g CrN-H/d for 7 d and 3.0 g/d for 21 d) 
compared to a standard loading and maintenance dose of CrM (12 g CrM/d for 7 d and 3 
g CrM/d for 21 d). The present study showed a significantly greater increase in muscle 
creatine retention with CrM (20.2±16.4%) compared to CrN-L (-6.8±5.6%) and PL (-
0.4±6.0%) after 7 d of supplementation. Although muscle creatine retention significantly 
increased with CrN-H by 8.5% there were no significant differences compared to CrM 
after 7 d of supplementation. After 28 d of supplementation muscle creatine retention 
was significantly greater with CrM (25.7±5.0%) compared to CrN-L (-8.5±4.6%), CrN-
H (1.1±4.6%), and PL (-4.2±5.0%). Regarding the CrN-H group, our findings suggest 
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that the loading phase (12 g CrN • d-1 • 7 d-1[providing 8 g/d of creatine) was sufficient 
to significantly increase muscle Cr concentrations after 7 d of supplementation, but the 
dose (3 g CrN • d-1 • 21 d-1[providing 2g/d of Cr]) provided during the maintenance 
phase was not sufficient to maintain elevated muscle Cr stores. These finding contrast 
claims that there is no need to load when taking CrN due to greater solubility and 
retention.  
Theoretically, 2 g of exogenous Cr should maintain elevated muscle Cr stores as 
the turn-over rate of endogenous Cr is approximately 2 g/d (122). However, some 
researcher have failed to observe a significant increase in muscle Cr when 
supplementing with 2 g Cr/d for 6 wk (114). Researchers have stated that 2 g of Cr 
supplementation may be insufficient to maintain muscle Cr store for larger, physically 
active individuals as high-intensity exercise training promotes greater Cr turnover (127). 
It is conceivable that participants in Study 2 required greater increment of CrM to 
maintained elevated muscle Cr stores as muscle Cr stores were not maintained with 
twice the recommended dose of CrN (3 g CrN) providing approximately 2 g of Cr. This 
suggests that CrN is not more efficacious than CrM at improving greater Cr uptake and 
storage. Other researchers have provided athletes with higher Cr doses during the 
maintenance phase of supplementation. For example, Kreider et al. (75), provided 
NCAA Division IA college football athletes with 15.75 g Cr during the loading phase 
and 5 – 10 g Cr during the maintenance phase of supplementation. Daily urinary Cr 
excretion (an estimate of whole body creatine retention) levels were low indicating that 
these athletes needed higher doses of Cr to maintain creatine stores.      
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Since CrN is approximately 66% Cr, the 3 g of CrN that were provided daily 
during the maintenance phase in CrN-H group provided approximately 1.98 g of 
exogenous Cr. Hultman et al., demonstrated that 0.03 g of Cr • kg body mass-1 • d-1 
during the maintenance phase maintained elevated Cr stores (58). The participants in the 
CrN-H group weighed 90.8±13.8 kg at d 7 and therefore received approximately 0.02 g 
of Cr • kg body mass-1 • d-1 for 21 d.  Others have based Cr dose on fat-free mass.  Burke 
et al. (21), showed a significant increase in total Cr (TCr) after 8 wk of Cr 
supplementation. Participants ingested 0.25 g of Cr • kg fat-free mass-1 • d-1 for 7 d, 
followed by 0.0625 g of Cr • kg fat-free mass-1 • d-1 for 49 d.  Using fat-free mass as a 
determinant for dosing guidelines, the participants in the CrN-H group received 0.11 g of 
Cr • kg fat-free mass-1 • d-1 for 7 d, followed by 0.0292 g of Cr • kg fat-free mass-1 • d-1 
for 21 d; approximately 50% less than what Burke et al. prescribed according to fat-free 
mass.  The inability to maintain elevated stores with 3 g of CrN (CrN-H) may be due to 
an insufficient dosage of creatine in these athletes.  
 Results of the present study indicated that there was a significant increase in 
body weight in all groups as has been reported by others. Volek et al. (120), have 
reported an increase in total body weight of 1.5 kg and 5.2 kg after one and 12 wk of 
CrM supplementation, respectively. The greatest changes in body weight were seen in 
the CrM group after 7-days of supplementation (0.63±0.81 kg) and with CrN-H after 28-
days of supplementation (1.17±1.38 kg). It is important to note that Volek et al. (120), 
supplemented their subjects with 25 g of CrM for 5 d followed by 5 g of 
supplementation for the remained of the 12 wk study. During our loading phase, the 
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CrM and CrN-H group received 12 g of CrM and 12 g of creatine nitrate (CrN) per d, 
respectively. During the loading phase, the CrM and CrN-H group received 3 g of CrM 
and 3 g of CrN per d, respectively.   
 We also observed a significant increase in fat-free mass in all groups with an 
average increase of 0.30±1.22 and 0.56±1.30 kg after 7 and 28 d of supplementation, 
respectively. These increases in fat-free mass are lesser than those seen in previous Cr 
supplementation studies (11, 47, 120). The lack of significant change in total body water 
among all groups suggests that the change in fat-free mass were not attributed to an 
increase in water retention that has been reported to follow Cr supplementation (99).  We 
failed to observe any significant differences in caloric and macronutrient intake and 
training volume suggesting that the significant change in body weight and fat-free mass 
observed results from the supplemental treatments provided.  
 Cr supplementation is well known for improving muscular strength and power 
(34, 94, 117, 121). In the present study, there was a significant improvement over time in 
all groups in maximum repetitions, workload (weight [kg] x repetitions), peak power, 
average power, and average velocity during the bench press test. On average the greatest 
percent increase in workload, peak power, average power, and average velocity were 
observed with CrN-H (35.4%, 16.2%, 9.3%, and 14.2%)  and CrM (26.9%, 16.7%, 
9.3%, and 12.9%). Despite the greater percent increase with CrN-H and CrM, there were 
no significant differences between groups in percent change in workload, peak power, 
average power, and average velocity after 28 d of supplementation. Maximum bench 
press repetitions increased by19.0%, 26.9%, 20.5%, and 35.5% with PL, CrM, CrN-L, 
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and CrN-H, respectively, after 28 d of supplementation; however, there were no 
significant difference in percent change among groups.   
Similar increases in maximum bench press repetitions using 70% of 1RM were 
observed by Earnest et al (34). Experienced resistance-trained males were examined on 
strength indices before and after Cr supplementation (20 g Cr • d-1 • 14 d-1).  The Cr 
group significantly increased 1RM bench press and bench press repetition using 70% of 
1RM by 35%. Others have reported similar changes in bench press power with a shorter 
supplementation period. Izquierdo et al., observed a significant increase (20%) in bench 
press power after five days of Cr (20 g Cr • d-1 • 5 d-1) supplementation in handball 
players (60).  
We observed no significant difference among groups in overall peak power, 
mean power, and total work during anaerobic sprint capacity test. On average, peak 
power increase by 0.4%, 4.0%, 5.3%, and 3.0% and with PL, CrM, CrN-L, and CrN-H, 
respectively. Mean power increased only with CrN-L and CrM by 7.6% and 5.5%, 
respectively; while mean power slightly decreased by 0.6% and 2.1% with CrN-H and 
PL. Changes in mean power during anaerobic sprint capacity test were not significant 
among groups. Total work increase by 3.9%, 3.0%, 7.3%, and 0.3% with CrN-H, CrN-L, 
PL, and CrN, respectively, but there was no significant difference among groups.   
Similar improvements were reported by others. Dawson et al. (30), observed a 4.5% and 
4.6% increase in total work and peak power, respectively, on a cycle ergometer after Cr 
supplementation (20 g Cr • d-1 • 5 d-1). Jagim et al. (63), reported a 3% improvement in 
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total work during a 30-second cycle ergometer test after 28-days of CrM and two doses 
of a buffered form of Cr supplementation.   
The lack of significant difference during the anaerobic sprint capacity may be 
explained by several factors.  It is possible that a learning effect was present, although 
we attempted to reduce a learning effect by having participants practice the anaerobic 
capacity test during the familiarization session. A normal intra-personal variation in 
performance could have also influence cycle ergometer performance before and after the 
supplementation period. The magnitude of change in muscle Cr concentration may have 
also played a role in performance outcomes. We observed an approximate -4%, 26%, 
8%, and 1% change  with PL, CrM, CrN-L, and CrN-H, respectively, in muscle Cr 
concentration after 28 d of supplementation. Finn et al. (37), examined cycle ergometer 
performance (4 x 20-sec sprints with 20-sec recovery between sprints) in triathletes after 
Cr supplementation (20 g Cr/d) for 5 d. They reported no significant changes in peak 
power and mean power performance during the cycle ergometer test as well as no 
significant increases in muscle Cr concentration, although muscle Cr increased by ~20% 
after the supplementation period. It is also possible that some participants in our study 
did not respond to the Cr supplementation protocol. Approximately 20 – 30% of those 
ingesting Cr supplementation show little to no response as evidence by muscle Cr 
concentrations (43). Greenhaff et al. (42), characterized non-responders as those with 
less than a 10 mmol/kg dw response in muscle total creatine after loading with Cr 
supplementation. Based on muscle Cr analysis we would have expected greater a 
significantly greater power output with CrM (42.5±0.9 mmol • kg-1 DW) as Cr stores 
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were significantly greater than CrN-L (32.3±5.6 mmol • kg-1 DW), CrN-H (40.9±9.9 
mmol • kg-1 DW), and PL (33.2±5.4 mmol • kg-1 DW), but that was not the case. This 
further demonstrates that CrN-L and CrN-H are not more efficacious than CrM during 
repeated anaerobic sprints on a cycle ergometer.  
 Similar to Study 1, we observed ALP values (10.48 – 19.48 U/L) slightly below 
normal (30 – 100 U/L) physiologic values at baseline, prior to supplementation (103).  
However, there were no significant differences among groups in changes in ALP after 7 
and 28 days of supplementation. With the exception of ALP values, all other markers of 
whole blood, clinical health, and blood lipids were within normal ranges.   
There is supporting evidence that shows Cr supplementation to have minimal to 
no negative effects on markers of clinical health and safety (19, 63, 75, 76). In the 
present study, neither dose of CrN or CrM resulted in significantly different side-effects 
or health outcomes compared to PL. These findings suggest that both doses of CrN are 
well tolerated and are just as safe to consume as CrM and PL.   
Summary and Conclusions 
 Results of Study 1 indicate that acute supplementation with a lower dose (CrN-L: 
1 g Cr, 0.5 g nitrate, 5 g dextrose) and higher dose (CrN-H: 2 g Cr, 1 g nitrate, 3.5 g 
dextrose) of CrN is as safe as CrM (5 g CrM, 1.5 g dextrose). In Study 1, all blood 
markers were within normal physiology range and lacked a clinically significant change 
during the 5 h treatment period. Although minimal side effects were infrequently 
reported, they were distributed among all groups including PL (6.5 g dextrose).   
 135 
 
Results of the Study 2 indicate that dietary supplementation with a lower dose 
(1.5 g CrN-L • 4 x/d-1 • 7 d-1; 1.5 g CrN-L • d-1 • 21-d-1) and higher dose (3.0 g CrN-H • 4 
x/day
-1 • 7 d-1; 3.0 g CrN-H • d-1 • 21-d-1) of CrN is safe for chronic consumption up to 
28 d. We found CrN-L and CrN-H to significantly increase plasma nitrate concentration 
after 7 days of supplementation; however, plasma nitrate concentrations did not remain 
significantly elevated, compared to baseline, after 28 d of supplementation. During 
Study 2 we observed a significant increase in plasma creatine only with CrM after the 7 
d loading phase (12 g CrM • d-1 • 7 d-1), while observing no significant increase from 
baseline or differences between CrN-L (6 g CrN • d-1 • 7 d-1) CrN-H (12 g CrN • d-1 • 7 d-
1
) and PL (26 g dextrose • d-1 • 7 d-1) after the 7 d loading period. Furthermore, muscle 
Cr concentration only significantly increase after the loading period with CrM and CrN-
H and only remained significantly elevated with CrM after 28 d of supplementation.  
Our findings refute claims that an increase in solubility leads to an increase in absorption 
and storage.  
We observed significant increase in bench press workload (weight [kg] x max 
reps) in all groups (but no group x time interaction) after supplementation, however, 
only CrN-H group demonstrated significance compared to PL group. Similar findings 
were observed for bench press peak and average power, with only CrN-H demonstrated 
significance compared to PL and CrN-L, but not significantly different than CrM. We 
failed to observe a significant treatment effect for the anaerobic sprint capacity test.  
Body mass also increased over time in all groups with significantly greater 
improvements in fat-free mass only observed with CrM and CrN-H.  Furthermore, only 
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changes in fat-free mass with CrN-H were significantly greater than CrN-L, but not 
significantly different than CrM and PL. The exercise performance and slight changes in 
body composition suggests little to no evidence that either dose of CrN is more 
efficacious than CrM. Overall, CrN was well tolerated, demonstrated similar 
performance benefits to loading and maintenance doses of CrM, and void of significant 
alterations in hemodynamics or blood enzymes denoting hepatorenal and muscle enzyme 
safety. However, we found no evidence that CrN at recommended or twice 
recommended doses is more efficacious than CrM at the doses studied.  
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APPENDIX A 
Consent Form 
 
Project Title: Pharmacokinetic Assessment of Acute Ingestion of Different Forms of 
Creatine  
 
You are invited to take part in a research study being conducted by Dr. Richard 
Kreider, a researcher from Texas A&M University and funded by Woodbolt 
International.  The information in this form is provided to help you decide whether 
or not to take part. If you decide to take part in the study, you will be asked to sign 
this consent form. If you decide you do not want to participate, there will be no 
penalty to you, and you will not lose any benefits you normally would have. 
 
Why Is This Study Being Done? 
The purpose of this study is to examine acute pharmacokinetics of different forms of 
creatine compared to placebo on serum creatine/creatinine, serum nitrate/nitrite, serum 
glucose, blood pressure, heart rate, endothelial function and self-reported side effects.   
 
Why Am I Being Asked To Be In This Study?  
You are being asked to be in this study because you are an apparently healthy and 
recreationally active man between the ages of 18 and 40.  You will not be allowed to 
participate if; you have a history of treatment for metabolic disease (i.e., diabetes), 
hypertension, hypotension, thyroid disease, arrhythmias and/or cardiovascular disease; 
you are currently using any prescription medications; you have a history of smoking; 
you drink excessively (12 drinks per week or more); or you have a recent history of 
creatine supplementation within six weeks of the start of supplementation.  If you do not 
qualify for this study we will keep your contact information (phone number and/or e-
mail) and contact you at a later date for potential entry into a similar study with your 
permission.     
 
How Many People Will Be Asked To Be In This Study? 
Approximately 12 people (participants) will be invited to participate in this study locally. 
 
What Are the Alternatives to being in this study? 
The alternative to being in the study is not to participate. 
 
What Will I Be Asked To Do In This Study? 
You will be asked to not exercise, consume no alcohol and refrain from non-steroidal 
anti-inflammatory drugs (NSAIDS) for 48 hours nor eat or drink calorie containing 
foods or drinks 12 hours before each testing session/visit.  Your participation in this 
study will last up to approximately four weeks and include five visits (visit 1 ~ 1 
hour/visits 2, 3, 4 & 5 ~ 6 hours/visit).  These visits are detailed below and in the 
protocol overview table below. 
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Protocol Overview  
Familiarization T1 T2 T3 T4 
 
Phone Screening 
 
Familiarization 
 
Physical Exam 
 
Body Weight 
 
Schedule Testing 
 
Randomized, Double Blind, 
Crossover Administration 
of Supplements with at 
least a 1 week washout 
period: 
 
1. CrM (5 gm 
CrM with 1.5 
gm dextrose) 
2. CrN-1 (1 gm 
CrM, 0.5 gm N 
with 5 gm 
dextrose) 
3. CrN-2 (2 gm 
CrM, 1 gm N 
with 3.5 gm 
dextrose) 
4. Placebo (6.5 
gm dextrose) 
 
 
 
 
4 Day Food Record 
 
48 hour prior: no 
exercise, alcohol, and 
NSAIDS 
 
8 hour fast 
 
Body Weight 
 
DEXA Body 
Composition 
 
Flow-mediated dilation 
(FMD) 
     0-h 
     1-h 
     2.5h 
 
Fasting Blood Samples 
(7 total) 
     0-h 
     0.5-h 
     1-h 
     2-h 
     3-h 
     4-h 
     5-h 
 
Blood pressure, heart 
rate and side effect 
questionnaire at each 
data collection point. 
 
 
 
4 Day Food Record 
 
48 hour prior: no 
exercise, alcohol, and 
NSAIDS 
 
8 hour fast 
 
Body Weight 
 
DEXA Body 
Composition 
 
Flow-mediated dilation 
(FMD) 
     0-h 
     1-h 
     2.5h 
 
Fasting Blood Samples 
(7 total) 
     0-h 
     0.5-h 
     1-h 
     2-h 
     3-h 
     4-h 
     5-h 
 
Blood pressure, heart 
rate and side effect 
questionnaire at each 
data collection point. 
 
 
4 Day Food Record 
 
48 hour prior: no 
exercise, alcohol, and 
NSAIDS 
 
8 hour fast 
 
Body Weight 
 
DEXA Body 
Composition 
 
Flow-mediated dilation 
(FMD) 
     0-h 
     1-h 
     2.5h 
 
Fasting Blood Samples 
(7 total) 
     0-h 
     0.5-h 
     1-h 
     2-h 
     3-h 
     4-h 
     5-h 
 
Blood pressure, heart 
rate and side effect 
questionnaire at each 
data collection point. 
 
4 Day Food Record 
 
48 hour prior: no 
exercise, alcohol, and 
NSAIDS 
 
8 hour fast 
 
Body Weight 
 
DEXA Body 
Composition 
 
Flow-mediated dilation 
(FMD) 
     0-h 
     1-h 
     2.5h 
 
Fasting Blood Samples 
(7 total) 
     0-h 
     0.5-h 
     1-h 
     2-h 
     3-h 
     4-h 
     5-h 
 
Blood pressure, heart 
rate and side effect 
questionnaire at each 
data collection point. 
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Visit 1 (week 1) – Familiarization   
This visit will last about one hour.  During this visit the details of the study will be 
explained, human subject consent forms will be signed, personal and medical history 
information will be completed and you will have a general physical that may include 
measurement of fasting blood to determine if you can participate in the study.  You will 
donate approximately 5 ml (about 1 teaspoon) of fasting blood from a vein in your arm 
according to standard procedures.  Next you will have your height and weight measured.  
Next you will be given four food logs and asked to record all calorie containing foods 
and drinks for a total of four days (including one weekend day) prior to your second, 
third, fourth and fifth visits.   
 
 
Visit 2, 3, 4 & 5 (week 2, 3, 4 & 5) – (T1, T2, T3 & T4) 
These visits will last about six hours.  You will first have your body weight measured.  
You will then have your total body composition measured.  Next flow-mediated dilation 
(FMD) will be measured using a noninvasive ultrasound probe and a blood pressure 
cuff.  You will then be asked to donate approximately 20 ml (about 4 teaspoons) of 
fasting blood from a vein in your arm according to standard procedures using either a 
venipuncture needle or a blood collection catheter set.  Next you will be randomized and 
counterbalanced to ingest either: 1.) creatine monohydrate (5 gm creatine + 1.5 gm 
dextrose); 2.) creatine nitrate – 1 (1 gm creatine + 0.5 gm nitrate + 5 gm dextrose): 3.) 
creatine nitrate – 2 (2 gm creatine + 1 gm nitrate + 3.5 gm dextrose); 4.) placebo (6.5 
gram dextrose).  After supplementation blood samples, blood pressure, heart rate and 
self-reported side effects will be taken at 0.5, 1, 2, 3, 4 and 5 hours post ingestion of the 
supplement.  FMD will be measured at 1 and 2.5 hours post ingestion.  You will be 
asked to repeat these procedures three additional times using an alternate supplement 
following a one week washout after each testing session.            
 
You may be removed from the study by the investigator for these reasons: 
 You do not show up for your scheduled testing sessions/visits and the 
investigators are unable to contact you to reschedule.   
 You do not follow your assigned supplemental protocol.   
 
Are There Any Risks To Me? 
The things that you will be doing are greater than risks that you would come across in 
everyday life.  Although the researchers have tried to avoid risks, you may feel that some 
questions/procedures that are asked of you will be stressful or upsetting.  You do not 
have to answer anything you do not want to.  You will be exposed to a low level of 
radiation during the body composition test, which is similar to the amount of natural 
background radiation you would receive in one month while living in College Station 
Texas.  The use of the body composition scanner has been shown to be a safe method of 
measuring body composition and is approved by the FDA.  During the non-invasive 
flow-mediated dilation (FMD) procedure, your hand might become slightly numb during 
the five minutes of blood pressure cuff inflation around the forearm.  This slight tingling 
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is normal and resolves quickly following cuff release.  You will donate approximately 5 
ml (about 1 teaspoon) of fasting blood during the initial familiarization/screening visit 
and then approximately 20 ml (about 4 teaspoons) of blood seven times at each of the 
four testing sessions throughout the study using standard procedures.  These procedures 
may cause a small amount of pain when the needle/catheter is inserted into the vein as 
well as some bleeding and bruising.  You may also experience some dizziness and/or 
faint if you are unaccustomed to having blood drawn.   
 
Are There Any Benefits To Me?  
The direct benefit to you by being in this study is to know more about your health and 
fitness status from the tests to be performed.  However, even if no individual benefit is 
obtained, you will be paid for your participation.     
 
Will There Be Any Costs To Me?  
Aside from your time, there are no costs for taking part in the study. 
 
Will I Have To Pay Anything If I Get Hurt In This Study?  
If you suffer any injury as a result of taking part in this research study, please understand 
that nothing has been arranged to provide free treatment of the injury or any other type 
of payment. However, all needed facilities, emergency treatment and professional 
services will be available to you, just as they are to the community in general. You 
should report any injury to Dr. Richard Kreider at 979-845-1333.  You will not give up 
any of your legal rights by signing this consent form. 
 
Side effects (injury) can happen in any research study. These effects may not be your 
fault or the fault of the researcher involved. Known side effects have been described in 
the “Are there any risks to me?” section of this consent form. However, side effects that 
are not currently known may happen and require care. You do not give up any of your 
legal rights by signing this form. 
 
Will I Be Paid To Be In This Study? 
You will receive a total of $125 ($25 for each visit) in one check at the end of the study.  
Payment will occur after finishing all five sessions and after all study materials 
(questionnaires, food records, etc.) have been turned in to the study staff.  You will be 
paid on a prorated basis if you are unable to complete the entire study.      
 
Will Information From This Study Be Kept Private? 
The records of this study will be kept private.  No identifiers linking you to this study 
will be included in any sort of report that might be published.  Research records will be 
stored securely and only Exercise & Sport Nutrition Laboratory staff will have access to 
the records.   
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Information about you will be stored in locked file cabinets in a locked file room in an 
ID card swipe access controlled laboratory.  Computer files will be protected with a 
password.  This consent form will be filed securely in an official area.   
 
People who have access to your information include the Principal Investigator and 
research study personnel.  Representatives of regulatory agencies such as the Office of 
Human Research Protections (OHRP) and entities such as the Texas A&M University 
Human Subjects Protection Program may access your records to make sure the study is 
being run correctly and that information is collected properly.  
 
The agency that is funding this study (Woodbolt International) and the institutions(s) 
where study procedures are being performed (Texas A&M University) may also see 
your information.  However, any information that is sent to them will be coded with a 
number so that they cannot tell who you are.  Representatives from these entities can see 
information that has your name on it if they come to the study site to view records.  If 
there are any reports about this study, your name will not be in them.   
  
Information about you and related to this study will be kept confidential to the extent 
permitted or required by law.  
 
Who may I Contact for More Information? 
You may contact the Principal Investigator, Richard Kreider, PhD, to tell him about a 
concern or complaint about this research at 979-845-1333 or rkreider@hlkn.tamu.edu.  
You may also contact the Protocol Director/Laboratory Research Associate, Chris 
Rasmussen, at 979-458-1741 or crasmussen@hlkn.tamu.edu.   
 
For questions about your rights as a research participant; or if you have questions, 
complaints, or concerns about the research, you may call the Texas A&M University 
Human Subjects Protection Program office at (979) 458-4067 or irb@tamu.edu.  
 
 
What if I Change My Mind About Participating?   
This research is voluntary and you have the choice whether or not to be in this research 
study.  You may decide to not begin or to stop participating at any time.   If you choose 
not to be in this study or stop being in the study, there will be no effect on your student 
status, medical care, employment, evaluation, relationship with Texas A&M University, 
etc.  Any new information discovered about the research will be provided to you. This 
information could affect your willingness to continue your participation. 
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STATEMENT OF CONSENT 
I agree to be in this study and know that I am not giving up any legal rights by 
signing this form.  The procedures, risks, and benefits have been explained to me, 
and my questions have been answered.  I know that new information about this 
research study will be provided to me as it becomes available and that the 
researcher will tell me if I must be removed from the study.   I can ask more 
questions if I want.  A copy of this entire consent form will be given to me. 
 
____________________________          _______________________________ 
Participant’s Signature              Date 
____________________________                      ______________________________ 
Printed Name           Date 
 
 
INVESTIGATOR'S AFFIDAVIT: 
Either I have or my agent has carefully explained to the participant the nature of the 
above project. I hereby certify that to the best of my knowledge the person who signed 
this consent form was informed of the nature, demands, benefits, and risks involved in 
his/her participation. 
 
_____________________________                        ______________________________ 
Signature of Presenter     Date 
 
_____________________________                       ______________________________ 
Printed Name Date 
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APPENDIX B 
Consent Form 
Project Title:  Effects of 28 Days of Different Forms of Creatine Supplementation on 
Muscle Creatine, Body Composition, and Exercise Performance in Recreationally 
Active Males  
 
You are invited to take part in a research study being conducted by Dr. Richard Kreider 
a researcher from Texas A&M University and funded by Woodbolt International.  The 
information in this form is provided to help you decide whether or not to take part. If 
you decide to take part in the study, you will be asked to sign this consent form. If you 
decide you do not want to participate, there will be no penalty to you, and you will not 
lose any benefits you normally would have. 
 
Why Is This Study Being Done? 
The purpose of this study is to determine whether ingesting creatine nitrate will enhance 
muscle creatine stores and/or promote greater training adaptations in comparison to a 
placebo.  This study will examine the effects of different forms of creatine nitrate on 
muscle creatine content, body composition, exercise capacity, bench press performance 
and blood panels in recreationally active males.   
 
Why Am I Being Asked To Be In This Study?  
You are being asked to be in this study because you are an apparently healthy and 
recreationally active male between the ages of 18 and 40.  You will need to have at least 
six months immediate prior history of resistance training on the bench press and leg 
press or squat.  You will not be allowed to participate if; you have a history of treatment 
for metabolic disease (i.e., diabetes), hypertension, hypotension, thyroid disease, 
arrhythmias and/or cardiovascular disease; you are currently using any prescription 
medications; you have a history of smoking; you drink excessively (12 drinks per week 
or more); or you have a recent history of creatine supplementation within six weeks of 
the start of supplementation.  If you do not qualify for this study we will keep your 
contact information (phone number and/or e-mail) and contact you at a later date for 
potential entry into a similar study with your permission.          
 
How Many People Will Be Asked To Be In This Study? 
Approximately 48 people (participants) will be invited to participate in this study locally.   
 
What Are the Alternatives to being in this study? 
The alternative to being in the study is not to participate. 
 
What Will I Be Asked To Do In This Study? 
You will be asked to not exercise for 48 hours nor eat or drink calorie containing foods 
or drinks 12 hours before each testing session/visit.  Your participation in this study will 
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last approximately six weeks and include six visits (visit 1 ~ 1 hour/visit 2&5 ~ 30 
minutes/visit 3&6 ~ 2 hours/visit 4 ~ 1 hour).  You will be asked to provide three muscle 
biopsies during this study.  These visits are detailed below in the table below.   
 
Protocol Overview 
Familiarization(T1) 
 
 
 
Visit 1 
T2 (Day 1 & 2) T3 (Day 9) 
 
Biopsy & Resting 
Measures 
Visit 4 
T4 (Day 30 & 31) 
Biopsy ~ 1 
day prior 
Visit 2 
Performance testing 
Visit 3 
Biopsy ~ 1 
day prior 
Visit 5 
Performance testing 
Visit 6 
 
Phone Screening 
 
Familiarization 
 
Physical Exam 
 
Body Weight 
 
Anaerobic Sprint Practice 
Test (load corresponding 
to 0.075 kp/kg body 
mass)  
 
1 Repetition Maximum 
Bench Press Test  
 
Schedule Testing 
 
Refrain from exercise, 
alcohol and NSAIDS 48 
hours prior to each testing 
session  
 
Instructions for 
standardized resistance 
training program (start 2 
weeks prior to T2) 
 
1 – (1.5 g CN, 0.5 g F, 3.5 
g D) – 5.5 g 
2 – (3 g CN, 0.5 g F, 2 g 
D) – 5.5 g 
3 – (5 g D, 0.5 g F) – 5.5 
g (placebo) 
4 – (3 g C, 0.5 g F, 2 g D) 
– 5.5 g 
 
CN – Creatine Nitrate 
F – Flavoring 
D – Dextrose 
C - Creatine 
 
 
Muscle 
Biopsy  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 Day Food Record 
 
12 Hour Fasting Blood 
Sample 
Body Weight 
Body Water 
Body Composition 
 
Bench Press Warm-Up 
 
Bench Press (3 sets of 
10 repetitions @ 70% 
of 1 Repetition  
2 minutes rest recovery 
between sets with total 
repetitions to failure on 
last set)  
 
3 minute warm-up 
cycle ergometer 
 
6 x 6 sprints with 30 
second rest between 
sprints  
 
3 minute rest 
 
30 sec. Anaerobic 
Sprint Test  
 
 
 
Muscle Biopsy  
 
4 Day Food Record 
 
12 Hour Fasting Blood 
Sample 
Body Weight 
Body Water 
Body Composition 
 
Self-Reported Side 
Effects 
 
 
 
Muscle 
Biopsy 
 
4 Day Food Record 
 
12 Hour Fasting 
Blood Sample 
Body Weight 
Body Water 
Body Composition 
 
Bench Press Warm-
Up 
 
Bench Press (3 sets 
of 10 repetitions @ 
70% of 1 Repetition 
2 minutes rest 
recovery between 
sets with total 
repetitions to failure 
on last set)  
 
3 minute warm-up 
cycle ergometer 
 
6 x 6 sprints with 30 
second rest between 
sprints  
 
3 minute rest 
 
30 sec Anaerobic 
Sprint Test  
 
Self-Reported Side 
Effects 
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Visit 1 – Familiarization (T1)  
This visit will last about one hour.  During this visit the details of the study will be 
explained, human subject consent forms will be signed, personal and medical history 
information will be completed and you will have a general physical that will include 
measurement of blood to determine if you can participate in the study.  You will donate 
approximately 5 ml (about 1 teaspoon) of blood from a vein in your arm according to 
standard procedures.  Next you will have your height and weight measured.  You will 
then be asked to perform a warm-up and one repetition maximum test on the bench press 
with a two minute recovery between attempts.  Next you will be familiarized to the 
sprint bike test.  You will then be asked to follow a standardized weight lifting program 
for a total of six weeks and record the amount of weight lifted and repetitions performed 
on training logs.  The first two weeks will be performed without supplementation.  The 
final four weeks will be performed with supplementation.  Finally you will be given 
three food logs and asked to record all calorie containing foods and drinks for a total of 
four days (including one weekend day) prior to your third, fourth and sixth visits.      
 
Visit 2 & 5 (day 1 and 30) – (T2 & T4 Biopsy)  
These visits will last about 30 minutes and will take place approximately one day prior 
to the T2 and T4 performance testing sessions.  Biopsies will be obtained from the 
middle portion of the thigh muscle between the knee and the upper leg using the 
Bergstrom biopsy (muscle tissue sample) technique.  All biopsies will be taken by 
trained and experienced personnel in the Human Countermeasures Laboratory or the 
Exercise & Sport Nutrition Laboratory at Texas A&M University.  The muscle biopsy 
procedure involves the following:  First, you will be asked to lie down or assume a 
comfortable reclining position on an exam table.  The biopsy technician will identify the 
point where the biopsy will be obtained.  The area will be shaved clean of any leg hair, 
washed with a sterilizing soap, cleaned with rubbing alcohol, and further cleansed by 
swabbing the area with a fluid sterilizing soap and then draped with sterile padding.  A 
small area of the thigh approximately 2 cm in diameter will be anesthetized with a 1.0 
mL injection of 2% Xylocaine/Lidocaine (a numbing agent).  Once the local anesthesia 
has taken effect (approximately 2-5 minutes) each biopsy procedure will take 
approximately 15-20 minutes.  A scalpel point will be used to produce the initial biopsy 
site by making an incision approximately 1 cm. in length through the skin, subcutaneous 
fat, and fascia.  Due to the localized effects of the anesthetic, you will feel little to no 
pain during this process.  The biopsy needle will be advanced into the incision 
approximately ½ inch.  During this part of the procedure you may feel pressure to the 
thigh area.  The biopsy procedure will obtain approximately 100 – 200 micro-grams of 
muscle tissue (smaller than a pencil eraser).  Once the muscle sample has been obtained, 
direct pressure will be immediately applied.  The site will be subsequently closed, and 
the wound dressed with a pressure bandage.  Due to the small incision site, only minimal 
bleeding is expected.  Afterwards, written instructions for post-biopsy care will be 
reviewed and issued.  You will be instructed to leave the bandages on for 24 hours 
(unless unexpected bleeding or pain occurs) and asked to report back to the lab within 24 
hours to have the old bandages removed, the incision inspected and new bandages 
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applied.  These suggestions will minimize pain and possible bleeding of the area.  If 
needed, you may take non-prescription analgesic medication such as Tylenol to relieve 
pain.  Soreness of the area may occur for about 24 hours post-biopsy. 
 
 
Visit 3 & 6 (day 2 and 31) – (T2 & T4 – Performance Testing) 
These visits will last about two hours.  You will first donate approximately 20 ml (about 
4 teaspoons) of fasting blood from a vein in your arm according to standard procedures.  
Next body weight, body water and body composition will be measured.  You will then 
be asked to perform a warm-up and three sets of 70% of your one repetition maximum 
on the bench press with two minutes recover between sets with total repetitions to failure 
on the last set.  Next you will be asked to perform a three minute warm-up at 100 W on a 
cycle ergometer.  You will then perform six, six second sprints on the cycle ergometer 
with 30 seconds rest between sprints.  After a three minute rest period you will be asked 
to perform one 30 second Wingate sprint test.  Next you will be assigned to ingest either: 
1.) 1.5 g. creatine nitrate, 0.5 g. flavoring and 3.5 g. dextrose; 2.) 3 g. creatine nitrate, 0.5 
g. flavoring, 2 g. dextrose; 3.) 5 g. dextrose, 0.5 g. flavoring (placebo); or 4.) 3 g. 
creatine, 0.5 g. flavoring, 2 g. dextrose.  You will be asked to consume your assigned 
supplement with eight ounces of water between approximately 7:00 to 8:00 a.m., 2:00 to 
3:00 p.m., 9:00 to 10:00 p.m., and 20 – 30 minutes prior to your workout (total of four 
doses per day) on days one through seven.  You will be asked to consume your assigned 
supplement with eight ounces of water 20 – 30 minutes prior to your workout (one dose 
per day) for the remainder of the study (days eight through 28).  You will also be asked 
to record supplement intake and complete weekly medical side effects questionnaires 
throughout the supplementation period.  After six weeks of training (four weeks of 
supplementation), you will be asked to repeat baseline testing. 
 
Visit 4 (day 9) – (T3 Biopsy and Resting Measures) 
This visit will last about one hour and will include everything as the normal biopsy visit 
along with a fasting blood draw.  In addition body weight, body water and body 
composition will also be measured and self-reported side effects will be recorded.    
 
You may be removed from the study by the investigator for these reasons: 
 You do not show up for your scheduled testing sessions/visits and the 
investigators are unable to contact you to reschedule 
 You do not follow your assigned supplemental protocol 
 You do not follow your assigned exercise protocol 
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Are There Any Risks To Me? 
The things that you will be doing are greater than risks that you would come across in 
everyday life.  Although the researchers have tried to avoid risks, you may feel that some 
questions/procedures that are asked of you will be stressful or upsetting.  You do not 
have to answer anything you do not want to.  You will be exposed to a low level of 
radiation three times during the body composition exam, which is similar to the amount 
of natural background radiation you would receive in one month while living in College 
Station Texas.  In addition, a very low level of electrical current will be passed through 
your body using a bioelectrical impedance analyzer.  This analyzer is commercially 
available and has been used in the health care/fitness industry as a means to assess body 
composition and body water for over 20 years.  The use of the body composition scanner 
and bioelectrical impedance analyzer have been shown to be safe methods of assessing 
body composition and total body water and are approved by the FDA.  You will donate 
approximately 5 ml (about 1 teaspoon) of fasting blood during the initial 
familiarization/screening visit and then approximately 20 ml (about 4 teaspoons) of 
blood three additional times at each of the three testing sessions throughout the study 
using standard procedures.  The procedures may cause a small amount of pain when the 
needle is inserted into the vein as well as some bleeding and bruising.  You may also 
experience some dizziness and/or faint if you are unaccustomed to having blood drawn.  
Similar risks as well as minimal bleeding, soreness and bruising may be involved with 
the three muscle biopsy procedures.  There is a slight risk of contracting an infection.  
However, only a trained phlebotomist will be performing blood sampling using 
previously approved sterile procedures.  The biopsy procedure may also carry a risk of 
soreness (100%), infection (<1%), and permanent numbness (<<1%).  Additional risks 
include discomfort, bleeding and possible scarring at the biopsy site.  The exercise tests 
that will be performed may cause symptoms of fatigue, shortness of breath and/or 
muscular fatigue/discomfort.  The exercise tests may cause short-term muscle soreness 
and moderate fatigue for several days following the tests.  You may also experience 
muscle strains/pulls during the exercise testing and/or training program.  However, 
exercise sessions will be conducted by trained personnel and monitored to ensure you 
follow appropriate exercise guidelines.      
 
Are There Any Benefits To Me?  
The direct benefit to you by being in this study is to know more about your health and 
fitness status from the tests to be performed.  However, even if no individual benefit is 
obtained, you will be paid for your participation.     
 
Will There Be Any Costs To Me?  
Aside from your time, there are no costs for taking part in the study. 
 
Will I Have To Pay Anything If I Get Hurt In This Study?  
If you suffer any injury as a result of taking part in this research study, please understand 
that nothing has been arranged to provide free treatment of the injury or any other type 
of payment. However, all needed facilities, emergency treatment and professional 
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services will be available to you, just as they are to the community in general. You 
should report any injury to Dr. Richard Kreider at 979-845-1333.  You will not give up 
any of your legal rights by signing this consent form. 
Side effects (injury) can happen in any research study. These effects may not be your 
fault or the fault of the researcher involved. Known side effects have been described in 
the “Are there any risks to me?” section of this consent form. However, side effects that 
are not currently known may happen and require care. In the event you experience side 
effects, particularly “unusual or adverse effects” you will be referred to or given the 
option of speaking with the Principle Investigator, Dr. Richard Kreider, the ESNL 
Research Nurse, Cassi Walkoviak, the ESNL Protocol Director/Laboratory Research 
Associate, Mr. Chris Rasmussen and/or the ESNL Supervising Physician Dr. J.P. 
Bramhall.  If you are not comfortable with these options you are encouraged to discuss 
these side effects with your personal physician.  You do not give up any of your legal 
rights by signing this form. 
 
Will I Be Paid To Be In This Study? 
You will receive a total of $225 ($25 for each visit plus $50 for each biopsy visit) in one 
check at the end of the study.  Payment will occur after finishing all testing sessions and 
after all study materials (questionnaires, food logs, etc.) have been turned in to the study 
staff.  You will be paid on a prorated basis if you are unable to complete the entire study.     
 
Will Information From This Study Be Kept Private? 
The records of this study will be kept private.  No identifiers linking you to this study 
will be included in any sort of report that might be published.  Research records will be 
stored securely and only Exercise & Sport Nutrition Laboratory staff will have access to 
the records. 
 
Information about you will be stored in locked file cabinets in a locked file room in an 
ID card swipe access controlled laboratory.  Computer files will be protected with a 
password.  This consent form will be filed securely in an official area.   
 
People who have access to your information include the Principal Investigator and 
research study personnel.  Representatives of regulatory agencies such as the Office of 
Human Research Protections (OHRP) and entities such as the Texas A&M University 
Human Subjects Protection Program may access your records to make sure the study is 
being run correctly and that information is collected properly.  
 
The agency that is funding this study (Woodbolt International) and the institutions(s) 
where study procedures are being performed (Texas A&M University) may also see 
your information.  However, any information that is sent to them will be coded with a 
number so that they cannot tell who you are.  Representatives from these entities can see 
information that has your name on it if they come to the study site to view records.  If 
there are any reports about this study, your name will not be in them.   
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Information about you and related to this study will be kept confidential to the extent 
permitted or required by law.  
 
Who may I Contact for More Information? 
You may contact the Principal Investigator, Richard Kreider, PhD, to tell him/her about 
a concern or complaint about this research at 979-845-1333 or rkreider@hlkn.tamu.edu.  
You may also contact the Protocol Director/Laboratory Research Associate, Chris 
Rasmussen, at 979-458-1741 or crasmussen@hlkn.tamu.edu.   
 
For questions about your rights as a research participant; or if you have questions, 
complaints, or concerns about the research, you may call the Texas A&M University 
Human Subjects Protection Program office at (979) 458-4067 or irb@tamu.edu.  
 
What if I Change My Mind About Participating? 
This research is voluntary and you have the choice whether or not to be in this research 
study.  You may decide to not begin or to stop participating at any time.   If you choose 
not to be in this study or stop being in the study, there will be no effect on your student 
status, medical care, employment, evaluation, relationship with Texas A&M University, 
etc.  Any new information discovered about the research will be provided to you. This 
information could affect your willingness to continue your participation. 
 
STATEMENT OF CONSENT 
I agree to be in this study and know that I am not giving up any legal rights by signing 
this form.  The procedures, risks, and benefits have been explained to me, and my 
questions have been answered.  I know that new information about this research study 
will be provided to me as it becomes available and that the researcher will tell me if I 
must be removed from the study.   I can ask more questions if I want.  A copy of this 
entire consent form will be given to me. 
 
 
______________________________ ___________________________________ 
Participant’s Signature   Date 
 
_______________________________          ___________________________________ 
Printed Name Date 
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INVESTIGATOR'S AFFIDAVIT: 
Either I have or my agent has carefully explained to the participant the nature of the 
above project. I hereby certify that to the best of my knowledge the person who signed 
this consent form was informed of the nature, demands, benefits, and risks involved in 
his/her participation. 
 
_______________________________          ___________________________________ 
Signature of Presenter Date 
 
_______________________________         ___________________________________ 
 Printed Name Date 
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APPENDIX C 
Texas A&M University: Exercise & Sport Nutrition Laboratory 
Trial:  Pharmacokinetic Assessment of Acute Ingestion of Different Forms of Creatine  
     
Demographics        ESNL Staff Initials:________ 
Name: _____________________________ 
D.O.B.: _____________________________ 
ID: _____________________________ 
FAM:                                                                               FMD Settings: 
Consent Form: _______  AC Dist: ______ Gain:  ______ 
Gen Scr Form: _______  PW Freq: ______ B Freq: ______ 
Height: _______in _______cm SV:  ______ Depth: ______ 
Weight: _______lbs _______kg     
T1 scheduled: _______       
T1: 
Date: ___________         
Group: ___________    FMD:  
Last Wkout: ___________    Disk: ___________ 
Last Meal: ___________ pm    0-h: ___________am/pm 
Hrs Fasted: ___________     1-h: ___________am/pm  
Weight: ___________ lbs ________kg   2.5-h: ___________am/pm 
DEXA Consent: ___________       
DEXA: ___________       
 
Heart Rate and Blood Pressure:                  Blood Samples (3) SST/(1) EDT   . 
0-h: _________bpm BP: _________/_________ mmHg 0-h: ___________am/pm 
[Complete side effects questionnaire at 0, 0.5, 1, 2, 3, 4, and 5-h] Supplement: ___________am/pm 
0.5-h: _________bpm BP: _________/_________ mmHg 0.5-h: ___________am/pm 
1-h: _________bpm BP: _________/_________ mmHg 1-h: ___________am/pm 
2-h: _________bpm BP: _________/_________ mmHg 2-h: ___________am/pm 
3-h: _________bpm BP: _________/_________ mmHg 3-h: ___________am/pm 
4-h: _________bpm BP: _________/_________ mmHg 4-h: ___________am/pm 
5-h: _________bpm BP: _________/_________ mmHg 5-h: ___________am/pm 
 
T2: 
Date: ___________      
Group: ___________    FMD:  
Last Wkout: ___________    Disk: ___________ 
Last Meal: ___________ pm    0-h: ___________am/pm 
Hrs Fasted: ___________   1-h: ___________am/pm  
Weight: ___________ lbs _______kg  2.5-h: ___________am/pm 
DEXA Consent: ___________       
DEXA: ___________       
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Heart Rate and Blood Pressure:     Blood Samples (3) SST/(1) EDTA: 
           . 
0-h: _________bpm BP: _________/_________ mmHg 0-h: ___________am/pm 
[Complete side effects questionnaire at 0, 0.5, 1, 2, 3, 4, and 5-h]  Supplement: ___________am/pm 
0.5-h: _________bpm BP: _________/_________ mmHg 0.5-h: ___________am/pm 
1-h: _________bpm BP: _________/_________ mmHg 1-h: ___________am/pm 
2-h: _________bpm BP: _________/_________ mmHg 2-h: ___________am/pm 
3-h: _________bpm BP: _________/_________ mmHg 3-h: ___________am/pm 
4-h: _________bpm BP: _________/_________ mmHg 4-h: ___________am/pm 
5-h: _________bpm BP: _________/_________ mmHg 5-h: ___________am/pm 
 
 
T3: 
Date: ___________      
Group: ___________    FMD:  
Last Wkout: ___________    Disk: ___________ 
Last Meal: ___________ pm    0-h: ___________am/pm 
Hrs Fasted: ___________     1-h: ___________am/pm  
Weight: ___________ lbs _______kg   2.5-h: ___________am/pm 
DEXA Consent: ___________       
DEXA: ___________       
 
Heart Rate and Blood Pressure:                 Blood Samples (3) 
SST/(1) EDTA: 
          . 
0-h: _________bpm BP: _________/_________ mmHg 0-h: ___________am/pm 
[Complete side effects questionnaire at 0, 0.5, 1, 2, 3, 4, and 5-h] Ingest 
Supplement: 
___________am/pm 
0.5-h: _________bpm BP: _________/_________ mmHg 0.5-h: ___________am/pm 
1-h: _________bpm BP: _________/_________ mmHg 1-h: ___________am/pm 
2-h: _________bpm BP: _________/_________ mmHg 2-h: ___________am/pm 
3-h: _________bpm BP: _________/_________ mmHg 3-h: ___________am/pm 
4-h: _________bpm BP: _________/_________ mmHg 4-h: ___________am/pm 
5-h: _________bpm BP: _________/_________ mmHg 5-h: ___________am/pm 
     
Financial Paperwork: BP: _________   
 
 
Notes:________________________________________________________________________________
_____________________________________________________________________________________
_____________________________________________________________________________________
_____________________________________________________________________________________
_____________________________________________________________________________________ 
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APPENDIX D 
Texas A&M University: Exercise & Sport Nutrition Laboratory 
Trial:  Effects of 28 Days of Different Forms of Creatine Supplementation on Muscle Creatine, Body 
Composition, and Exercise Performance in Recreationally Active Males 
     
Demographics                        ESNL Staff Initials:__________ 
Name: _____________________________ 
D.O.B.: _____________________________ 
ID: _____________________________ 
FAM:                                                                                                    Wingate Settings: 
Consent Form: __________  Seat ht: ______ 
Gen Screening Form: __________  Seat position: ______ 
Height: __________in __________cm Bar ht:  ______ 
Weight: __________lbs __________kg Bar position: ______ 
[1RM Test before Practice Wingate]  Practice Wingate: ______ 
1RM Bench Press Test:  [0.075 kp/kg body mass]  
Estimated 1RM: __________lbs   
50% of estimated 1RM, 10 reps, 2 sets  __________lbs   
70% of estimated 1RM,  5 reps, 1 set    __________lbs RT Program Instructions:  ______ 
 
Actual 1 RM: determine in 3 – 5 sets  
 
__________lbs   
 
Schedule T1: 
 
______ 
    
T1: Day 0 
Date: __________    ESNL Staff Initials:__________ 
-24 h biopsy: __________    BIA:   
Group: __________    FFM (kg): ______ ______ 
Last Wkout: __________    FM (kg): ______ ______ 
Last Meal: __________pm    TBW (L): ______ ______ 
Hrs Fasted: __________    ICW (L): ______ ______ 
Weight: __________lbs _________kg   ECW (L): ______ ______ 
DEXA Consent: __________       
DEXA: __________     
Blood: __________     
      
[Bench Press before Wingate Protocol]  
Bench Press:   Wingate Protocol:  
50% of actual 1RM:  __________lbs  [start 5 min after Bench Press] 
70% of actual 1RM:  __________lbs    
1.  50% of 1RM, 10 reps, 1 set: _________ 1. 3-min warm-up: ______ 
2.  70% of 1RM, 10 reps, 1 set:   _________   2. 6 x 6-sec sprints: ______ 
3.  70% of 1RM, 10 reps, 1 set:   _________ 3. 3-minute rest: ______ 
4.                70% of 1RM, max reps,1set: _________ # of reps 4. 30-sec sprint: ______ 
  [must remain seated during sprints] 
Supplementation Instructions: ________  
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T2: Day 7 
     .Date: __________   ESNL Staff Initials:__________ 
-24 h biopsy: __________   BIA:   
Last Wkout: __________   FFM (kg): ______ ______ 
Last Meal: __________pm   FM (kg): ______ ______ 
Hrs Fasted: __________   TBW (L): ______ ______ 
Weight: __________lbs _________kg  ICW (L): ______ ______ 
DEXA Consent: __________   ECW (L): ______ ______ 
DEXA: __________      
Blood: __________  Side effects 
questionnaire: 
______ 
     
T3: Day 28 
Date: __________   ESNL Staff Initials:__________ 
-24 h biopsy: __________      
Last Wkout: __________   BIA:   
Last Meal: __________pm   FFM (kg): ______ ______ 
Hrs Fasted: __________   FM (kg): ______ ______ 
Weight: __________lbs _________kg  TBW (L): ______ ______ 
DEXA Consent: __________   ICW (L): ______ ______ 
DEXA: __________   ECW (L): ______ ______ 
Blood: __________     
      
[Bench Press before Wingate Protocol]  
Bench Press:   Wingate Protocol:  
50% of actual 1RM:  __________lbs  [start 5 min after Bench Press] 
70% of actual 1RM:  __________lbs    
1.  50% of 1RM, 10 reps, 1 set: _________ 1. 3-min warm-up: ______ 
2.  70% of 1RM, 10 reps, 1 set:   _________   2. 6 x 6-sec sprints: ______ 
3.  70% of 1RM, 10 reps, 1 set:   _________ 3. 3-minute rest: ______ 
4.                70% of 1RM, max reps,1set: _________ # of reps 4. 30-sec sprint ______ 
  [must remain seated during sprints] 
 
Notes:________________________________________________________________________________
_____________________________________________________________________________________
_____________________________________________________________________________________
_____________________________________________________________________________________
_____________________________________________________________________________________ 
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APPENDIX E 
 
 
